NCTId;BriefTitle;LeadSponsorName;CollaboratorName;OverallStatus;StudyType;HasResults;StudyFirstPostDate;StartDate;CompletionDate;pmid;type;citation;title;authors;doi;date;publication_types
NCT02566148;Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France;ANRS, Emerging Infectious Diseases;Ministry of Health, France | Institut de Recherche pour le Developpement | Institut National de la Santé Et de la Recherche Médicale, France | Institut national de prevention et d'education pour la sante;COMPLETED;OBSERVATIONAL;False;2015-10-02;2012-02;2013-05;29437866;DERIVED;"Gosselin A, Desgrees du Lou A, Lelievre E; PARCOURS Study Group. How to use sequence analysis for life course epidemiology? An example on HIV-positive Sub-Saharan migrants in France. J Epidemiol Community Health. 2018 Jun;72(6):507-512. doi: 10.1136/jech-2017-209739. Epub 2018 Feb 2.";How to use sequence analysis for life course epidemiology? An example on HIV-positive Sub-Saharan migrants in France.;"Gosselin A; Desgrées du Loû A; Lelièvre E; PARCOURS Study Group";10.1136/jech-2017-209739;2018/06/01 00:00;['Journal Article']
NCT02566148;Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France;ANRS, Emerging Infectious Diseases;Ministry of Health, France | Institut de Recherche pour le Developpement | Institut National de la Santé Et de la Recherche Médicale, France | Institut national de prevention et d'education pour la sante;COMPLETED;OBSERVATIONAL;False;2015-10-02;2012-02;2013-05;29982518;DERIVED;"Vignier N, Dray Spira R, Pannetier J, Ravalihasy A, Gosselin A, Lert F, Lydie N, Bouchaud O, Desgrees Du Lou A, Chauvin P; PARCOURS Study Group. Refusal to provide healthcare to sub-Saharan migrants in France: a comparison according to their HIV and HBV status. Eur J Public Health. 2018 Oct 1;28(5):904-910. doi: 10.1093/eurpub/cky118.";Refusal to provide healthcare to sub-Saharan migrants in France: a comparison according to their HIV and HBV status.;"Vignier N; Dray Spira R; Pannetier J; Ravalihasy A; Gosselin A; Lert F; Lydie N; Bouchaud O; Desgrees Du Lou A; Chauvin P; PARCOURS Study Group";10.1093/eurpub/cky118;2018/10/01 00:00;['Journal Article']
NCT02566148;Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France;ANRS, Emerging Infectious Diseases;Ministry of Health, France | Institut de Recherche pour le Developpement | Institut National de la Santé Et de la Recherche Médicale, France | Institut national de prevention et d'education pour la sante;COMPLETED;OBSERVATIONAL;False;2015-10-02;2012-02;2013-05;29307383;DERIVED;"Pannetier J, Ravalihasy A, Lydie N, Lert F, Desgrees du Lou A; Parcours study group. Prevalence and circumstances of forced sex and post-migration HIV acquisition in sub-Saharan African migrant women in France: an analysis of the ANRS-PARCOURS retrospective population-based study. Lancet Public Health. 2018 Jan;3(1):e16-e23. doi: 10.1016/S2468-2667(17)30211-6. Epub 2017 Nov 23.";Prevalence and circumstances of forced sex and post-migration HIV acquisition in sub-Saharan African migrant women in France: an analysis of the ANRS-PARCOURS retrospective population-based study.;"Pannetier J; Ravalihasy A; Lydié N; Lert F; Desgrées du Loû A; Parcours study group";10.1016/S2468-2667(17)30211-6;2018/01/01 00:00;['Journal Article']
NCT01620957;Longitudinal Study of the Default-mode Network Connectivity in Brain Injured Patients Recovering From Coma;Institut National de la Santé Et de la Recherche Médicale, France;University Hospital, Toulouse | Association des Traumatisés du Crane et de la Face, Paris, France;COMPLETED;OBSERVATIONAL;False;2012-06-15;2012-07-10;2017-07;;;;;;;;
NCT02987530;National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-12-09;2017-04-11;2020-01-31;;;;;;;;
NCT02073630;Contribution of the Cerebellum In Sensory-motor Adaptation Via Gamma Oscillations: the Case of Dystonia;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-02-27;2014-02;2016-08;;;;;;;;
NCT05311865;Transmission of Covid-19 During Clubbing Events in Closed Places;ANRS, Emerging Infectious Diseases;Cerballiance | Kappa Santé;COMPLETED;INTERVENTIONAL;False;2022-04-05;2021-09-04;2022-02-26;37795682;PUBMED;;A randomised controlled trial to study the transmission of SARS-CoV-2 and other respiratory viruses during indoor clubbing events (ANRS0066s ITOC study).;"Luong Nguyen LB; Goupil de Bouillé J; Menant L; Noret M; Dumas A; Salmona M; Le Goff J; Delaugerre C; Crépey P; Zeggagh J; ITOC Study Group";10.1093/cid/ciad603;2023/10/05 00:00;['Journal Article']
NCT05311865;Transmission of Covid-19 During Clubbing Events in Closed Places;ANRS, Emerging Infectious Diseases;Cerballiance | Kappa Santé;COMPLETED;INTERVENTIONAL;False;2022-04-05;2021-09-04;2022-02-26;36438274;PUBMED;;Transmission of SARS-CoV-2 during indoor clubbing events: A clustered randomized, controlled, multicentre trial protocol.;"Goupil de Bouillé J; Luong Nguyen LB; Crépey P; Garlantezec R; Doré V; Dumas A; Ben Mechlia M; Tattevin P; Gaudart J; Spire B; Lert F; Yazdanpanah Y; Delaugerre C; Noret M; Zeggagh J";10.3389/fpubh.2022.981213;2022/11/04 00:00;['Journal Article']
NCT02081066;Identification of CETP as a Marker of Atherosclerosis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-03-07;2014-09-25;2020-09;;;;;;;;
NCT02497274;Obesity and Lipids: a Matter of Taste?;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2016-01-11;2019-01;;;;;;;;
NCT02116374;Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2014-04-16;2014-12;2016-06;;;;;;;;
NCT03078439;EPIPAGE2 Cohort Study Follow up at Five and a Half Years;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2017-03-13;2016-09-02;2018-01-08;38408861;PUBMED;;Birth weight and head circumference discordance and outcome in preterms: results from the EPIPAGE-2 cohort.;"Guellec I; Brunet A; Lapillonne A; Taine M; Torchin H; Favrais G; Gascoin G; Simon L; Heude B; Scherdel P; Kayem G; Delorme P; Jarreau PH; Ancel PY";10.1136/archdischild-2023-326336;2024/02/26 00:00;['Journal Article']
NCT03546127;Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study;Institut National de la Santé Et de la Recherche Médicale, France;Institut Bergonié | Plateforme labellisée Inca - Institut Bergonié, Bordeaux | Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris | CNRGH, Evry | EUCLID Clinical Trial Platform;COMPLETED;OBSERVATIONAL;False;2018-06-06;2017-05-23;2017-09-21;;;;;;;;
NCT02014727;Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults;Institut National de la Santé Et de la Recherche Médicale, France;EVI Industries, Inc. | BPRC | Recherche Clinique Paris Descartes Necker Cochin Sainte Anne | Centre national de recherche et de formation sur le paludisme;COMPLETED;INTERVENTIONAL;False;2013-12-18;2014-01;2015-07;28947345;DERIVED;"Sirima SB, Durier C, Kara L, Houard S, Gansane A, Loulergue P, Bahuaud M, Benhamouda N, Nebie I, Faber B, Remarque E, Launay O; AMA1-DiCo Study Group. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel(R) in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial. Vaccine. 2017 Oct 27;35(45):6218-6227. doi: 10.1016/j.vaccine.2017.09.027. Epub 2017 Sep 22.";Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.;"Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O; AMA1-DiCo Study Group";10.1016/j.vaccine.2017.09.027;2017/10/27 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT05199831;Situational Analysis of HIV-related Disability in the Context of Ivory Coast;Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire;Institute of Research for Development, France | Institut de Sante Publique, d'Epidemiologie et de Developpement | University of Toronto | Université de Lille;COMPLETED;OBSERVATIONAL;False;2022-01-20;2021-02-05;2022-08-10;;;;;;;;
NCT02107365;Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO);ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb;COMPLETED;INTERVENTIONAL;False;2014-04-08;2013-11;2015-04;;;;;;;;
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement;COMPLETED;OBSERVATIONAL;False;2014-04-01;2009-01;2013-12;27798339;DERIVED;"Desmarchelier C, Borel P, Goncalves A, Kopec R, Nowicki M, Morange S, Lesavre N, Portugal H, Reboul E. A Combination of Single-Nucleotide Polymorphisms Is Associated with Interindividual Variability in Cholecalciferol Bioavailability in Healthy Men. J Nutr. 2016 Dec;146(12):2421-2428. doi: 10.3945/jn.116.237115. Epub 2016 Oct 26.";A Combination of Single-Nucleotide Polymorphisms Is Associated with Interindividual Variability in Cholecalciferol Bioavailability in Healthy Men.;"Desmarchelier C; Borel P; Goncalves A; Kopec R; Nowicki M; Morange S; Lesavre N; Portugal H; Reboul E";10.3945/jn.116.237115;2016/12/01 00:00;['Journal Article']
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement;COMPLETED;OBSERVATIONAL;False;2014-04-01;2009-01;2013-12;21957063;BACKGROUND;"Borel P. Genetic variations involved in interindividual variability in carotenoid status. Mol Nutr Food Res. 2012 Feb;56(2):228-40. doi: 10.1002/mnfr.201100322. Epub 2011 Sep 29.";Genetic variations involved in interindividual variability in carotenoid status.;Borel P;10.1002/mnfr.201100322;2012/02/01 00:00;['Journal Article', 'Review']
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement;COMPLETED;OBSERVATIONAL;False;2014-04-01;2009-01;2013-12;26063065;DERIVED;"Borel P, Desmarchelier C, Nowicki M, Bott R. A Combination of Single-Nucleotide Polymorphisms Is Associated with Interindividual Variability in Dietary beta-Carotene Bioavailability in Healthy Men. J Nutr. 2015 Aug;145(8):1740-7. doi: 10.3945/jn.115.212837. Epub 2015 Jun 10.";A Combination of Single-Nucleotide Polymorphisms Is Associated with Interindividual Variability in Dietary β-Carotene Bioavailability in Healthy Men.;"Borel P; Desmarchelier C; Nowicki M; Bott R";10.3945/jn.115.212837;2015/08/01 00:00;['Journal Article']
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement;COMPLETED;OBSERVATIONAL;False;2014-04-01;2009-01;2013-12;24808487;DERIVED;"Borel P, Desmarchelier C, Nowicki M, Bott R, Morange S, Lesavre N. Interindividual variability of lutein bioavailability in healthy men: characterization, genetic variants involved, and relation with fasting plasma lutein concentration. Am J Clin Nutr. 2014 Jul;100(1):168-75. doi: 10.3945/ajcn.114.085720. Epub 2014 May 7.";Interindividual variability of lutein bioavailability in healthy men: characterization, genetic variants involved, and relation with fasting plasma lutein concentration.;"Borel P; Desmarchelier C; Nowicki M; Bott R; Morange S; Lesavre N";10.3945/ajcn.114.085720;2014/07/01 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT02273765;Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC | Ministry of Health, Brazil;COMPLETED;INTERVENTIONAL;False;2014-10-24;2015-09-11;2018-11-28;33667406;DERIVED;"De Castro N, Marcy O, Chazallon C, Messou E, Eholie S, N'takpe JB, Bhatt N, Khosa C, Timana Massango I, Laureillard D, Chau GD, Domergue A, Veloso V, Escada R, Wagner Cardoso S, Delaugerre C, Anglaret X, Molina JM, Grinsztejn B; ANRS 12300 Reflate TB2 study group. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial. Lancet Infect Dis. 2021 Jun;21(6):813-822. doi: 10.1016/S1473-3099(20)30869-0. Epub 2021 Mar 2.";Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.;"De Castro N; Marcy O; Chazallon C; Messou E; Eholié S; N'takpe JB; Bhatt N; Khosa C; Timana Massango I; Laureillard D; Chau GD; Domergue A; Veloso V; Escada R; Wagner Cardoso S; Delaugerre C; Anglaret X; Molina JM; Grinsztejn B; ANRS 12300 Reflate TB2 study group";10.1016/S1473-3099(20)30869-0;2021/06/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35512728;DERIVED;"WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022 May 21;399(10339):1941-1953. doi: 10.1016/S0140-6736(22)00519-0. Epub 2022 May 2. Erratum In: Lancet. 2022 Oct 29;400(10362):1512. Lancet. 2024 Jan 13;403(10422):146.";Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.;WHO Solidarity Trial Consortium;10.1016/S0140-6736(22)00519-0;2022/05/21 00:00;['Journal Article', 'Meta-Analysis']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;32304640;DERIVED;"Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med. 2020 Jun;8(6):539-541. doi: 10.1016/S2213-2600(20)30172-7. Epub 2020 Apr 15. No abstract available.";Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.;"Taccone FS; Gorham J; Vincent JL";10.1016/S2213-2600(20)30172-7;2020/06/01 00:00;['Journal Article']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35233617;RESULT;"Lingas G, Neant N, Gaymard A, Belhadi D, Peytavin G, Hites M, Staub T, Greil R, Paiva JA, Poissy J, Peiffer-Smadja N, Costagliola D, Yazdanpanah Y, Wallet F, Gagneux-Brunon A, Mentre F, Ader F, Burdet C, Guedj J, Bouscambert-Duchamp M. Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial. J Antimicrob Chemother. 2022 Apr 27;77(5):1404-1412. doi: 10.1093/jac/dkac048.";Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.;"Lingas G; Néant N; Gaymard A; Belhadi D; Peytavin G; Hites M; Staub T; Greil R; Paiva JA; Poissy J; Peiffer-Smadja N; Costagliola D; Yazdanpanah Y; Wallet F; Gagneux-Brunon A; Mentré F; Ader F; Burdet C; Guedj J; Bouscambert-Duchamp M";10.1093/jac/dkac048;2022/04/27 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34534511;RESULT;"Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Le MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentre F; DisCoVeRy Study Group. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022 Feb;22(2):209-221. doi: 10.1016/S1473-3099(21)00485-0. Epub 2021 Sep 14.";Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.;"Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F; DisCoVeRy Study Group";10.1016/S1473-3099(21)00485-0;2022/02/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;36828006;BACKGROUND;"Amstutz A, Speich B, Mentre F, Rueegg CS, Belhadi D, Assoumou L, Burdet C, Murthy S, Dodd LE, Wang Y, Tikkinen KAO, Ader F, Hites M, Bouscambert M, Trabaud MA, Fralick M, Lee TC, Pinto R, Barratt-Due A, Lund-Johansen F, Muller F, Nevalainen OPO, Cao B, Bonnett T, Griessbach A, Taji Heravi A, Schonenberger C, Janiaud P, Werlen L, Aghlmandi S, Schandelmaier S, Yazdanpanah Y, Costagliola D, Olsen IC, Briel M. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir Med. 2023 May;11(5):453-464. doi: 10.1016/S2213-2600(22)00528-8. Epub 2023 Feb 21. Erratum In: Lancet Respir Med. 2023 Aug;11(8):e77.";Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials.;"Amstutz A; Speich B; Mentré F; Rueegg CS; Belhadi D; Assoumou L; Burdet C; Murthy S; Dodd LE; Wang Y; Tikkinen KAO; Ader F; Hites M; Bouscambert M; Trabaud MA; Fralick M; Lee TC; Pinto R; Barratt-Due A; Lund-Johansen F; Müller F; Nevalainen OPO; Cao B; Bonnett T; Griessbach A; Taji Heravi A; Schönenberger C; Janiaud P; Werlen L; Aghlmandi S; Schandelmaier S; Yazdanpanah Y; Costagliola D; Olsen IC; Briel M";10.1016/S2213-2600(22)00528-8;2023/05/01 00:00;['Meta-Analysis', 'Journal Article']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;33264556;RESULT;"WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernandez Garcia C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, Garcia PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portoles A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Rottingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.";Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.;"WHO Solidarity Trial Consortium; Pan H; Peto R; Henao-Restrepo AM; Preziosi MP; Sathiyamoorthy V; Abdool Karim Q; Alejandria MM; Hernández García C; Kieny MP; Malekzadeh R; Murthy S; Reddy KS; Roses Periago M; Abi Hanna P; Ader F; Al-Bader AM; Alhasawi A; Allum E; Alotaibi A; Alvarez-Moreno CA; Appadoo S; Asiri A; Aukrust P; Barratt-Due A; Bellani S; Branca M; Cappel-Porter HBC; Cerrato N; Chow TS; Como N; Eustace J; García PJ; Godbole S; Gotuzzo E; Griskevicius L; Hamra R; Hassan M; Hassany M; Hutton D; Irmansyah I; Jancoriene L; Kirwan J; Kumar S; Lennon P; Lopardo G; Lydon P; Magrini N; Maguire T; Manevska S; Manuel O; McGinty S; Medina MT; Mesa Rubio ML; Miranda-Montoya MC; Nel J; Nunes EP; Perola M; Portolés A; Rasmin MR; Raza A; Rees H; Reges PPS; Rogers CA; Salami K; Salvadori MI; Sinani N; Sterne JAC; Stevanovikj M; Tacconelli E; Tikkinen KAO; Trelle S; Zaid H; Røttingen JA; Swaminathan S";10.1056/NEJMoa2023184;2021/02/11 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;38552208;PUBMED;;Cardiac Adverse Events and Remdesivir in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19): A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.;"Terzić V; Miantezila Basilua J; Billard N; de Gastines L; Belhadi D; Fougerou-Leurent C; Peiffer-Smadja N; Mercier N; Delmas C; Ferrane A; Dechanet A; Poissy J; Espérou H; Ader F; Hites M; Andrejak C; Greil R; Paiva JA; Staub T; Tacconelli E; Burdet C; Costagliola D; Mentré F; Yazdanpanah Y; Diallo A; DisCoVeRy study group";10.1093/cid/ciae170;2024/03/29 00:00;['Journal Article']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34350582;DERIVED;"Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V, Metzendorf MI, Stegemann M, Benstoem C, Fichtner F. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD014962. doi: 10.1002/14651858.CD014962.";Remdesivir for the treatment of COVID-19.;"Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F";10.1002/14651858.CD014962;2021/08/05 00:00;['Journal Article']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34763056;BACKGROUND;"EU-Response investigators group; Diallo A, Troseid M, Simensen VC, Boston A, Demotes J, Olsen IC, Chung F, Paiva JA, Hites M, Ader F, Arribas JR, Baratt-Due A, Melien O, Tacconelli E, Staub T, Greil R, Tsiodras S, Briel M, Esperou H, Mentre F, Eustace J, Saillard J, Delmas C, LeMestre S, Dumousseaux M, Costagliola D, Rottingen JA, Yazdanpanah Y. Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. Clin Microbiol Infect. 2022 Jan;28(1):1-5. doi: 10.1016/j.cmi.2021.10.011. Epub 2021 Nov 8. No abstract available.";Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group.;"EU-Response investigators group; Diallo A; Trøseid M; Simensen VC; Boston A; Demotes J; Olsen IC; Chung F; Paiva JA; Hites M; Ader F; Arribas JR; Baratt-Due A; Melien Ø; Tacconelli E; Staub T; Greil R; Tsiodras S; Briel M; Esperou H; Mentré F; Eustace J; Saillard J; Delmas C; LeMestre S; Dumousseaux M; Costagliola D; Røttingen JA; Yazdanpanah Y";10.1016/j.cmi.2021.10.011;2022/01/01 00:00;['Journal Article']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35643099;RESULT;"Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Mentre F, Burdet C; DisCoVeRy Study Group. Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19. Lancet Infect Dis. 2022 Jun;22(6):764-765. doi: 10.1016/S1473-3099(22)00295-X. No abstract available.";Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19.;"Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Mentré F; Burdet C; DisCoVeRy Study Group";10.1016/S1473-3099(22)00295-X;2022/06/01 00:00;['Letter']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35623577;BACKGROUND;"Troseid M, Hentzien M, Ader F, Cardoso SW, Arribas JR, Molina JM, Mueller N, Hites M, Bonnet F, Manuel O, Costagliola D, Grinsztejn B, Olsen IC, Yazdapanah Y, Calmy A; EU RESPONSE; COMBINE. Immunocompromised patients have been neglected in COVID-19 trials: a call for action. Clin Microbiol Infect. 2022 Sep;28(9):1182-1183. doi: 10.1016/j.cmi.2022.05.005. Epub 2022 May 25. No abstract available.";Immunocompromised patients have been neglected in COVID-19 trials: a call for action.;"Trøseid M; Hentzien M; Ader F; Cardoso SW; Arribas JR; Molina JM; Mueller N; Hites M; Bonnet F; Manuel O; Costagliola D; Grinsztejn B; Olsen IC; Yazdapanah Y; Calmy A; EU RESPONSE; COMBINE";10.1016/j.cmi.2022.05.005;2022/09/01 00:00;['Journal Article']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;36680782;BACKGROUND;"Terzic V, Levoyer L, Figarella M, Bigagli E, Mercier N, De Gastines L, Gibowski S, Troseid M, Demotes J, Olsen IC, Hites M, Ader F, Lopez JRA, Mentre F, Esperou H, Costagliola D, Rottingen JA, Poissy J, Roze JC, Warris A, O'Leary J, Fernandes RM, Assoumou L, Hankard R, Turner MA, Yazdanpanah Y, Diallo A; EU-Response safety group; c4c safety group. Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia. Br J Clin Pharmacol. 2023 Apr;89(4):1318-1328. doi: 10.1111/bcp.15669. Epub 2023 Feb 8.";Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia.;"Terzić V; Levoyer L; Figarella M; Bigagli E; Mercier N; De Gastines L; Gibowski S; Trøseid M; Demotes J; Olsen IC; Hites M; Ader F; Lopez JRA; Mentré F; Espérou H; Costagliola D; Røttingen JA; Poissy J; Rozé JC; Warris A; O'Leary J; Fernandes RM; Assoumou L; Hankard R; Turner MA; Yazdanpanah Y; Diallo A; EU-Response safety group; c4c safety group";10.1111/bcp.15669;2023/04/01 00:00;['Journal Article', 'Review']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34048876;RESULT;"Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, Delmas C, Saillard J, Dechanet A, Mercier N, Dupont A, Alfaiate T, Lescure FX, Raffi F, Goehringer F, Kimmoun A, Jaureguiberry S, Reignier J, Nseir S, Danion F, Clere-Jehl R, Bouiller K, Navellou JC, Tolsma V, Cabie A, Dubost C, Courjon J, Leroy S, Mootien J, Gaci R, Mourvillier B, Faure E, Pourcher V, Gallien S, Launay O, Lacombe K, Lanoix JP, Makinson A, Martin-Blondel G, Bouadma L, Botelho-Nevers E, Gagneux-Brunon A, Epaulard O, Piroth L, Wallet F, Richard JC, Reuter J, Staub T, Lina B, Noret M, Andrejak C, Le MP, Peytavin G, Hites M, Costagliola D, Yazdanpanah Y, Burdet C, Mentre F; DisCoVeRy study group. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021 Dec;27(12):1826-1837. doi: 10.1016/j.cmi.2021.05.020. Epub 2021 May 26.";An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.;"Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F; DisCoVeRy study group";10.1016/j.cmi.2021.05.020;2021/12/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;36695483;PUBMED;;Remdesivir for the treatment of COVID-19.;"Grundeis F; Ansems K; Dahms K; Thieme V; Metzendorf MI; Skoetz N; Benstoem C; Mikolajewska A; Griesel M; Fichtner F; Stegemann M";10.1002/14651858.CD014962.pub2;2023/01/25 00:00;['Journal Article', 'Review']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34473343;DERIVED;"Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.";SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.;"Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N";10.1002/14651858.CD013825.pub2;2021/09/02 00:00;['Journal Article', 'Review']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;33089306;BACKGROUND;"Le MP, Peiffer-Smadja N, Guedj J, Neant N, Mentre F, Ader F, Yazdanpanah Y, Peytavin G; C-20-15 DisCoVeRy French Steering Committee. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response. J Antimicrob Chemother. 2021 Jan 1;76(1):277-279. doi: 10.1093/jac/dkaa415. No abstract available.";Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response.;"Lê MP; Peiffer-Smadja N; Guedj J; Neant N; Mentré F; Ader F; Yazdanpanah Y; Peytavin G; C-20-15 DisCoVeRy French Steering Committee";10.1093/jac/dkaa415;2021/01/01 00:00;['Journal Article', 'Comment']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;32473020;BACKGROUND;"Le MP, Peiffer-Smadja N, Guedj J, Neant N, Mentre F, Ader F, Yazdanpanah Y, Peytavin G. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. J Antimicrob Chemother. 2020 Sep 1;75(9):2376-2380. doi: 10.1093/jac/dkaa191.";Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.;"Lê MP; Peiffer-Smadja N; Guedj J; Néant N; Mentré F; Ader F; Yazdanpanah Y; Peytavin G";10.1093/jac/dkaa191;2020/09/01 00:00;['Journal Article', 'Review']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;37728045;RESULT;"Neant N, Lingas G, Gaymard A, Belhadi D, Hites M, Staub T, Greil R, Paiva JA, Poissy J, Peiffer-Smadja N, Costagliola D, Yazdanpanah Y, Bouscambert-Duchamp M, Gagneux-Brunon A, Ader F, Mentre F, Wallet F, Burdet C, Guedj J; DisCoVeRy study group. Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients. CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):2027-2037. doi: 10.1002/psp4.13051. Epub 2023 Oct 11.";Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients.;"Néant N; Lingas G; Gaymard A; Belhadi D; Hites M; Staub T; Greil R; Paiva JA; Poissy J; Peiffer-Smadja N; Costagliola D; Yazdanpanah Y; Bouscambert-Duchamp M; Gagneux-Brunon A; Ader F; Mentré F; Wallet F; Burdet C; Guedj J; DisCoVeRy study group";10.1002/psp4.13051;2023/12/01 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;32958495;BACKGROUND;"Ader F; Discovery French Trial Management Team. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. BMJ Open. 2020 Sep 21;10(9):e041437. doi: 10.1136/bmjopen-2020-041437.";Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.;"Ader F; Discovery French Trial Management Team";10.1136/bmjopen-2020-041437;2020/09/21 00:00;['Journal Article']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;37269068;BACKGROUND;"Mercier N, Belhadi D, DeChanet A, Delmas C, Saillard J, Dumousseaux M, Le Mestre S, Fougerou-Leurent C, Ferrane A, Burdet C, Esperou H, Ader F, Hites M, Peiffer-Smadja N, Poissy J, Andrejak C, Paiva JA, Tacconelli E, Staub T, Greil R, Costagliola D, Mentre F, Yazdanpanah Y, Diallo A; DisCoVeRy Safety Working group. Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial. Pharmacol Res Perspect. 2023 Jun;11(3):e01072. doi: 10.1002/prp2.1072.";Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial.;"Mercier N; Belhadi D; DeChanet A; Delmas C; Saillard J; Dumousseaux M; Le Mestre S; Fougerou-Leurent C; Ferrane A; Burdet C; Espérou H; Ader F; Hites M; Peiffer-Smadja N; Poissy J; Andrejak C; Paiva JA; Tacconelli E; Staub T; Greil R; Costagliola D; Mentre F; Yazdanpanah Y; Diallo A; DisCoVeRy Safety Working group";10.1002/prp2.1072;2023/06/01 00:00;['Journal Article', 'Review']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;37302469;BACKGROUND;"Fougerou-Leurent C, Delmas C, Saillard J, Dumousseaux M, Ferrane A, Mercier N, Terzic V, Le Mestre S, Dechanet A, Belhadi D, Metois A, Burdet C, Mentre F, Noret M, Diallo A, Petrov-Sanchez V, Couffin-Cadiergues S, Hites M, Ader F, Esperou H. Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20-15 DisCoVeRy study. Contemp Clin Trials. 2023 Aug;131:107267. doi: 10.1016/j.cct.2023.107267. Epub 2023 Jun 9.";Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20-15 DisCoVeRy study.;"Fougerou-Leurent C; Delmas C; Saillard J; Dumousseaux M; Ferrane A; Mercier N; Terzic V; Le Mestre S; Dechanet A; Belhadi D; Metois A; Burdet C; Mentré F; Noret M; Diallo A; Petrov-Sanchez V; Couffin-Cadiergues S; Hites M; Ader F; Esperou H";10.1016/j.cct.2023.107267;2023/08/01 00:00;['Journal Article']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35533972;RESULT;"Ader F; DisCoVeRy Study Group. An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-beta-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results. Clin Microbiol Infect. 2022 Sep;28(9):1293-1296. doi: 10.1016/j.cmi.2022.04.016. Epub 2022 May 7. No abstract available.";An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results.;"Ader F; DisCoVeRy Study Group";10.1016/j.cmi.2022.04.016;2022/09/01 00:00;['Letter', 'Randomized Controlled Trial']
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;19625486;BACKGROUND;"Skerry CM, Cassidy JP, English K, Feunou-Feunou P, Locht C, Mahon BP. A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice. Clin Vaccine Immunol. 2009 Sep;16(9):1344-51. doi: 10.1128/CVI.00082-09. Epub 2009 Jul 22.";A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice.;"Skerry CM; Cassidy JP; English K; Feunou-Feunou P; Locht C; Mahon BP";10.1128/CVI.00082-09;2009/09/01 00:00;['Journal Article']
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;18762220;BACKGROUND;"Feunou PF, Ismaili J, Debrie AS, Huot L, Hot D, Raze D, Lemoine Y, Locht C. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine. 2008 Oct 23;26(45):5722-7. doi: 10.1016/j.vaccine.2008.08.018. Epub 2008 Aug 30.";Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.;"Feunou PF; Ismaili J; Debrie AS; Huot L; Hot D; Raze D; Lemoine Y; Locht C";10.1016/j.vaccine.2008.08.018;2008/10/23 00:00;['Journal Article']
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;22814407;BACKGROUND;"Kammoun H, Feunou PF, Foligne B, Debrie AS, Raze D, Mielcarek N, Locht C. Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in mice. Vaccine. 2012 Aug 31;30(40):5864-70. doi: 10.1016/j.vaccine.2012.07.005. Epub 2012 Jul 17.";Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in mice.;"Kammoun H; Feunou PF; Foligne B; Debrie AS; Raze D; Mielcarek N; Locht C";10.1016/j.vaccine.2012.07.005;2012/08/31 00:00;['Journal Article']
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;21147936;BACKGROUND;"Skerry CM, Mahon BP. A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model. Clin Vaccine Immunol. 2011 Feb;18(2):187-93. doi: 10.1128/CVI.00371-10. Epub 2010 Dec 8.";A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model.;"Skerry CM; Mahon BP";10.1128/CVI.00371-10;2011/02/01 00:00;['Journal Article']
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;20107007;BACKGROUND;"Mielcarek N, Debrie AS, Mahieux S, Locht C. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin Vaccine Immunol. 2010 Mar;17(3):317-24. doi: 10.1128/CVI.00322-09. Epub 2010 Jan 27.";Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.;"Mielcarek N; Debrie AS; Mahieux S; Locht C";10.1128/CVI.00322-09;2010/03/01 00:00;['Journal Article']
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;24950361;BACKGROUND;"Feunou PF, Kammoun H, Debrie AS, Locht C. Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice. Vaccine. 2014 Jul 23;32(34):4281-8. doi: 10.1016/j.vaccine.2014.06.019. Epub 2014 Jun 17.";Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice.;"Feunou PF; Kammoun H; Debrie AS; Locht C";10.1016/j.vaccine.2014.06.019;2014/07/23 00:00;['Journal Article']
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;31945015;DERIVED;"Lin A, Apostolovic D, Jahnmatz M, Liang F, Ols S, Tecleab T, Wu C, van Hage M, Solovay K, Rubin K, Locht C, Thorstensson R, Thalen M, Lore K. Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans. J Clin Invest. 2020 May 1;130(5):2332-2346. doi: 10.1172/JCI135020.";Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans.;"Lin A; Apostolovic D; Jahnmatz M; Liang F; Ols S; Tecleab T; Wu C; van Hage M; Solovay K; Rubin K; Locht C; Thorstensson R; Thalen M; Loré K";10.1172/JCI135020;2020/05/01 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;24421886;BACKGROUND;"Thorstensson R, Trollfors B, Al-Tawil N, Jahnmatz M, Bergstrom J, Ljungman M, Torner A, Wehlin L, Van Broekhoven A, Bosman F, Debrie AS, Mielcarek N, Locht C. A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One. 2014 Jan 8;9(1):e83449. doi: 10.1371/journal.pone.0083449. eCollection 2014.";"A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers.";"Thorstensson R; Trollfors B; Al-Tawil N; Jahnmatz M; Bergström J; Ljungman M; Törner A; Wehlin L; Van Broekhoven A; Bosman F; Debrie AS; Mielcarek N; Locht C";10.1371/journal.pone.0083449;2014/01/08 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;21430219;BACKGROUND;"Fedele G, Bianco M, Debrie AS, Locht C, Ausiello CM. Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response. J Immunol. 2011 May 1;186(9):5388-96. doi: 10.4049/jimmunol.1003765. Epub 2011 Mar 23.";Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response.;"Fedele G; Bianco M; Debrie AS; Locht C; Ausiello CM";10.4049/jimmunol.1003765;2011/05/01 00:00;['Journal Article']
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;20419113;BACKGROUND;"Feunou PF, Bertout J, Locht C. T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis. PLoS One. 2010 Apr 15;5(4):e10178. doi: 10.1371/journal.pone.0010178.";T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis.;"Feunou PF; Bertout J; Locht C";10.1371/journal.pone.0010178;2010/04/15 00:00;['Journal Article']
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;20708998;BACKGROUND;"Feunou PF, Kammoun H, Debrie AS, Mielcarek N, Locht C. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine. 2010 Oct 8;28(43):7047-53. doi: 10.1016/j.vaccine.2010.08.017. Epub 2010 Aug 13.";Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.;"Feunou PF; Kammoun H; Debrie AS; Mielcarek N; Locht C";10.1016/j.vaccine.2010.08.017;2010/10/08 00:00;['Journal Article']
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;32687804;DERIVED;"Jahnmatz M, Richert L, Al-Tawil N, Storsaeter J, Colin C, Bauduin C, Thalen M, Solovay K, Rubin K, Mielcarek N, Thorstensson R, Locht C; BPZE1 study team. Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study. Lancet Infect Dis. 2020 Nov;20(11):1290-1301. doi: 10.1016/S1473-3099(20)30274-7. Epub 2020 Jul 17. Erratum In: Lancet Infect Dis. 2020 Sep;20(9):e215.";Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study.;"Jahnmatz M; Richert L; Al-Tawil N; Storsaeter J; Colin C; Bauduin C; Thalen M; Solovay K; Rubin K; Mielcarek N; Thorstensson R; Locht C; BPZE1 study team";10.1016/S1473-3099(20)30274-7;2020/11/01 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;24793938;BACKGROUND;"Jahnmatz M, Amu S, Ljungman M, Wehlin L, Chiodi F, Mielcarek N, Locht C, Thorstensson R. B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial. Vaccine. 2014 Jun 5;32(27):3350-6. doi: 10.1016/j.vaccine.2014.04.048. Epub 2014 Apr 29.";B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial.;"Jahnmatz M; Amu S; Ljungman M; Wehlin L; Chiodi F; Mielcarek N; Locht C; Thorstensson R";10.1016/j.vaccine.2014.04.048;2014/06/05 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT05040048;Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease;Institut National de la Santé Et de la Recherche Médicale, France;Innovative Medicines Initiative | Institut d'Investigacions Biomèdiques August Pi i Sunyer | ICM Co. Ltd. | University Hospital, Bonn | Karolinska Institutet;COMPLETED;OBSERVATIONAL;False;2021-09-10;2015-09-04;2018-02;;;;;;;;
NCT03459157;Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP);ANRS, Emerging Infectious Diseases;Expertise France | Université Montpellier | SESSTIM (IRD, Inserm, Université Aix-Marseille) | Coalition Internationale Sida | Institut de Médecine Tropicale, Anvers, Belgique | ARCAD-SIDA MALI | Association African Solidarité | Centre de Recherche Internationale pour la Santé, Université de Ouagadougou | Espace Confiance, Côte d'Ivoire | Espoir Vie-Togo - ONG | Laboratoire BIOLIM, Université de Lomé;COMPLETED;INTERVENTIONAL;False;2018-03-08;2017-11-20;2021-06-30;34048794;DERIVED;"Laurent C, Dembele Keita B, Yaya I, Le Guicher G, Sagaon-Teyssier L, Agboyibor MK, Coulibaly A, Traore I, Malan JB, De Baetselier I, Eubanks A, Riegel L, Rojas Castro D, Faye-Kette H, Kone A, Diande S, Dagnra CA, Serrano L, Diallo F, Mensah E, Dah TTE, Anoma C, Vuylsteke B, Spire B; CohMSM-PrEP Study Group. HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study. Lancet HIV. 2021 Jul;8(7):e420-e428. doi: 10.1016/S2352-3018(21)00005-9. Epub 2021 May 25.";HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study.;"Laurent C; Dembélé Keita B; Yaya I; Le Guicher G; Sagaon-Teyssier L; Agboyibor MK; Coulibaly A; Traoré I; Malan JB; De Baetselier I; Eubanks A; Riegel L; Rojas Castro D; Fayé-Ketté H; Koné A; Diandé S; Dagnra CA; Serrano L; Diallo F; Mensah E; Dah TTE; Anoma C; Vuylsteke B; Spire B; CohMSM-PrEP Study Group";10.1016/S2352-3018(21)00005-9;2021/07/01 00:00;['Journal Article']
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;28612212;RESULT;"Duong HT, Jarlais DD, Khuat OHT, Arasteh K, Feelemyer J, Khue PM, Giang HT, Laureillard D, Hai VV, Vallo R, Michel L, Moles JP, Nagot N; Drive Study Group. Risk Behaviors for HIV and HCV Infection Among People Who Inject Drugs in Hai Phong, Viet Nam, 2014. AIDS Behav. 2018 Jul;22(7):2161-2171. doi: 10.1007/s10461-017-1814-6.";Risk Behaviors for HIV and HCV Infection Among People Who Inject Drugs in Hai Phong, Viet Nam, 2014.;"Duong HT; Jarlais DD; Khuat OHT; Arasteh K; Feelemyer J; Khue PM; Giang HT; Laureillard D; Hai VV; Vallo R; Michel L; Moles JP; Nagot N; Drive Study Group";10.1007/s10461-017-1814-6;2018/07/01 00:00;['Journal Article']
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;26050614;BACKGROUND;"Perlman DC, Jordan AE, Uuskula A, Huong DT, Masson CL, Schackman BR, Des Jarlais DC. An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. Int J Drug Policy. 2015 Nov;26(11):1056-63. doi: 10.1016/j.drugpo.2015.04.015. Epub 2015 Apr 27.";An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential.;"Perlman DC; Jordan AE; Uuskula A; Huong DT; Masson CL; Schackman BR; Des Jarlais DC";10.1016/j.drugpo.2015.04.015;2015/11/01 00:00;['Journal Article']
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;28800503;RESULT;"Michel L, Des Jarlais DC, Duong Thi H, Khuat Thi Hai O, Pham Minh K, Peries M, Vallo R, Nham Thi Tuyet T, Hoang Thi G, Le Sao M, Feelemyer J, Vu Hai V, Moles JP, Laureillard D, Nagot N; DRIVE Study Team. Intravenous heroin use in Haiphong, Vietnam: Need for comprehensive care including methamphetamine use-related interventions. Drug Alcohol Depend. 2017 Oct 1;179:198-204. doi: 10.1016/j.drugalcdep.2017.07.004. Epub 2017 Aug 2.";Intravenous heroin use in Haiphong, Vietnam: Need for comprehensive care including methamphetamine use-related interventions.;"Michel L; Des Jarlais DC; Duong Thi H; Khuat Thi Hai O; Pham Minh K; Peries M; Vallo R; Nham Thi Tuyet T; Hoang Thi G; Le Sao M; Feelemyer J; Vu Hai V; Moles JP; Laureillard D; Nagot N; DRIVE Study Team";10.1016/j.drugalcdep.2017.07.004;2017/10/01 00:00;['Journal Article']
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;25540950;BACKGROUND;"Des Jarlais DC. AIDS, people who use drugs, and altruism: reflection on a personal image. Subst Use Misuse. 2015 Mar;50(4):532-3. doi: 10.3109/10826084.2015.978185. Epub 2014 Dec 26. No abstract available.";AIDS, people who use drugs, and altruism: reflection on a personal image.;Des Jarlais DC;10.3109/10826084.2015.978185;2015/03/01 00:00;['Journal Article']
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;26075647;BACKGROUND;"Perlman DC, Des Jarlais DC, Feelemyer J. Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs? J Addict Dis. 2015;34(2-3):198-205. doi: 10.1080/10550887.2015.1059111.";Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs?;"Perlman DC; Des Jarlais DC; Feelemyer J";10.1080/10550887.2015.1059111;2015/01/01 00:00;['Journal Article']
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;26032121;BACKGROUND;"Hatzakis A, Sypsa V, Paraskevis D, Nikolopoulos G, Tsiara C, Micha K, Panopoulos A, Malliori M, Psichogiou M, Pharris A, Wiessing L, van de Laar M, Donoghoe M, Heckathorn DD, Friedman SR, Des Jarlais DC. Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme. Addiction. 2015 Sep;110(9):1453-67. doi: 10.1111/add.12999. Epub 2015 Jul 14.";Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme.;"Hatzakis A; Sypsa V; Paraskevis D; Nikolopoulos G; Tsiara C; Micha K; Panopoulos A; Malliori M; Psichogiou M; Pharris A; Wiessing L; van de Laar M; Donoghoe M; Heckathorn DD; Friedman SR; Des Jarlais DC";10.1111/add.12999;2015/09/01 00:00;['Journal Article']
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;27178119;RESULT;"Des Jarlais D, Duong HT, Pham Minh K, Khuat OH, Nham TT, Arasteh K, Feelemyer J, Heckathorn DD, Peries M, Moles JP, Laureillard D, Nagot N; (The Drive Study Team). Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions. AIDS Care. 2016 Oct;28(10):1312-5. doi: 10.1080/09540121.2016.1178698. Epub 2016 May 13.";Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.;"Des Jarlais D; Duong HT; Pham Minh K; Khuat OH; Nham TT; Arasteh K; Feelemyer J; Heckathorn DD; Peries M; Moles JP; Laureillard D; Nagot N; (The Drive Study Team)";10.1080/09540121.2016.1178698;2016/10/01 00:00;['Journal Article']
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;27006257;RESULT;"Des Jarlais DC, Thi Huong D, Thi Hai Oanh K, Khue Pham M, Thi Giang H, Thi Tuyet Thanh N, Arasteh K, Feelemyer J, Hammett T, Peries M, Michel L, Vu Hai V, Roustide MJ, Moles JP, Laureillard D, Nagot N; DRIVE Study Team. Prospects for ending the HIV epidemic among persons who inject drugs in Haiphong, Vietnam. Int J Drug Policy. 2016 Jun;32:50-6. doi: 10.1016/j.drugpo.2016.02.021. Epub 2016 Feb 27.";Prospects for ending the HIV epidemic among persons who inject drugs in Haiphong, Vietnam.;"Des Jarlais DC; Thi Huong D; Thi Hai Oanh K; Khuê Pham M; Thi Giang H; Thi Tuyet Thanh N; Arasteh K; Feelemyer J; Hammett T; Peries M; Michel L; Vu Hai V; Roustide MJ; Moles JP; Laureillard D; Nagot N; DRIVE Study Team";10.1016/j.drugpo.2016.02.021;2016/06/01 00:00;['Journal Article']
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;26080690;BACKGROUND;"Elliott JC, Hasin DS, Stohl M, Des Jarlais DC. HIV, Hepatitis C, and Abstinence from Alcohol Among Injection and Non-injection Drug Users. AIDS Behav. 2016 Mar;20(3):548-54. doi: 10.1007/s10461-015-1113-z.";HIV, Hepatitis C, and Abstinence from Alcohol Among Injection and Non-injection Drug Users.;"Elliott JC; Hasin DS; Stohl M; Des Jarlais DC";10.1007/s10461-015-1113-z;2016/03/01 00:00;['Journal Article']
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;15313841;RESULT;"Stevanin G, Hahn V, Lohmann E, Bouslam N, Gouttard M, Soumphonphakdy C, Welter ML, Ollagnon-Roman E, Lemainque A, Ruberg M, Brice A, Durr A. Mutation in the catalytic domain of protein kinase C gamma and extension of the phenotype associated with spinocerebellar ataxia type 14. Arch Neurol. 2004 Aug;61(8):1242-8. doi: 10.1001/archneur.61.8.1242.";Mutation in the catalytic domain of protein kinase C gamma and extension of the phenotype associated with spinocerebellar ataxia type 14.;"Stevanin G; Hahn V; Lohmann E; Bouslam N; Gouttard M; Soumphonphakdy C; Welter ML; Ollagnon-Roman E; Lemainque A; Ruberg M; Brice A; Durr A";10.1001/archneur.61.8.1242;2004/08/01 00:00;['Journal Article']
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;18378516;RESULT;"du Montcel ST, Charles P, Ribai P, Goizet C, Le Bayon A, Labauge P, Guyant-Marechal L, Forlani S, Jauffret C, Vandenberghe N, N'guyen K, Le Ber I, Devos D, Vincitorio CM, Manto MU, Tison F, Hannequin D, Ruberg M, Brice A, Durr A. Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment. Brain. 2008 May;131(Pt 5):1352-61. doi: 10.1093/brain/awn059. Epub 2008 Mar 31.";Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment.;"du Montcel ST; Charles P; Ribai P; Goizet C; Le Bayon A; Labauge P; Guyant-Maréchal L; Forlani S; Jauffret C; Vandenberghe N; N'guyen K; Le Ber I; Devos D; Vincitorio CM; Manto MU; Tison F; Hannequin D; Ruberg M; Brice A; Durr A";10.1093/brain/awn059;2008/05/01 00:00;['Journal Article', 'Multicenter Study']
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;17098887;RESULT;"Depienne C, Fedirko E, Forlani S, Cazeneuve C, Ribai P, Feki I, Tallaksen C, Nguyen K, Stankoff B, Ruberg M, Stevanin G, Durr A, Brice A. Exon deletions of SPG4 are a frequent cause of hereditary spastic paraplegia. J Med Genet. 2007 Apr;44(4):281-4. doi: 10.1136/jmg.2006.046425. Epub 2006 Nov 10.";Exon deletions of SPG4 are a frequent cause of hereditary spastic paraplegia.;"Depienne C; Fedirko E; Forlani S; Cazeneuve C; Ribaï P; Feki I; Tallaksen C; Nguyen K; Stankoff B; Ruberg M; Stevanin G; Durr A; Brice A";10.1136/jmg.2006.046425;2007/04/01 00:00;['Letter']
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;17957230;RESULT;"Ribai P, Depienne C, Fedirko E, Jothy AC, Viveweger C, Hahn-Barma V, Brice A, Durr A. Mental deficiency in three families with SPG4 spastic paraplegia. Eur J Hum Genet. 2008 Jan;16(1):97-104. doi: 10.1038/sj.ejhg.5201922. Epub 2007 Oct 24.";Mental deficiency in three families with SPG4 spastic paraplegia.;"Ribaï P; Depienne C; Fedirko E; Jothy AC; Viveweger C; Hahn-Barma V; Brice A; Durr A";10.1038/sj.ejhg.5201922;2008/01/01 00:00;['Journal Article']
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;17597328;RESULT;"Depienne C, Fedirko E, Faucheux JM, Forlani S, Bricka B, Goizet C, Lesourd S, Stevanin G, Ruberg M, Durr A, Brice A. A de novo SPAST mutation leading to somatic mosaicism is associated with a later age at onset in HSP. Neurogenetics. 2007 Aug;8(3):231-3. doi: 10.1007/s10048-007-0090-4. Epub 2007 Jun 28.";A de novo SPAST mutation leading to somatic mosaicism is associated with a later age at onset in HSP.;"Depienne C; Fedirko E; Faucheux JM; Forlani S; Bricka B; Goizet C; Lesourd S; Stevanin G; Ruberg M; Durr A; Brice A";10.1007/s10048-007-0090-4;2007/08/01 00:00;['Letter']
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;16193476;RESULT;"Klebe S, Durr A, Rentschler A, Hahn-Barma V, Abele M, Bouslam N, Schols L, Jedynak P, Forlani S, Denis E, Dussert C, Agid Y, Bauer P, Globas C, Wullner U, Brice A, Riess O, Stevanin G. New mutations in protein kinase Cgamma associated with spinocerebellar ataxia type 14. Ann Neurol. 2005 Nov;58(5):720-9. doi: 10.1002/ana.20628.";New mutations in protein kinase Cgamma associated with spinocerebellar ataxia type 14.;"Klebe S; Durr A; Rentschler A; Hahn-Barma V; Abele M; Bouslam N; Schöls L; Jedynak P; Forlani S; Denis E; Dussert C; Agid Y; Bauer P; Globas C; Wüllner U; Brice A; Riess O; Stevanin G";10.1002/ana.20628;2005/11/01 00:00;['Journal Article']
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;16501573;RESULT;"Waters MF, Minassian NA, Stevanin G, Figueroa KP, Bannister JP, Nolte D, Mock AF, Evidente VG, Fee DB, Muller U, Durr A, Brice A, Papazian DM, Pulst SM. Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes. Nat Genet. 2006 Apr;38(4):447-51. doi: 10.1038/ng1758. Epub 2006 Feb 26.";Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes.;"Waters MF; Minassian NA; Stevanin G; Figueroa KP; Bannister JP; Nolte D; Mock AF; Evidente VG; Fee DB; Müller U; Dürr A; Brice A; Papazian DM; Pulst SM";10.1038/ng1758;2006/04/01 00:00;['Journal Article']
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;24780882;DERIVED;"Tezenas du Montcel S, Durr A, Rakowicz M, Nanetti L, Charles P, Sulek A, Mariotti C, Rola R, Schols L, Bauer P, Dufaure-Gare I, Jacobi H, Forlani S, Schmitz-Hubsch T, Filla A, Timmann D, van de Warrenburg BP, Marelli C, Kang JS, Giunti P, Cook A, Baliko L, Melegh B, Boesch S, Szymanski S, Berciano J, Infante J, Buerk K, Masciullo M, Di Fabio R, Depondt C, Ratka S, Stevanin G, Klockgether T, Brice A, Golmard JL. Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6. J Med Genet. 2014 Jul;51(7):479-86. doi: 10.1136/jmedgenet-2013-102200. Epub 2014 Apr 29. Erratum In: J Med Genet. 2014 Sep;51(9):613. Bela, Melegh [corrected to Melegh, Bela].";Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6.;"Tezenas du Montcel S; Durr A; Rakowicz M; Nanetti L; Charles P; Sulek A; Mariotti C; Rola R; Schols L; Bauer P; Dufaure-Garé I; Jacobi H; Forlani S; Schmitz-Hübsch T; Filla A; Timmann D; van de Warrenburg BP; Marelli C; Kang JS; Giunti P; Cook A; Baliko L; Melegh B; Boesch S; Szymanski S; Berciano J; Infante J; Buerk K; Masciullo M; Di Fabio R; Depondt C; Ratka S; Stevanin G; Klockgether T; Brice A; Golmard JL";10.1136/jmedgenet-2013-102200;2014/07/01 00:00;['Journal Article']
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;15365159;RESULT;"Stevanin G, Durr A, Dussert C, Penet C, Brice A. Mutations in the FGF14 gene are not a major cause of spinocerebellar ataxia in Caucasians. Neurology. 2004 Sep 14;63(5):936. doi: 10.1212/01.wnl.0000137020.30604.1e. No abstract available.";Mutations in the FGF14 gene are not a major cause of spinocerebellar ataxia in Caucasians.;"Stevanin G; Durr A; Dussert C; Penet C; Brice A";10.1212/01.wnl.0000137020.30604.1e;2004/09/14 00:00;['Journal Article']
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;17605047;RESULT;"Hanein S, Durr A, Ribai P, Forlani S, Leutenegger AL, Nelson I, Babron MC, Elleuch N, Depienne C, Charon C, Brice A, Stevanin G. A novel locus for autosomal dominant ""uncomplicated"" hereditary spastic paraplegia maps to chromosome 8p21.1-q13.3. Hum Genet. 2007 Nov;122(3-4):261-73. doi: 10.1007/s00439-007-0396-1. Epub 2007 Jun 28.";"A novel locus for autosomal dominant ""uncomplicated"" hereditary spastic paraplegia maps to chromosome 8p21.1-q13.3.";"Hanein S; Dürr A; Ribai P; Forlani S; Leutenegger AL; Nelson I; Babron MC; Elleuch N; Depienne C; Charon C; Brice A; Stevanin G";10.1007/s00439-007-0396-1;2007/11/01 00:00;['Journal Article']
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;22491195;DERIVED;"Tezenas du Montcel S, Charles P, Goizet C, Marelli C, Ribai P, Vincitorio C, Anheim M, Guyant-Marechal L, Le Bayon A, Vandenberghe N, Tchikviladze M, Devos D, Le Ber I, N'Guyen K, Cazeneuve C, Tallaksen C, Brice A, Durr A. Factors influencing disease progression in autosomal dominant cerebellar ataxia and spastic paraplegia. Arch Neurol. 2012 Apr;69(4):500-8. doi: 10.1001/archneurol.2011.2713.";Factors influencing disease progression in autosomal dominant cerebellar ataxia and spastic paraplegia.;"Tezenas du Montcel S; Charles P; Goizet C; Marelli C; Ribai P; Vincitorio C; Anheim M; Guyant-Maréchal L; Le Bayon A; Vandenberghe N; Tchikviladzé M; Devos D; Le Ber I; N'Guyen K; Cazeneuve C; Tallaksen C; Brice A; Durr A";10.1001/archneurol.2011.2713;2012/04/01 00:00;['Journal Article', 'Multicenter Study']
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;18853458;RESULT;"Goizet C, Boukhris A, Mundwiller E, Tallaksen C, Forlani S, Toutain A, Carriere N, Paquis V, Depienne C, Durr A, Stevanin G, Brice A. Complicated forms of autosomal dominant hereditary spastic paraplegia are frequent in SPG10. Hum Mutat. 2009 Feb;30(2):E376-85. doi: 10.1002/humu.20920.";Complicated forms of autosomal dominant hereditary spastic paraplegia are frequent in SPG10.;"Goizet C; Boukhris A; Mundwiller E; Tallaksen C; Forlani S; Toutain A; Carriere N; Paquis V; Depienne C; Durr A; Stevanin G; Brice A";10.1002/humu.20920;2009/02/01 00:00;['Journal Article']
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;16055926;RESULT;"Depienne C, Tallaksen C, Lephay JY, Bricka B, Poea-Guyon S, Fontaine B, Labauge P, Brice A, Durr A. Spastin mutations are frequent in sporadic spastic paraparesis and their spectrum is different from that observed in familial cases. J Med Genet. 2006 Mar;43(3):259-65. doi: 10.1136/jmg.2005.035311. Epub 2005 Jul 31.";Spastin mutations are frequent in sporadic spastic paraparesis and their spectrum is different from that observed in familial cases.;"Depienne C; Tallaksen C; Lephay JY; Bricka B; Poea-Guyon S; Fontaine B; Labauge P; Brice A; Durr A";10.1136/jmg.2005.035311;2006/03/01 00:00;['Letter']
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;31995857;RESULT;"Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.";Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.;"Li Q; Guan X; Wu P; Wang X; Zhou L; Tong Y; Ren R; Leung KSM; Lau EHY; Wong JY; Xing X; Xiang N; Wu Y; Li C; Chen Q; Li D; Liu T; Zhao J; Liu M; Tu W; Chen C; Jin L; Yang R; Wang Q; Zhou S; Wang R; Liu H; Luo Y; Liu Y; Shao G; Li H; Tao Z; Yang Y; Deng Z; Liu B; Ma Z; Zhang Y; Shi G; Lam TTY; Wu JT; Gao GF; Cowling BJ; Yang B; Leung GM; Feng Z";10.1056/NEJMoa2001316;2020/03/26 00:00;['Journal Article']
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32109013;RESULT;"Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.";Clinical Characteristics of Coronavirus Disease 2019 in China.;"Guan WJ; Ni ZY; Hu Y; Liang WH; Ou CQ; He JX; Liu L; Shan H; Lei CL; Hui DSC; Du B; Li LJ; Zeng G; Yuen KY; Chen RC; Tang CL; Wang T; Chen PY; Xiang J; Li SY; Wang JL; Liang ZJ; Peng YX; Wei L; Liu Y; Hu YH; Peng P; Wang JM; Liu JY; Chen Z; Li G; Zheng ZJ; Qiu SQ; Luo J; Ye CJ; Zhu SY; Zhong NS; China Medical Treatment Expert Group for Covid-19";10.1056/NEJMoa2002032;2020/04/30 00:00;['Journal Article']
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32224310;RESULT;"Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, Gaymard A, Bouscambert-Duchamp M, Donati F, Le Hingrat Q, Enouf V, Houhou-Fidouh N, Valette M, Mailles A, Lucet JC, Mentre F, Duval X, Descamps D, Malvy D, Timsit JF, Lina B, van-der-Werf S, Yazdanpanah Y. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020 Jun;20(6):697-706. doi: 10.1016/S1473-3099(20)30200-0. Epub 2020 Mar 27. Erratum In: Lancet Infect Dis. 2020 May 19;: Lancet Infect Dis. 2020 Jun;20(6):e116.";Clinical and virological data of the first cases of COVID-19 in Europe: a case series.;"Lescure FX; Bouadma L; Nguyen D; Parisey M; Wicky PH; Behillil S; Gaymard A; Bouscambert-Duchamp M; Donati F; Le Hingrat Q; Enouf V; Houhou-Fidouh N; Valette M; Mailles A; Lucet JC; Mentre F; Duval X; Descamps D; Malvy D; Timsit JF; Lina B; van-der-Werf S; Yazdanpanah Y";10.1016/S1473-3099(20)30200-0;2020/06/01 00:00;['Journal Article']
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32070465;RESULT;"Bernard Stoecklin S, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, Mechain M, Meurice L, Nguyen M, Bassi C, Yamani E, Behillil S, Ismael S, Nguyen D, Malvy D, Lescure FX, Georges S, Lazarus C, Tabai A, Stempfelet M, Enouf V, Coignard B, Levy-Bruhl D; Investigation team. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro Surveill. 2020 Feb;25(6):2000094. doi: 10.2807/1560-7917.ES.2020.25.6.2000094.";First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020.;"Bernard Stoecklin S; Rolland P; Silue Y; Mailles A; Campese C; Simondon A; Mechain M; Meurice L; Nguyen M; Bassi C; Yamani E; Behillil S; Ismael S; Nguyen D; Malvy D; Lescure FX; Georges S; Lazarus C; Tabaï A; Stempfelet M; Enouf V; Coignard B; Levy-Bruhl D; Investigation team";10.2807/1560-7917.ES.2020.25.6.2000094;2020/02/01 00:00;['Journal Article']
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;31978945;RESULT;"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.";A Novel Coronavirus from Patients with Pneumonia in China, 2019.;"Zhu N; Zhang D; Wang W; Li X; Yang B; Song J; Zhao X; Huang B; Shi W; Lu R; Niu P; Zhan F; Ma X; Wang D; Xu W; Wu G; Gao GF; Tan W; China Novel Coronavirus Investigating and Research Team";10.1056/NEJMoa2001017;2020/02/20 00:00;['Journal Article']
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32046819;RESULT;"Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill. 2020 Feb;25(5):2000062. doi: 10.2807/1560-7917.ES.2020.25.5.2000062.";Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020.;"Backer JA; Klinkenberg D; Wallinga J";10.2807/1560-7917.ES.2020.25.5.2000062;2020/02/01 00:00;['Journal Article']
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32371096;RESULT;"Deslandes A, Berti V, Tandjaoui-Lambotte Y, Alloui C, Carbonnelle E, Zahar JR, Brichler S, Cohen Y. SARS-CoV-2 was already spreading in France in late December 2019. Int J Antimicrob Agents. 2020 Jun;55(6):106006. doi: 10.1016/j.ijantimicag.2020.106006. Epub 2020 May 3.";SARS-CoV-2 was already spreading in France in late December 2019.;"Deslandes A; Berti V; Tandjaoui-Lambotte Y; Alloui C; Carbonnelle E; Zahar JR; Brichler S; Cohen Y";10.1016/j.ijantimicag.2020.106006;2020/06/01 00:00;['Journal Article']
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32338732;RESULT;"Baggett TP, Keyes H, Sporn N, Gaeta JM. Prevalence of SARS-CoV-2 Infection in Residents of a Large Homeless Shelter in Boston. JAMA. 2020 Jun 2;323(21):2191-2192. doi: 10.1001/jama.2020.6887.";Prevalence of SARS-CoV-2 Infection in Residents of a Large Homeless Shelter in Boston.;"Baggett TP; Keyes H; Sporn N; Gaeta JM";10.1001/jama.2020.6887;2020/06/02 00:00;['Journal Article']
NCT02592174;Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2015-10-30;2016-01-26;2017-10-27;31755936;DERIVED;"Makinson A, Dubois J, Eymard-Duvernay S, Leclercq P, Zaegel-Faucher O, Bernard L, Vassallo M, Barbuat C, Geny C, Thouvenot E, Costagliola D, Ozguler A, Zins M, Simony M, Reynes J, Berr C. Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55-70 Study. Clin Infect Dis. 2020 Jun 10;70(12):2641-2648. doi: 10.1093/cid/ciz670.";Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55-70 Study.;"Makinson A; Dubois J; Eymard-Duvernay S; Leclercq P; Zaegel-Faucher O; Bernard L; Vassallo M; Barbuat C; Gény C; Thouvenot E; Costagliola D; Ozguler A; Zins M; Simony M; Reynes J; Berr C";10.1093/cid/ciz670;2020/06/10 00:00;['Journal Article']
NCT02650427;A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-01-08;2016-02;2018-09;;;;;;;;
NCT02099474;Evaluation of Raltegravir During the Third Trimester of Pregnancy;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-03-31;2014-06-30;2017-04;32661003;DERIVED;"Zheng Y, Hirt D, Delmas S, Lui G, Benaboud S, Lechedanec J, Treluyer JM, Chenevier-Gobeaux C, Arezes E, Gelley A, Amri I, Urien S, Bouazza N, Foissac F, Warszawski J, Ghosn J. Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial. Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00759-20. doi: 10.1128/AAC.00759-20. Print 2020 Sep 21.";Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial.;"Zheng Y; Hirt D; Delmas S; Lui G; Benaboud S; Lechedanec J; Tréluyer JM; Chenevier-Gobeaux C; Arezes E; Gelley A; Amri I; Urien S; Bouazza N; Foissac F; Warszawski J; Ghosn J";10.1128/AAC.00759-20;2020/09/21 00:00;['Journal Article', 'Multicenter Study']
NCT04133012;Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone;ANRS, Emerging Infectious Diseases;ViiV Healthcare;COMPLETED;INTERVENTIONAL;False;2019-10-21;2020-02-10;2023-06-09;;;;;;;;
NCT02078076;IRM Cardiaque en Respiration Libre Pour Des Patients Atteints de Dystrophinopathie sévère;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-03-05;2013-06;2015-11;;;;;;;;
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;27537841;BACKGROUND;"Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL; C-EDGE CO-STAR Study Group. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Ann Intern Med. 2016 Nov 1;165(9):625-634. doi: 10.7326/M16-0816. Epub 2016 Aug 9.";Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.;"Dore GJ; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Grebely J; Howe AY; Gendrano IN; Chen E; Huang HC; Dutko FJ; Nickle DC; Nguyen BY; Wahl J; Barr E; Robertson MN; Platt HL; C-EDGE CO-STAR Study Group";10.7326/M16-0816;2016/11/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;22310560;BACKGROUND;"Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812.";Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact.;"Curran GM; Bauer M; Mittman B; Pyne JM; Stetler C";10.1097/MLR.0b013e3182408812;2012/03/01 00:00;['Journal Article']
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;29432973;BACKGROUND;"Des Jarlais D, Khue PM, Feelemyer J, Arasteh K, Thi Huong D, Thi Hai Oanh K, Thi Giang H, Thi Tuyet Thanh N, Vinh VH, Heckathorn DD, Moles JP, Vallo R, Quillet C, Rapoud D, Michel L, Laureillard D, Hammett T, Nagot N. Using dual capture/recapture studies to estimate the population size of persons who inject drugs (PWID) in the city of Hai Phong, Vietnam. Drug Alcohol Depend. 2018 Apr 1;185:106-111. doi: 10.1016/j.drugalcdep.2017.11.033. Epub 2018 Feb 2.";Using dual capture/recapture studies to estimate the population size of persons who inject drugs (PWID) in the city of Hai Phong, Vietnam.;"Des Jarlais D; Khue PM; Feelemyer J; Arasteh K; Thi Huong D; Thi Hai Oanh K; Thi Giang H; Thi Tuyet Thanh N; Vinh VH; Heckathorn DD; Moles JP; Vallo R; Quillet C; Rapoud D; Michel L; Laureillard D; Hammett T; Nagot N";10.1016/j.drugalcdep.2017.11.033;2018/04/01 00:00;['Journal Article']
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;35774932;DERIVED;"Nagot N, D'Ottavi M, Quillet C, Debellefontaine A, Castellani J, Langendorfer N, Hanslik B, Guichard S, Baglioni R, Faucherre V, Tuaillon E, Pageaux GP, Laureillard D, Donnadieu-Rigole H. Reaching Hard-to-Reach People Who Use Drugs: A Community-Based Strategy for the Elimination of Hepatitis C. Open Forum Infect Dis. 2022 Apr 14;9(6):ofac181. doi: 10.1093/ofid/ofac181. eCollection 2022 Jun.";Reaching Hard-to-Reach People Who Use Drugs: A Community-Based Strategy for the Elimination of Hepatitis C.;"Nagot N; D'Ottavi M; Quillet C; Debellefontaine A; Castellani J; Langendorfer N; Hanslik B; Guichard S; Baglioni R; Faucherre V; Tuaillon E; Pageaux GP; Laureillard D; Donnadieu-Rigole H";10.1093/ofid/ofac181;2022/04/14 00:00;['Journal Article']
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;28004616;BACKGROUND;"Leon L, Kasereka S, Barin F, Larsen C, Weill-Barillet L, Pascal X, Chevaliez S, Pillonel J, Jauffret-Roustide M, LE Strat Y. Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys. Epidemiol Infect. 2017 Apr;145(5):895-907. doi: 10.1017/S0950268816002934. Epub 2016 Dec 22.";Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys.;"Leon L; Kasereka S; Barin F; Larsen C; Weill-Barillet L; Pascal X; Chevaliez S; Pillonel J; Jauffret-Roustide M; LE Strat Y";10.1017/S0950268816002934;2017/04/01 00:00;['Journal Article']
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;27178119;BACKGROUND;"Des Jarlais D, Duong HT, Pham Minh K, Khuat OH, Nham TT, Arasteh K, Feelemyer J, Heckathorn DD, Peries M, Moles JP, Laureillard D, Nagot N; (The Drive Study Team). Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions. AIDS Care. 2016 Oct;28(10):1312-5. doi: 10.1080/09540121.2016.1178698. Epub 2016 May 13.";Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.;"Des Jarlais D; Duong HT; Pham Minh K; Khuat OH; Nham TT; Arasteh K; Feelemyer J; Heckathorn DD; Peries M; Moles JP; Laureillard D; Nagot N; (The Drive Study Team)";10.1080/09540121.2016.1178698;2016/10/01 00:00;['Journal Article']
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;27168667;BACKGROUND;"Blackburn NA, Patel RC, Zibbell JE. Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012-2014. Public Health Rep. 2016 May-Jun;131 Suppl 2(Suppl 2):91-7. doi: 10.1177/00333549161310S214.";Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012-2014.;"Blackburn NA; Patel RC; Zibbell JE";10.1177/00333549161310S214;2016/05/01 00:00;['Journal Article']
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;26806260;BACKGROUND;"Chevaliez S, Poiteau L, Rosa I, Soulier A, Roudot-Thoraval F, Laperche S, Hezode C, Pawlotsky JM. Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care. Clin Microbiol Infect. 2016 May;22(5):459.e1-6. doi: 10.1016/j.cmi.2016.01.009. Epub 2016 Jan 22.";Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care.;"Chevaliez S; Poiteau L; Rosa I; Soulier A; Roudot-Thoraval F; Laperche S; Hézode C; Pawlotsky JM";10.1016/j.cmi.2016.01.009;2016/05/01 00:00;['Journal Article']
NCT01022476;Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2009-12-01;2010-05;2013-05;;;;;;;;
NCT00670839;Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST);ANRS, Emerging Infectious Diseases;MCM Vaccines B.V.;COMPLETED;INTERVENTIONAL;False;2008-05-02;2008-05;2013-02;26257021;DERIVED;"Rey D, Piroth L, Wendling MJ, Miailhes P, Michel ML, Dufour C, Haour G, Sogni P, Rohel A, Ajana F, Billaud E, Molina JM, Launay O, Carrat F; ANRS HB04 B-BOOST study group. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis. 2015 Nov;15(11):1283-91. doi: 10.1016/S1473-3099(15)00220-0. Epub 2015 Aug 6.";Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial.;"Rey D; Piroth L; Wendling MJ; Miailhes P; Michel ML; Dufour C; Haour G; Sogni P; Rohel A; Ajana F; Billaud E; Molina JM; Launay O; Carrat F; ANRS HB04 B-BOOST study group";10.1016/S1473-3099(15)00220-0;2015/11/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT02886416;Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular Immunity;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2016-09-01;2016-08;2017-04;;;;;;;;
NCT01693848;"""Cancersensor"" Metastasis Resection";Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-09-26;2012-09;2014-11;;;;;;;;
NCT03446430;Validation of Laser Doppler Vibrometer (LDV) for Measurement of Arterial Stiffness in Hypertensive Patients;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2018-02-26;2018-06-21;2018-12-04;;;;;;;;
NCT01579435;Experimental Therapeutics in Essential Tremor Using Transcranial Direct Current Stimulation;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-04-18;2012-04;2013-04;;;;;;;;
NCT01713335;Proteasis Evaluation in COPD;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-10-24;2012-10-18;2017-04;;;;;;;;
NCT06260319;Decoding Developmental Disorders in Humams;Institut National de la Santé Et de la Recherche Médicale, France;Imagine Institute | Commissariat A L'energie Atomique;COMPLETED;OBSERVATIONAL;False;2024-02-15;2019-01-01;2024-01-01;;;;;;;;
NCT04631224;Longitudinal Analysis of Oral Communication in Friedreich's Ataxia;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2020-11-17;2015-02;2017-02;;;;;;;;
NCT01493934;Development of a Fast Measurement Technique of Insulin Resistance in Human;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-16;2010-04;2013-03;;;;;;;;
NCT01801618;National Evaluation of PI-based 2nd Line Efficacy in Cambodia;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2013-03-01;2013-02;2014-12;29662875;PUBMED;;Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study.;"Ségéral O; Nerrienet E; Neth S; Spire B; Khol V; Ferradini L; Sarun S; Mom C; Ngin S; Charpentier C; Men P; Mora M; Mean Chhi V; Ly P; Saphonn V";10.3389/fpubh.2018.00063;2018/03/19 00:00;['Journal Article']
NCT03671291;Missed Opportunities to Pre-exposure Prophylaxis for HIV Infection on Person Newly Diagnosed With HIV;French National Agency for Research on AIDS and Viral Hepatitis;University Hospital, Marseille | University Hospital, Grenoble | Centre Hospitalier Universitaire de Nice | University Hospital, Montpellier | Hospital Purpan | University Hospital, Bordeaux | Hôpital de la Croix-Rousse | Centre Hospitalier Universitaire Dijon | University Hospital of Saint-Etienne | University Hospital, Clermont-Ferrand | Centre Hospitalier Universitaire de Besancon | Tourcoing Hospital | University Hospital, Strasbourg | Nantes University Hospital | Centre Hospitalier Régional d'Orléans | Rennes University Hospital | Saint Antoine University Hospital | Tenon Hospital, Paris | Saint-Louis Hospital, Paris, France | Hôpital Necker-Enfants Malades | Bicetre Hospital | Pitié-Salpêtrière Hospital | Bichat Hospital | University Hospital Center of Martinique;COMPLETED;INTERVENTIONAL;False;2018-09-14;2019-04-03;2021-10-03;;;;;;;;
NCT01882062;Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2013-06-20;2013-05;2013-07;25568297;RESULT;"Adanyeguh IM, Rinaldi D, Henry PG, Caillet S, Valabregue R, Durr A, Mochel F. Triheptanoin improves brain energy metabolism in patients with Huntington disease. Neurology. 2015 Feb 3;84(5):490-5. doi: 10.1212/WNL.0000000000001214. Epub 2015 Jan 7.";Triheptanoin improves brain energy metabolism in patients with Huntington disease.;"Adanyeguh IM; Rinaldi D; Henry PG; Caillet S; Valabregue R; Durr A; Mochel F";10.1212/WNL.0000000000001214;2015/02/03 00:00;['Clinical Trial', 'Journal Article']
NCT04780191;Investigation of Treatment Using the MyoRegulator® Device in Patients With Spasticity in the Lower Limb Due to Stroke;Institut National de la Santé Et de la Recherche Médicale, France;PathMaker Neurosystems Inc.;COMPLETED;INTERVENTIONAL;False;2021-03-03;2018-07-19;2021-01-19;32232101;BACKGROUND;"Paget-Blanc A, Chang JL, Saul M, Lin R, Ahmed Z, Volpe BT. Non-invasive treatment of patients with upper extremity spasticity following stroke using paired trans-spinal and peripheral direct current stimulation. Bioelectron Med. 2019 Jul 23;5:11. doi: 10.1186/s42234-019-0028-9. eCollection 2019.";Non-invasive treatment of patients with upper extremity spasticity following stroke using paired trans-spinal and peripheral direct current stimulation.;"Paget-Blanc A; Chang JL; Saul M; Lin R; Ahmed Z; Volpe BT";10.1186/s42234-019-0028-9;2019/07/23 00:00;['Journal Article']
NCT01335529;Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin;ANRS, Emerging Infectious Diseases;Rennes University Hospital | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2011-04-14;2011-05;2014-05;27077673;DERIVED;"Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, Renault A, Bourliere M, Halfon P, Ghosn J, Alric L, Naqvi A, Carrieri P, Molina JM; ANRS HC27 BOCEPREVIH Study Group. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. HIV Clin Trials. 2016 Mar;17(2):63-71. doi: 10.1080/15284336.2015.1135553. Epub 2016 Feb 11.";Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.;"Poizot-Martin I; Bellissant E; Garraffo R; Colson P; Piroth L; Solas C; Renault A; Bourlière M; Halfon P; Ghosn J; Alric L; Naqvi A; Carrieri P; Molina JM; ANRS HC27 BOCEPREVIH Study Group";10.1080/15284336.2015.1135553;2016/03/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT03109067;Genetic and Metabolism of Post-prandial HDL Particles;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2017-04-12;2011-09-21;2015-11-21;;;;;;;;
NCT02384967;Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2015-03-10;2015-03;2016-10;29905808;DERIVED;"Le MP, Chaix ML, Chevret S, Bertrand J, Raffi F, Gallien S, El Abbassi EMB, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G; ANRS 165 DARULIGHT Study Group. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study. J Antimicrob Chemother. 2018 Aug 1;73(8):2120-2128. doi: 10.1093/jac/dky193.";Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.;"Lê MP; Chaix ML; Chevret S; Bertrand J; Raffi F; Gallien S; El Abbassi EMB; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G; ANRS 165 DARULIGHT Study Group";10.1093/jac/dky193;2018/08/01 00:00;['Journal Article', 'Multicenter Study']
NCT02486731;Hormonal Sensitivity in Patients With Noonan and LEOPARD Syndromes;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2015-07-01;2015-12-16;2018-12;;;;;;;;
NCT01771562;Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2013-01-18;2013-04;2016-04;30081838;DERIVED;"Cames C, Pascal L, Ba A, Mbodj H, Ouattara B, Diallo NF, Msellati P, Mbaye N, Sy Signate H, Blanche S, Diack A; MAGGSEN Cohort Study Group. Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study. BMC Infect Dis. 2018 Aug 6;18(1):374. doi: 10.1186/s12879-018-3282-7.";Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study.;"Cames C; Pascal L; Ba A; Mbodj H; Ouattara B; Diallo NF; Msellati P; Mbaye N; Sy Signate H; Blanche S; Diack A; MAGGSEN Cohort Study Group";10.1186/s12879-018-3282-7;2018/08/06 00:00;['Journal Article']
NCT01771562;Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2013-01-18;2013-04;2016-04;27881690;DERIVED;"Cames C, Varloteaux M, Have NN, Diom AB, Msellati P, Mbaye N, Mbodj H, Sy Signate H, Diack A; ANRS 12279 MAGGSEN Cohort Study Group. Acceptability of Outpatient Ready-To-Use Food-Based Protocols in HIV-Infected Senegalese Children and Adolescents Within the MAGGSEN Cohort Study. Food Nutr Bull. 2017 Mar;38(1):27-36. doi: 10.1177/0379572116679053. Epub 2016 Nov 23.";Acceptability of Outpatient Ready-To-Use Food-Based Protocols in HIV-Infected Senegalese Children and Adolescents Within the MAGGSEN Cohort Study.;"Cames C; Varloteaux M; Have NN; Diom AB; Msellati P; Mbaye N; Mbodj H; Sy Signate H; Diack A; ANRS 12279 MAGGSEN Cohort Study Group";10.1177/0379572116679053;2017/03/01 00:00;['Journal Article']
NCT01453192;Renal Transplantation and Raltegravir in HIV-Infected Patients;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2011-10-17;2011-12;2015-11;30688008;PUBMED;;Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.;"Matignon M; Lelièvre JD; Lahiani A; Abbassi K; Desvaux D; Diallo A; Peraldi MN; Taburet AM; Saillard J; Delaugerre C; Costagliola D; Assoumou L; Grimbert P; ANRS 153 TREVE study group";10.1111/hiv.12700;2019/03/01 00:00;['Journal Article', 'Multicenter Study']
NCT01508494;Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-01-12;2011-06-29;2016-06-22;;;;;;;;
NCT02542891;European Comparative Effectiveness Research on Internet-based Depression Treatment;Institut National de la Santé Et de la Recherche Médicale, France;European Commission | Fondation FondaMental | Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2015-09-07;2015-09;2018-09-15;34874888;DERIVED;"van Genugten CR, Schuurmans J, Hoogendoorn AW, Araya R, Andersson G, Banos R, Botella C, Cerga Pashoja A, Cieslak R, Ebert DD, Garcia-Palacios A, Hazo JB, Herrero R, Holtzmann J, Kemmeren L, Kleiboer A, Krieger T, Smoktunowicz E, Titzler I, Topooco N, Urech A, Smit JH, Riper H. Examining the Theoretical Framework of Behavioral Activation for Major Depressive Disorder: Smartphone-Based Ecological Momentary Assessment Study. JMIR Ment Health. 2021 Dec 6;8(12):e32007. doi: 10.2196/32007.";Examining the Theoretical Framework of Behavioral Activation for Major Depressive Disorder: Smartphone-Based Ecological Momentary Assessment Study.;"van Genugten CR; Schuurmans J; Hoogendoorn AW; Araya R; Andersson G; Baños R; Botella C; Cerga Pashoja A; Cieslak R; Ebert DD; García-Palacios A; Hazo JB; Herrero R; Holtzmann J; Kemmeren L; Kleiboer A; Krieger T; Smoktunowicz E; Titzler I; Topooco N; Urech A; Smit JH; Riper H";10.2196/32007;2021/12/06 00:00;['Journal Article']
NCT02542891;European Comparative Effectiveness Research on Internet-based Depression Treatment;Institut National de la Santé Et de la Recherche Médicale, France;European Commission | Fondation FondaMental | Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2015-09-07;2015-09;2018-09-15;27488181;DERIVED;"Kleiboer A, Smit J, Bosmans J, Ruwaard J, Andersson G, Topooco N, Berger T, Krieger T, Botella C, Banos R, Chevreul K, Araya R, Cerga-Pashoja A, Cieslak R, Rogala A, Vis C, Draisma S, van Schaik A, Kemmeren L, Ebert D, Berking M, Funk B, Cuijpers P, Riper H. European COMPARative Effectiveness research on blended Depression treatment versus treatment-as-usual (E-COMPARED): study protocol for a randomized controlled, non-inferiority trial in eight European countries. Trials. 2016 Aug 3;17(1):387. doi: 10.1186/s13063-016-1511-1.";European COMPARative Effectiveness research on blended Depression treatment versus treatment-as-usual (E-COMPARED): study protocol for a randomized controlled, non-inferiority trial in eight European countries.;"Kleiboer A; Smit J; Bosmans J; Ruwaard J; Andersson G; Topooco N; Berger T; Krieger T; Botella C; Baños R; Chevreul K; Araya R; Cerga-Pashoja A; Cieślak R; Rogala A; Vis C; Draisma S; van Schaik A; Kemmeren L; Ebert D; Berking M; Funk B; Cuijpers P; Riper H";10.1186/s13063-016-1511-1;2016/08/03 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01033760;Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM);ANRS, Emerging Infectious Diseases;Gilead Sciences | Merck Sharp & Dohme LLC | Pfizer | Janssen-Cilag Ltd.;COMPLETED;INTERVENTIONAL;False;2009-12-16;2010-04;2013-12;25701561;DERIVED;"Cheret A, Nembot G, Melard A, Lascoux C, Slama L, Miailhes P, Yeni P, Abel S, Avettand-Fenoel V, Venet A, Chaix ML, Molina JM, Katlama C, Goujard C, Tamalet C, Raffi F, Lafeuillade A, Reynes J, Ravaux I, Hoen B, Delfraissy JF, Meyer L, Rouzioux C; OPTIPRIM ANRS Study Group. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. Lancet Infect Dis. 2015 Apr;15(4):387-96. doi: 10.1016/S1473-3099(15)70021-6. Epub 2015 Feb 18.";Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.;"Chéret A; Nembot G; Mélard A; Lascoux C; Slama L; Miailhes P; Yeni P; Abel S; Avettand-Fenoel V; Venet A; Chaix ML; Molina JM; Katlama C; Goujard C; Tamalet C; Raffi F; Lafeuillade A; Reynes J; Ravaux I; Hoën B; Delfraissy JF; Meyer L; Rouzioux C; OPTIPRIM ANRS Study Group";10.1016/S1473-3099(15)70021-6;2015/04/01 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT01033760;Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM);ANRS, Emerging Infectious Diseases;Gilead Sciences | Merck Sharp & Dohme LLC | Pfizer | Janssen-Cilag Ltd.;COMPLETED;INTERVENTIONAL;False;2009-12-16;2010-04;2013-12;28708873;DERIVED;"Cheret A, Durier C, Melard A, Ploquin M, Heitzmann J, Lecuroux C, Avettand-Fenoel V, David L, Pialoux G, Chennebault JM, Muller-Trutwin M, Goujard C, Rouzioux C, Meyer L; ANRS OPTIPRIM study group. Impact of early cART on HIV blood and semen compartments at the time of primary infection. PLoS One. 2017 Jul 14;12(7):e0180191. doi: 10.1371/journal.pone.0180191. eCollection 2017.";Impact of early cART on HIV blood and semen compartments at the time of primary infection.;"Chéret A; Durier C; Mélard A; Ploquin M; Heitzmann J; Lécuroux C; Avettand-Fenoël V; David L; Pialoux G; Chennebault JM; Müller-Trutwin M; Goujard C; Rouzioux C; Meyer L; ANRS OPTIPRIM study group";10.1371/journal.pone.0180191;2017/07/14 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;10436334;BACKGROUND;"Pasquier F, Lebert F, Lavenu I, Guillaume B. The clinical picture of frontotemporal dementia: diagnosis and follow-up. Dement Geriatr Cogn Disord. 1999;10 Suppl 1:10-4. doi: 10.1159/000051206.";The clinical picture of frontotemporal dementia: diagnosis and follow-up.;"Pasquier F; Lebert F; Lavenu I; Guillaume B";10.1159/000051206;1999/01/01 00:00;['Journal Article']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;19933975;BACKGROUND;"Le Jeune F, Drapier D, Bourguignon A, Peron J, Mesbah H, Drapier S, Sauleau P, Haegelen C, Travers D, Garin E, Malbert CH, Millet B, Verin M. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology. 2009 Nov 24;73(21):1746-51. doi: 10.1212/WNL.0b013e3181c34b34.";Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study.;"Le Jeune F; Drapier D; Bourguignon A; Péron J; Mesbah H; Drapier S; Sauleau P; Haegelen C; Travers D; Garin E; Malbert CH; Millet B; Vérin M";10.1212/WNL.0b013e3181c34b34;2009/11/24 00:00;['Clinical Trial', 'Journal Article']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;12461757;BACKGROUND;"Robert PH, Clairet S, Benoit M, Koutaich J, Bertogliati C, Tible O, Caci H, Borg M, Brocker P, Bedoucha P. The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment. Int J Geriatr Psychiatry. 2002 Dec;17(12):1099-105. doi: 10.1002/gps.755.";The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment.;"Robert PH; Clairet S; Benoit M; Koutaich J; Bertogliati C; Tible O; Caci H; Borg M; Brocker P; Bedoucha P";10.1002/gps.755;2002/12/01 00:00;['Journal Article']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;16207933;BACKGROUND;"Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex. 2006 Jul;16(7):916-28. doi: 10.1093/cercor/bhj043. Epub 2005 Oct 5.";Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits.;"Levy R; Dubois B";10.1093/cercor/bhj043;2006/07/01 00:00;['Journal Article', 'Review']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;15897497;BACKGROUND;"Czernecki V, Pillon B, Houeto JL, Welter ML, Mesnage V, Agid Y, Dubois B. Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease? J Neurol Neurosurg Psychiatry. 2005 Jun;76(6):775-9. doi: 10.1136/jnnp.2003.033258.";Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?;"Czernecki V; Pillon B; Houeto JL; Welter ML; Mesnage V; Agid Y; Dubois B";10.1136/jnnp.2003.033258;2005/06/01 00:00;['Journal Article']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;16421064;BACKGROUND;"Muller U, Czymmek J, Thone-Otto A, Von Cramon DY. Reduced daytime activity in patients with acquired brain damage and apathy: a study with ambulatory actigraphy. Brain Inj. 2006 Feb;20(2):157-60. doi: 10.1080/02699050500443467.";Reduced daytime activity in patients with acquired brain damage and apathy: a study with ambulatory actigraphy.;"Müller U; Czymmek J; Thöne-Otto A; Von Cramon DY";10.1080/02699050500443467;2006/02/01 00:00;['Journal Article']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;19533496;BACKGROUND;"Lane-Brown AT, Tate RL. Apathy after acquired brain impairment: a systematic review of non-pharmacological interventions. Neuropsychol Rehabil. 2009 Aug;19(4):481-516. doi: 10.1080/09602010902949207.";Apathy after acquired brain impairment: a systematic review of non-pharmacological interventions.;"Lane-Brown AT; Tate RL";10.1080/09602010902949207;2009/08/01 00:00;['Journal Article', 'Review']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;17131230;BACKGROUND;"Levy R, Czernecki V. Apathy and the basal ganglia. J Neurol. 2006 Dec;253 Suppl 7:VII54-61. doi: 10.1007/s00415-006-7012-5.";Apathy and the basal ganglia.;"Levy R; Czernecki V";10.1007/s00415-006-7012-5;2006/12/01 00:00;['Journal Article', 'Review']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;17027767;BACKGROUND;"Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, Bradshaw JL, White OB. Negative symptoms: A review of schizophrenia, melancholic depression and Parkinson's disease. Brain Res Bull. 2006 Oct 16;70(4-6):312-21. doi: 10.1016/j.brainresbull.2006.06.007. Epub 2006 Jul 5.";Negative symptoms: A review of schizophrenia, melancholic depression and Parkinson's disease.;"Winograd-Gurvich C; Fitzgerald PB; Georgiou-Karistianis N; Bradshaw JL; White OB";10.1016/j.brainresbull.2006.06.007;2006/10/16 00:00;['Journal Article', 'Review']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;10678322;BACKGROUND;"Marin RS, Firinciogullari S, Biedrzycki RC. Group differences in the relationship between apathy and depression. J Nerv Ment Dis. 1994 Apr;182(4):235-9. doi: 10.1097/00005053-199404000-00008.";Group differences in the relationship between apathy and depression.;"Marin RS; Firinciogullari S; Biedrzycki RC";10.1097/00005053-199404000-00008;1994/04/01 00:00;['Journal Article']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;10941190;BACKGROUND;"Brown RG, Pluck G. Negative symptoms: the 'pathology' of motivation and goal-directed behaviour. Trends Neurosci. 2000 Sep;23(9):412-7. doi: 10.1016/s0166-2236(00)01626-x.";Negative symptoms: the 'pathology' of motivation and goal-directed behaviour.;"Brown RG; Pluck G";10.1016/s0166-2236(00)01626-x;2000/09/01 00:00;['Journal Article', 'Review']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;1821241;BACKGROUND;"Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991 Summer;3(3):243-54. doi: 10.1176/jnp.3.3.243.";Apathy: a neuropsychiatric syndrome.;Marin RS;10.1176/jnp.3.3.243;1991/07/01 00:00;['Journal Article', 'Review']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;21895376;BACKGROUND;"Funkiewiez A, Bertoux M, de Souza LC, Levy R, Dubois B. The SEA (Social cognition and Emotional Assessment): a clinical neuropsychological tool for early diagnosis of frontal variant of frontotemporal lobar degeneration. Neuropsychology. 2012 Jan;26(1):81-90. doi: 10.1037/a0025318. Epub 2011 Sep 5.";The SEA (Social cognition and Emotional Assessment): a clinical neuropsychological tool for early diagnosis of frontal variant of frontotemporal lobar degeneration.;"Funkiewiez A; Bertoux M; de Souza LC; Lévy R; Dubois B";10.1037/a0025318;2012/01/01 00:00;['Journal Article']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;18307266;BACKGROUND;"Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L. The Lille Apathy Rating Scale: validation of a caregiver-based version. Mov Disord. 2008 Apr 30;23(6):845-9. doi: 10.1002/mds.21968.";The Lille Apathy Rating Scale: validation of a caregiver-based version.;"Dujardin K; Sockeel P; Delliaux M; Destée A; Defebvre L";10.1002/mds.21968;2008/04/30 00:00;['Journal Article']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;19713543;BACKGROUND;"Mayo NE, Fellows LK, Scott SC, Cameron J, Wood-Dauphinee S. A longitudinal view of apathy and its impact after stroke. Stroke. 2009 Oct;40(10):3299-307. doi: 10.1161/STROKEAHA.109.554410. Epub 2009 Aug 27.";A longitudinal view of apathy and its impact after stroke.;"Mayo NE; Fellows LK; Scott SC; Cameron J; Wood-Dauphinee S";10.1161/STROKEAHA.109.554410;2009/10/01 00:00;['Journal Article']
NCT01525472;Accelerated Aging of the Cells of Visceral Adipose Tissue in Morbid Obese Subjects;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-02-03;2012-02-13;2015-10-20;;;;;;;;
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;28453240;DERIVED;"Amani-Bosse C, Dahourou DL, Malateste K, Amorissani-Folquet M, Coulibaly M, Dattez S, Emieme A, Barry M, Rouzioux C, N'gbeche S, Yonaba C, Timite-Konan M, Mea V, Ouedraogo S, Blanche S, Meda N, Seguin-Devaux C, Leroy V. Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort. J Int AIDS Soc. 2017 Apr 25;20(1):21362. doi: 10.7448/IAS.20.01.21362.";Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.;"Amani-Bosse C; Dahourou DL; Malateste K; Amorissani-Folquet M; Coulibaly M; Dattez S; Emieme A; Barry M; Rouzioux C; N'gbeche S; Yonaba C; Timité-Konan M; Mea V; Ouédraogo S; Blanche S; Meda N; Seguin-Devaux C; Leroy V";10.7448/IAS.20.01.21362;2017/04/25 00:00;['Journal Article']
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;28434406;DERIVED;"Dahourou DL, Amorissani-Folquet M, Malateste K, Amani-Bosse C, Coulibaly M, Seguin-Devaux C, Toni T, Ouedraogo R, Blanche S, Yonaba C, Eboua F, Lepage P, Avit D, Ouedraogo S, Van de Perre P, N'Gbeche S, Kalmogho A, Salamon R, Meda N, Timite-Konan M, Leroy V; MONOD Study Group. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Cote d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial. BMC Med. 2017 Apr 24;15(1):85. doi: 10.1186/s12916-017-0842-4.";Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.;"Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V; MONOD Study Group";10.1186/s12916-017-0842-4;2017/04/24 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;28483965;DERIVED;"Pressiat C, Amorissani-Folquet M, Yonaba C, Treluyer JM, Dahourou DL, Eboua F, Blanche S, Mea-Assande V, Bouazza N, Foissac F, Malateste K, Ouedraogo S, Lui G, Leroy V, Hirt D. Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old. Antimicrob Agents Chemother. 2017 Jun 27;61(7):e00297-17. doi: 10.1128/AAC.00297-17. Print 2017 Jul.";Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old.;"Pressiat C; Amorissani-Folquet M; Yonaba C; Treluyer JM; Dahourou DL; Eboua F; Blanche S; Mea-Assande V; Bouazza N; Foissac F; Malateste K; Ouedraogo S; Lui G; Leroy V; Hirt D";10.1128/AAC.00297-17;2017/06/27 00:00;['Journal Article']
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;31334298;DERIVED;"Desmonde S, Frank SC, Coovadia A, Dahourou DL, Hou T, Abrams EJ, Amorissani-Folquet M, Walensky RP, Strehlau R, Penazzato M, Freedberg KA, Kuhn L, Leroy V, Ciaranello AL. Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus. Open Forum Infect Dis. 2019 Jun 11;6(7):ofz276. doi: 10.1093/ofid/ofz276. eCollection 2019 Jul.";Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus.;"Desmonde S; Frank SC; Coovadia A; Dahourou DL; Hou T; Abrams EJ; Amorissani-Folquet M; Walensky RP; Strehlau R; Penazzato M; Freedberg KA; Kuhn L; Leroy V; Ciaranello AL";10.1093/ofid/ofz276;2019/06/11 00:00;['Journal Article']
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;28800382;DERIVED;"Pressiat C, Mea-Assande V, Yonaba C, Treluyer JM, Dahourou DL, Amorissani-Folquet M, Blanche S, Eboua F, Ye D, Lui G, Malateste K, Zheng Y, Leroy V, Hirt D; MONOD Study Group. Suboptimal cotrimoxazole prophylactic concentrations in HIV-infected children according to the WHO guidelines. Br J Clin Pharmacol. 2017 Dec;83(12):2729-2740. doi: 10.1111/bcp.13397. Epub 2017 Sep 20.";Suboptimal cotrimoxazole prophylactic concentrations in HIV-infected children according to the WHO guidelines.;"Pressiat C; Mea-Assande V; Yonaba C; Treluyer JM; Dahourou DL; Amorissani-Folquet M; Blanche S; Eboua F; Ye D; Lui G; Malateste K; Zheng Y; Leroy V; Hirt D; MONOD Study Group";10.1111/bcp.13397;2017/12/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;27015798;DERIVED;"Dahourou DL, Amorissani-Folquet M, Coulibaly M, Avit-Edi D, Meda N, Timite-Konan M, Arendt V, Ye D, Amani-Bosse C, Salamon R, Lepage P, Leroy V; Monod Anrs 12206 Study Group. Missed opportunities of inclusion in a cohort of HIV-infected children to initiate antiretroviral treatment before the age of two in West Africa, 2011 to 2013. J Int AIDS Soc. 2016 Mar 23;19(1):20601. doi: 10.7448/IAS.19.1.20601. eCollection 2016.";Missed opportunities of inclusion in a cohort of HIV-infected children to initiate antiretroviral treatment before the age of two in West Africa, 2011 to 2013.;"Dahourou DL; Amorissani-Folquet M; Coulibaly M; Avit-Edi D; Meda N; Timite-Konan M; Arendt V; Ye D; Amani-Bosse C; Salamon R; Lepage P; Leroy V; Monod Anrs 12206 Study Group";10.7448/IAS.19.1.20601;2016/03/23 00:00;['Journal Article']
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;34723858;DERIVED;"Pressiat C, Toni TD, Treluyer JM, Yonaba C, Dahourou DL, Malateste K, Seguin-Devaux C, Leroy V, Hirt D; MONOD ANRS Study Group. High nevirapine levels in breast milk and consequences in HIV-infected child when initiated on antiretroviral therapy. AIDS. 2021 Nov 15;35(14):2409-2410. doi: 10.1097/QAD.0000000000003043. No abstract available.";High nevirapine levels in breast milk and consequences in HIV-infected child when initiated on antiretroviral therapy.;"Pressiat C; Toni TD; Treluyer JM; Yonaba C; Dahourou DL; Malateste K; Seguin-Devaux C; Leroy V; Hirt D; MONOD ANRS Study Group";10.1097/QAD.0000000000003043;2021/11/15 00:00;['Letter']
NCT00323804;Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC | Rennes University Hospital;COMPLETED;INTERVENTIONAL;False;2006-05-10;2006-05;2013-03;;;;;;;;
NCT01552044;Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-03-13;2012-01;2013-02;;;;;;;;
NCT04484740;Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue;Institut National de la Santé Et de la Recherche Médicale, France;Medical University of Vienna;COMPLETED;INTERVENTIONAL;False;2020-07-24;2021-01-29;2023-05-27;;;;;;;;
NCT03047967;Effects of Prenatal Tobacco Smoke Exposure on Lung Function and Respiratory Epithelium Functionality in Newborns;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2017-02-09;2017-11-10;2019-02-09;;;;;;;;
NCT04849767;National Survey About Trajectory and Life Conditions of HIV Trans People in France;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;OBSERVATIONAL;False;2021-04-19;2020-10-01;2023-12-31;34916316;DERIVED;"Mora M, Rincon G, Bourrelly M, Maradan G, Freire Maresca A, Michard F, Rouveix E, Pannetier J, Leriche D, Alain T, Yazdanpanah Y, Michels D, Spire B. Living conditions, HIV and gender affirmation care pathways of transgender people living with HIV in France: a nationwide, comprehensive, cross-sectional, community-based research protocol (ANRS Trans&HIV). BMJ Open. 2021 Dec 16;11(12):e052691. doi: 10.1136/bmjopen-2021-052691.";Living conditions, HIV and gender affirmation care pathways of transgender people living with HIV in France: a nationwide, comprehensive, cross-sectional, community-based research protocol (ANRS Trans&HIV).;"Mora M; Rincon G; Bourrelly M; Maradan G; Freire Maresca A; Michard F; Rouveix E; Pannetier J; Leriche D; Alain T; Yazdanpanah Y; Michels D; Spire B";10.1136/bmjopen-2021-052691;2021/12/16 00:00;['Journal Article']
NCT01874808;From Movement Preparation to Gait Execution in ALS;Institut National de la Santé Et de la Recherche Médicale, France;Université Paris Ouest-EA 2931-CEntre de Recherches sur le Sport et le Mouvement;COMPLETED;OBSERVATIONAL;False;2013-06-11;2013-06-21;2015-12-21;;;;;;;;
NCT01696708;Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-10-01;2012-12-06;2015-11;25568297;DERIVED;"Adanyeguh IM, Rinaldi D, Henry PG, Caillet S, Valabregue R, Durr A, Mochel F. Triheptanoin improves brain energy metabolism in patients with Huntington disease. Neurology. 2015 Feb 3;84(5):490-5. doi: 10.1212/WNL.0000000000001214. Epub 2015 Jan 7.";Triheptanoin improves brain energy metabolism in patients with Huntington disease.;"Adanyeguh IM; Rinaldi D; Henry PG; Caillet S; Valabregue R; Durr A; Mochel F";10.1212/WNL.0000000000001214;2015/02/03 00:00;['Clinical Trial', 'Journal Article']
NCT03298360;A Chronological Study of the Formation of HIV Cellular Reservoirs Through the Expression of Surface Markers on CD4 + T Lymphocytes, Including CD32a;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-10-02;2018-06-28;2020-06-25;;;;;;;;
NCT01490489;EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-13;2011-07-11;2015-03-13;17531315;RESULT;"Hoffmann P, Feige JJ, Alfaidy N. Placental expression of EG-VEGF and its receptors PKR1 (prokineticin receptor-1) and PKR2 throughout mouse gestation. Placenta. 2007 Oct;28(10):1049-58. doi: 10.1016/j.placenta.2007.03.008. Epub 2007 May 25.";Placental expression of EG-VEGF and its receptors PKR1 (prokineticin receptor-1) and PKR2 throughout mouse gestation.;"Hoffmann P; Feige JJ; Alfaidy N";10.1016/j.placenta.2007.03.008;2007/10/01 00:00;['Journal Article']
NCT01490489;EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-13;2011-07-11;2015-03-13;19602057;RESULT;"Hoffmann P, Saoudi Y, Benharouga M, Graham CH, Schaal JP, Mazouni C, Feige JJ, Alfaidy N. Role of EG-VEGF in human placentation: Physiological and pathological implications. J Cell Mol Med. 2009 Aug;13(8B):2224-2235. doi: 10.1111/j.1582-4934.2008.00554.x.";Role of EG-VEGF in human placentation: Physiological and pathological implications.;"Hoffmann P; Saoudi Y; Benharouga M; Graham CH; Schaal JP; Mazouni C; Feige JJ; Alfaidy N";10.1111/j.1582-4934.2008.00554.x;2009/08/01 00:00;['Journal Article']
NCT01490489;EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-13;2011-07-11;2015-03-13;16384869;RESULT;"Hoffmann P, Feige JJ, Alfaidy N. Expression and oxygen regulation of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 and its receptors in human placenta during early pregnancy. Endocrinology. 2006 Apr;147(4):1675-84. doi: 10.1210/en.2005-0912. Epub 2005 Dec 29.";Expression and oxygen regulation of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 and its receptors in human placenta during early pregnancy.;"Hoffmann P; Feige JJ; Alfaidy N";10.1210/en.2005-0912;2006/04/01 00:00;['Journal Article']
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;ANRS, Emerging Infectious Diseases;NEAT - European AIDS Treatment Network;COMPLETED;INTERVENTIONAL;False;2010-02-10;2010-08;2013-10;26520926;DERIVED;"Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, Reiss P, Katlama C, De Wit S, Richert L, Babiker A, Buno A, Castagna A, Girard PM, Chene G, Raffi F, Arribas JR; NEAT001/ANRS143 Study Group. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV. 2015 Nov;2(11):e464-73. doi: 10.1016/S2352-3018(15)00181-2. Epub 2015 Sep 30.";Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.;"Bernardino JI; Mocroft A; Mallon PW; Wallet C; Gerstoft J; Russell C; Reiss P; Katlama C; De Wit S; Richert L; Babiker A; Buño A; Castagna A; Girard PM; Chene G; Raffi F; Arribas JR; NEAT001/ANRS143 Study Group";10.1016/S2352-3018(15)00181-2;2015/11/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;ANRS, Emerging Infectious Diseases;NEAT - European AIDS Treatment Network;COMPLETED;INTERVENTIONAL;False;2010-02-10;2010-08;2013-10;25103176;DERIVED;"Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chene G, Pozniak A; NEAT001/ANRS143 Study Group. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4.";Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.;"Raffi F; Babiker AG; Richert L; Molina JM; George EC; Antinori A; Arribas JR; Grarup J; Hudson F; Schwimmer C; Saillard J; Wallet C; Jansson PO; Allavena C; Van Leeuwen R; Delfraissy JF; Vella S; Chêne G; Pozniak A; NEAT001/ANRS143 Study Group";10.1016/S0140-6736(14)61170-3;2014/11/29 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;ANRS, Emerging Infectious Diseases;NEAT - European AIDS Treatment Network;COMPLETED;INTERVENTIONAL;False;2010-02-10;2010-08;2013-10;30365452;DERIVED;"Ammassari A, Stohr W, Antinori A, Molina JM, Schwimmer C, Domingo P, Thalme A, Di Pietro M, Wallet C, Pozniak A, Richert L, Raffi F; NEAT001/ANRS143 Trial Study Group. Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial. J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):481-490. doi: 10.1097/QAI.0000000000001834.";Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial.;"Ammassari A; Stöhr W; Antinori A; Molina JM; Schwimmer C; Domingo P; Thalme A; Di Pietro M; Wallet C; Pozniak A; Richert L; Raffi F; NEAT001/ANRS143 Trial Study Group";10.1097/QAI.0000000000001834;2018/12/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;ANRS, Emerging Infectious Diseases;NEAT - European AIDS Treatment Network;COMPLETED;INTERVENTIONAL;False;2010-02-10;2010-08;2013-10;33794182;DERIVED;"Esteban-Cantos A, Rodriguez-Centeno J, Barruz P, Alejos B, Saiz-Medrano G, Nevado J, Martin A, Gaya F, De Miguel R, Bernardino JI, Montejano R, Mena-Garay B, Cadinanos J, Florence E, Mulcahy F, Banhegyi D, Antinori A, Pozniak A, Wallet C, Raffi F, Rodes B, Arribas JR; NEAT001/ANRS143 Study Group. Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV. 2021 Apr;8(4):e197-e205. doi: 10.1016/S2352-3018(21)00006-0. Erratum In: Lancet HIV. 2021 Dec;8(12):e734.";Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial.;"Esteban-Cantos A; Rodríguez-Centeno J; Barruz P; Alejos B; Saiz-Medrano G; Nevado J; Martin A; Gayá F; De Miguel R; Bernardino JI; Montejano R; Mena-Garay B; Cadiñanos J; Florence E; Mulcahy F; Banhegyi D; Antinori A; Pozniak A; Wallet C; Raffi F; Rodés B; Arribas JR; NEAT001/ANRS143 Study Group";10.1016/S2352-3018(21)00006-0;2021/04/01 00:00;['Journal Article']
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;31339676;DERIVED;"NAMSAL ANRS 12313 Study Group; Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S, Peeters M, Calmy A, Delaporte E. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019 Aug 29;381(9):816-826. doi: 10.1056/NEJMoa1904340. Epub 2019 Jul 24.";Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.;"NAMSAL ANRS 12313 Study Group; Kouanfack C; Mpoudi-Etame M; Omgba Bassega P; Eymard-Duvernay S; Leroy S; Boyer S; Peeters M; Calmy A; Delaporte E";10.1056/NEJMoa1904340;2019/08/29 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;33355914;DERIVED;"Bousmah MA, Nishimwe ML, Tovar-Sanchez T, Lantche Wandji M, Mpoudi-Etame M, Maradan G, Omgba Bassega P, Varloteaux M, Montoyo A, Kouanfack C, Delaporte E, Boyer S; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group. Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial). Pharmacoeconomics. 2021 Mar;39(3):331-343. doi: 10.1007/s40273-020-00987-3. Epub 2020 Dec 23.";Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).;"Bousmah MA; Nishimwe ML; Tovar-Sanchez T; Lantche Wandji M; Mpoudi-Etame M; Maradan G; Omgba Bassega P; Varloteaux M; Montoyo A; Kouanfack C; Delaporte E; Boyer S; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group";10.1007/s40273-020-00987-3;2021/03/01 00:00;['Journal Article']
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;38156046;PUBMED;;Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study.;"Mpoudi-Etame M; Tovar Sanchez T; Bousmah MA; Omgba Bassega P; Olinga J; Mimbe E; Foalem M; Chiep C; Edimo S; Varloteaux M; Pelloquin R; Lamare N; Boyer S; Peeters M; Reynes J; Calmy A; Hill A; Delaporte E; Kouanfack C; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-income countries (NAMSAL-ANRS-12313) study group";10.1093/ofid/ofad582;2023/11/20 00:00;['Journal Article']
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;33010241;DERIVED;"Calmy A, Tovar Sanchez T, Kouanfack C, Mpoudi-Etame M, Leroy S, Perrineau S, Lantche Wandji M, Tetsa Tata D, Omgba Bassega P, Abong Bwenda T, Varloteaux M, Tongo M, Mpoudi-Ngole E, Montoyo A, Mercier N, LeMoing V, Peeters M, Reynes J, Delaporte E; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. Lancet HIV. 2020 Oct;7(10):e677-e687. doi: 10.1016/S2352-3018(20)30238-1.";Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.;"Calmy A; Tovar Sanchez T; Kouanfack C; Mpoudi-Etame M; Leroy S; Perrineau S; Lantche Wandji M; Tetsa Tata D; Omgba Bassega P; Abong Bwenda T; Varloteaux M; Tongo M; Mpoudi-Ngolé E; Montoyo A; Mercier N; LeMoing V; Peeters M; Reynes J; Delaporte E; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group";10.1016/S2352-3018(20)30238-1;2020/10/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;37851566;PUBMED;;Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial).;"Bousmah MA; Protopopescu C; Mpoudi-Etame M; Omgba Bassega P; Maradan G; Olinga J; Varloteaux M; Tovar-Sanchez T; Delaporte É; Kouanfack C; Boyer S; NAMSAL ANRS 12313 Study Group";10.1097/QAI.0000000000003273;2023/11/01 00:00;['Randomized Controlled Trial', 'Journal Article']
NCT05349162;Epicardial vs. Transvenous ICDs in Children;Paris Cardiovascular Research Center (Inserm U970);Hôpital Necker-Enfants Malades;COMPLETED;OBSERVATIONAL;False;2022-04-27;2003-01-01;2022-04-01;36735263;PUBMED;;Epicardial vs. transvenous implantable cardioverter defibrillators in children.;"Le Bos PA; Pontailler M; Maltret A; Kraiche D; Gaudin R; Barbanti C; Marijon E; Raisky O; Bonnet D; Waldmann V";10.1093/europace/euad015;2023/03/30 00:00;['Clinical Trial', 'Journal Article']
NCT01703962;Non Invasive IDentification of Gliomas With IDH1 Mutation;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-10-11;2012-03-14;2014-03-20;37668523;PUBMED;;Neurochemical Differences between 1p/19q Codeleted and Noncodeleted IDH-mutant Gliomas by in Vivo MR Spectroscopy.;"Branzoli F; Liserre R; Deelchand DK; Poliani PL; Bielle F; Nichelli L; Sanson M; Lehéricy S; Marjańska M";10.1148/radiol.223255;2023/09/01 00:00;['Journal Article']
NCT01514890;French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2012-01-23;2011-02;2014-03;25556540;DERIVED;"Sultanik P, Mallet V, Lagaye S, Casrouge A, Dorival C, Barthe Y, Fontaine H, Hezode C, Mottez E, Bronowicki JP, Carrat F, Theodorou I, Abel L, Gayat E, Fontanet A, Pol S, Albert ML; ANRS CO20-CUPIC. Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy. Liver Int. 2015 Jul;35(7):1833-44. doi: 10.1111/liv.12759. Epub 2015 Jan 23.";Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.;"Sultanik P; Mallet V; Lagaye S; Casrouge A; Dorival C; Barthe Y; Fontaine H; Hézode C; Mottez E; Bronowicki JP; Carrat F; Theodorou I; Abel L; Gayat E; Fontanet A; Pol S; Albert ML; ANRS CO20-CUPIC";10.1111/liv.12759;2015/07/01 00:00;['Clinical Trial', 'Journal Article', 'Multicenter Study']
NCT01514890;French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2012-01-23;2011-02;2014-03;23669289;DERIVED;"Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourliere M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Metivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP; CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013 Sep;59(3):434-41. doi: 10.1016/j.jhep.2013.04.035. Epub 2013 May 10.";Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.;"Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP; CUPIC Study Group";10.1016/j.jhep.2013.04.035;2013/09/01 00:00;['Clinical Trial', 'Journal Article', 'Multicenter Study']
NCT01514890;French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2012-01-23;2011-02;2014-03;24704719;DERIVED;"Hezode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP; CUPIC Study Group. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014 Jul;147(1):132-142.e4. doi: 10.1053/j.gastro.2014.03.051. Epub 2014 Apr 3.";Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.;"Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP; CUPIC Study Group";10.1053/j.gastro.2014.03.051;2014/07/01 00:00;['Journal Article', 'Multicenter Study']
NCT03150290;Brown Adipose Tissue in ALS;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2017-05-12;2017-10-26;2019-04-01;;;;;;;;
NCT02992184;PoC-HCV Genedrive Viral Detection Assay Validation Study;ANRS, Emerging Infectious Diseases;EPISTEM;COMPLETED;OBSERVATIONAL;False;2016-12-14;2016-09;2016-12;29615488;DERIVED;"Llibre A, Shimakawa Y, Mottez E, Ainsworth S, Buivan TP, Firth R, Harrison E, Rosenberg AR, Meritet JF, Fontanet A, Castan P, Madejon A, Laverick M, Glass A, Viana R, Pol S, McClure CP, Irving WL, Miele G, Albert ML, Duffy D. Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus. Gut. 2018 Nov;67(11):2017-2024. doi: 10.1136/gutjnl-2017-315783. Epub 2018 Apr 3.";Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.;"Llibre A; Shimakawa Y; Mottez E; Ainsworth S; Buivan TP; Firth R; Harrison E; Rosenberg AR; Meritet JF; Fontanet A; Castan P; Madejón A; Laverick M; Glass A; Viana R; Pol S; McClure CP; Irving WL; Miele G; Albert ML; Duffy D";10.1136/gutjnl-2017-315783;2018/11/01 00:00;['Clinical Trial', 'Journal Article']
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;15037514;RESULT;"Ahmad S, Fowler LJ, Whitton PS. Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat. Br J Pharmacol. 2004 May;142(1):136-42. doi: 10.1038/sj.bjp.0705737. Epub 2004 Mar 22.";Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat.;"Ahmad S; Fowler LJ; Whitton PS";10.1038/sj.bjp.0705737;2004/05/01 00:00;['Journal Article']
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;15777732;RESULT;"Ahmad S, Fowler LJ, Whitton PS. Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. Epilepsy Res. 2005 Feb;63(2-3):141-9. doi: 10.1016/j.eplepsyres.2005.02.002.";Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids.;"Ahmad S; Fowler LJ; Whitton PS";10.1016/j.eplepsyres.2005.02.002;2005/02/01 00:00;['Journal Article']
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;15249613;RESULT;"Biraben A, Semah F, Ribeiro MJ, Douaud G, Remy P, Depaulis A. PET evidence for a role of the basal ganglia in patients with ring chromosome 20 epilepsy. Neurology. 2004 Jul 13;63(1):73-7. doi: 10.1212/01.wnl.0000132840.40838.13.";PET evidence for a role of the basal ganglia in patients with ring chromosome 20 epilepsy.;"Biraben A; Semah F; Ribeiro MJ; Douaud G; Remy P; Depaulis A";10.1212/01.wnl.0000132840.40838.13;2004/07/13 00:00;['Journal Article']
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;12914551;RESULT;"Aymard G, Berlin I, de Brettes B, Diquet B. Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. Fundam Clin Pharmacol. 2003 Aug;17(4):473-81. doi: 10.1046/j.1472-8206.2003.00152.x.";Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects.;"Aymard G; Berlin I; de Brettes B; Diquet B";10.1046/j.1472-8206.2003.00152.x;2003/08/01 00:00;['Clinical Trial', 'Journal Article', 'Randomized Controlled Trial']
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;2271377;RESULT;"Blin O, Masson G, Azulay JP, Fondarai J, Serratrice G. Apomorphine-induced blinking and yawning in healthy volunteers. Br J Clin Pharmacol. 1990 Nov;30(5):769-73. doi: 10.1111/j.1365-2125.1990.tb03848.x.";Apomorphine-induced blinking and yawning in healthy volunteers.;"Blin O; Masson G; Azulay JP; Fondarai J; Serratrice G";10.1111/j.1365-2125.1990.tb03848.x;1990/11/01 00:00;['Clinical Trial', 'Journal Article', 'Randomized Controlled Trial']
NCT02126384;Identifocation the B Cell Subsets Responsible for Anti-pneumococcal Response;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-04-30;2014-11-18;2016-04-05;;;;;;;;
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;22160145;BACKGROUND;"Valantin MA, Lambert-Niclot S, Flandre P, Morand-Joubert L, Cabie A, Meynard JL, Ponscarme D, Ajana F, Slama L, Curjol A, Cuzin L, Schneider L, Taburet AM, Marcelin AG, Katlama C; MONOI ANRS 136 Study Group. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother. 2012 Mar;67(3):691-5. doi: 10.1093/jac/dkr504. Epub 2011 Dec 7.";Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.;"Valantin MA; Lambert-Niclot S; Flandre P; Morand-Joubert L; Cabiè A; Meynard JL; Ponscarme D; Ajana F; Slama L; Curjol A; Cuzin L; Schneider L; Taburet AM; Marcelin AG; Katlama C; MONOI ANRS 136 Study Group";10.1093/jac/dkr504;2012/03/01 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;26709605;BACKGROUND;"Arribas JR, Girard PM, Paton N, Winston A, Marcelin AG, Elbirt D, Hill A, Hadacek MB. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. HIV Med. 2016 May;17(5):358-67. doi: 10.1111/hiv.12348. Epub 2015 Dec 28.";Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.;"Arribas JR; Girard PM; Paton N; Winston A; Marcelin AG; Elbirt D; Hill A; Hadacek MB";10.1111/hiv.12348;2016/05/01 00:00;['Journal Article', 'Meta-Analysis']
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;23559464;BACKGROUND;"Andre-Schmutz I, Dal-Cortivo L, Six E, Kaltenbach S, Cocchiarella F, Le Chenadec J, Cagnard N, Cordier AG, Benachi A, Mandelbrot L, Azria E, Bouallag N, Luce S, Ternaux B, Reimann C, Revy P, Radford-Weiss I, Leschi C, Recchia A, Mavilio F, Cavazzana M, Blanche S. Genotoxic signature in cord blood cells of newborns exposed in utero to a Zidovudine-based antiretroviral combination. J Infect Dis. 2013 Jul 15;208(2):235-43. doi: 10.1093/infdis/jit149. Epub 2013 Apr 4.";Genotoxic signature in cord blood cells of newborns exposed in utero to a Zidovudine-based antiretroviral combination.;"André-Schmutz I; Dal-Cortivo L; Six E; Kaltenbach S; Cocchiarella F; Le Chenadec J; Cagnard N; Cordier AG; Benachi A; Mandelbrot L; Azria E; Bouallag N; Luce S; Ternaux B; Reimann C; Revy P; Radford-Weiss I; Leschi C; Recchia A; Mavilio F; Cavazzana M; Blanche S";10.1093/infdis/jit149;2013/07/15 00:00;['Journal Article']
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;26197844;BACKGROUND;"Mandelbrot L, Tubiana R, Le Chenadec J, Dollfus C, Faye A, Pannier E, Matheron S, Khuong MA, Garrait V, Reliquet V, Devidas A, Berrebi A, Allisy C, Elleau C, Arvieux C, Rouzioux C, Warszawski J, Blanche S; ANRS-EPF Study Group. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin Infect Dis. 2015 Dec 1;61(11):1715-25. doi: 10.1093/cid/civ578. Epub 2015 Jul 21.";No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception.;"Mandelbrot L; Tubiana R; Le Chenadec J; Dollfus C; Faye A; Pannier E; Matheron S; Khuong MA; Garrait V; Reliquet V; Devidas A; Berrebi A; Allisy C; Elleau C; Arvieux C; Rouzioux C; Warszawski J; Blanche S; ANRS-EPF Study Group";10.1093/cid/civ578;2015/12/01 00:00;['Journal Article', 'Multicenter Study']
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;23766338;BACKGROUND;"Tubiana R, Mandelbrot L, Le Chenadec J, Delmas S, Rouzioux C, Hirt D, Treluyer JM, Ekoukou D, Bui E, Chaix ML, Blanche S, Warszawski J; ANRS 135 PRIMEVA (Protease Inhibitor Monotherapy Evaluation) Study Group. Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial. Clin Infect Dis. 2013 Sep;57(6):891-902. doi: 10.1093/cid/cit390. Epub 2013 Jun 12.";Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial.;"Tubiana R; Mandelbrot L; Le Chenadec J; Delmas S; Rouzioux C; Hirt D; Treluyer JM; Ekoukou D; Bui E; Chaix ML; Blanche S; Warszawski J; ANRS 135 PRIMEVA (Protease Inhibitor Monotherapy Evaluation) Study Group";10.1093/cid/cit390;2013/09/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;22848481;BACKGROUND;"Lambert-Niclot S, Flandre P, Valantin MA, Soulie C, Fourati S, Wirden M, Sayon S, Pakianather S, Bocket L, Masquelier B, Dos Santos G, Katlama C, Calvez V, Marcelin AG. Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks. PLoS One. 2012;7(7):e41390. doi: 10.1371/journal.pone.0041390. Epub 2012 Jul 25.";Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.;"Lambert-Niclot S; Flandre P; Valantin MA; Soulie C; Fourati S; Wirden M; Sayon S; Pakianather S; Bocket L; Masquelier B; Dos Santos G; Katlama C; Calvez V; Marcelin AG";10.1371/journal.pone.0041390;2012/01/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;26854809;BACKGROUND;"Hleyhel M, Goujon S, Delteil C, Vasiljevic A, Luzi S, Stephan JL, Reliquet V, Jannier S, Tubiana R, Dollfus C, Faye A, Mandelbrot L, Clavel J, Warszawski J, Blanche S; ANRS French Perinatal Cohort Study Group. Risk of cancer in children exposed to didanosine in utero. AIDS. 2016 May 15;30(8):1245-56. doi: 10.1097/QAD.0000000000001051.";Risk of cancer in children exposed to didanosine in utero.;"Hleyhel M; Goujon S; Delteil C; Vasiljevic A; Luzi S; Stephan JL; Reliquet V; Jannier S; Tubiana R; Dollfus C; Faye A; Mandelbrot L; Clavel J; Warszawski J; Blanche S; ANRS French Perinatal Cohort Study Group";10.1097/QAD.0000000000001051;2016/05/15 00:00;['Journal Article', 'Multicenter Study']
NCT02071784;Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2014-02-26;2014-07-08;2016-10-24;;;;;;;;
NCT03652090;Primary Nasal Cell Culture as a Tool for Personalized Therapy in Cystic Fibrosis;Institut National de la Santé Et de la Recherche Médicale, France;ABCF2;COMPLETED;OBSERVATIONAL;False;2018-08-29;2010-09-01;2016-03-03;;;;;;;;
NCT01605890;Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients;ANRS, Emerging Infectious Diseases;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;True;2012-05-25;2012-07;2015-12;29590335;DERIVED;"Matheron S, Descamps D, Gallien S, Besseghir A, Sellier P, Blum L, Mortier E, Charpentier C, Tubiana R, Damond F, Peytavin G, Ponscarme D, Collin F, Brun-Vezinet F, Chene G; France REcherche Nord&Sud Sida-Hiv Hepatites (ANRS) 159 HIV-2 Trial Study Group. First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2). Clin Infect Dis. 2018 Sep 28;67(8):1161-1167. doi: 10.1093/cid/ciy245.";First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).;"Matheron S; Descamps D; Gallien S; Besseghir A; Sellier P; Blum L; Mortier E; Charpentier C; Tubiana R; Damond F; Peytavin G; Ponscarme D; Collin F; Brun-Vezinet F; Chene G; France REcherche Nord&Sud Sida-Hiv Hépatites (ANRS) 159 HIV-2 Trial Study Group";10.1093/cid/ciy245;2018/09/28 00:00;['Journal Article', 'Multicenter Study']
NCT03519503;Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2018-05-09;2017-02-27;2018-02-15;22814853;BACKGROUND;"Van de Perre P, Rubbo PA, Viljoen J, Nagot N, Tylleskar T, Lepage P, Vendrell JP, Tuaillon E. HIV-1 reservoirs in breast milk and challenges to elimination of breast-feeding transmission of HIV-1. Sci Transl Med. 2012 Jul 18;4(143):143sr3. doi: 10.1126/scitranslmed.3003327.";HIV-1 reservoirs in breast milk and challenges to elimination of breast-feeding transmission of HIV-1.;"Van de Perre P; Rubbo PA; Viljoen J; Nagot N; Tylleskär T; Lepage P; Vendrell JP; Tuaillon E";10.1126/scitranslmed.3003327;2012/07/18 00:00;['Journal Article', 'Review']
NCT03519503;Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2018-05-09;2017-02-27;2018-02-15;21602695;BACKGROUND;"Heidari S, Mofenson L, Cotton MF, Marlink R, Cahn P, Katabira E. Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):290-6. doi: 10.1097/QAI.0b013e318221c56a.";Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children.;"Heidari S; Mofenson L; Cotton MF; Marlink R; Cahn P; Katabira E";10.1097/QAI.0b013e318221c56a;2011/08/01 00:00;['Journal Article', 'Review']
NCT03519503;Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2018-05-09;2017-02-27;2018-02-15;26603917;BACKGROUND;"Nagot N, Kankasa C, Tumwine JK, Meda N, Hofmeyr GJ, Vallo R, Mwiya M, Kwagala M, Traore H, Sunday A, Singata M, Siuluta C, Some E, Rutagwera D, Neboua D, Ndeezi G, Jackson D, Marechal V, Neveu D, Engebretsen IMS, Lombard C, Blanche S, Sommerfelt H, Rekacewicz C, Tylleskar T, Van de Perre P; ANRS 12174 Trial Group. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. Lancet. 2016 Feb 6;387(10018):566-573. doi: 10.1016/S0140-6736(15)00984-8. Epub 2015 Nov 19. Erratum In: Lancet. 2019 Jun 22;393(10190):2492.";Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.;"Nagot N; Kankasa C; Tumwine JK; Meda N; Hofmeyr GJ; Vallo R; Mwiya M; Kwagala M; Traore H; Sunday A; Singata M; Siuluta C; Some E; Rutagwera D; Neboua D; Ndeezi G; Jackson D; Maréchal V; Neveu D; Engebretsen IMS; Lombard C; Blanche S; Sommerfelt H; Rekacewicz C; Tylleskär T; Van de Perre P; ANRS 12174 Trial Group";10.1016/S0140-6736(15)00984-8;2016/02/06 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT02212379;Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC | Janssen-Cilag Ltd.;COMPLETED;INTERVENTIONAL;True;2014-08-08;2015-01;2018-04;31269208;PUBMED;;Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.;"Katlama C; Assoumou L; Valantin MA; Soulié C; Martinez E; Béniguel L; Bouchaud O; Raffi F; Molina JM; Fellahi S; Peytavin G; Marcelin AG; Kolta S; Capeau J; Gibowski S; Cardon F; Reynes J; Costagliola D; members of the ANRS 163 ETRAL study";10.1093/jac/dkz224;2019/09/01 00:00;['Journal Article', 'Multicenter Study']
NCT02113943;Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Citalopram on Motivation;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-04-15;2014-04;2014-06;;;;;;;;
NCT01426243;The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2011-08-31;2011-07;2017-12;30096071;DERIVED;"Colin de Verdiere N, Durier C, Samri A, Meiffredy V, Launay O, Matheron S, Mercier-Delarue S, Even S, Aboulker JP, Molina JM, Autran B, Simon F; ANRS EP46 NOVAA Group. Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients. AIDS. 2018 Oct 23;32(16):2291-2299. doi: 10.1097/QAD.0000000000001963.";Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients.;"Colin de Verdiere N; Durier C; Samri A; Meiffredy V; Launay O; Matheron S; Mercier-Delarue S; Even S; Aboulker JP; Molina JM; Autran B; Simon F; ANRS EP46 NOVAA Group";10.1097/QAD.0000000000001963;2018/10/23 00:00;['Journal Article']
NCT01426243;The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2011-08-31;2011-07;2017-12;26314624;PUBMED;;Molecular characterization of the 17D-204 yellow fever vaccine.;"Salmona M; Gazaignes S; Mercier-Delarue S; Garnier F; Korimbocus J; Colin de Verdière N; LeGoff J; Roques P; Simon F";10.1016/j.vaccine.2015.08.055;2015/10/05 00:00;['Journal Article']
NCT03870438;Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention;ANRS, Emerging Infectious Diseases;University Teaching Hospital, Lusaka, Zambia | Centre Muraz | Institut National de la Santé Et de la Recherche Médicale, France | University of Bergen;COMPLETED;INTERVENTIONAL;False;2019-03-12;2019-12-14;2022-10-31;26603917;BACKGROUND;"Nagot N, Kankasa C, Tumwine JK, Meda N, Hofmeyr GJ, Vallo R, Mwiya M, Kwagala M, Traore H, Sunday A, Singata M, Siuluta C, Some E, Rutagwera D, Neboua D, Ndeezi G, Jackson D, Marechal V, Neveu D, Engebretsen IMS, Lombard C, Blanche S, Sommerfelt H, Rekacewicz C, Tylleskar T, Van de Perre P; ANRS 12174 Trial Group. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. Lancet. 2016 Feb 6;387(10018):566-573. doi: 10.1016/S0140-6736(15)00984-8. Epub 2015 Nov 19. Erratum In: Lancet. 2019 Jun 22;393(10190):2492.";Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.;"Nagot N; Kankasa C; Tumwine JK; Meda N; Hofmeyr GJ; Vallo R; Mwiya M; Kwagala M; Traore H; Sunday A; Singata M; Siuluta C; Some E; Rutagwera D; Neboua D; Ndeezi G; Jackson D; Maréchal V; Neveu D; Engebretsen IMS; Lombard C; Blanche S; Sommerfelt H; Rekacewicz C; Tylleskär T; Van de Perre P; ANRS 12174 Trial Group";10.1016/S0140-6736(15)00984-8;2016/02/06 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT03870438;Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention;ANRS, Emerging Infectious Diseases;University Teaching Hospital, Lusaka, Zambia | Centre Muraz | Institut National de la Santé Et de la Recherche Médicale, France | University of Bergen;COMPLETED;INTERVENTIONAL;False;2019-03-12;2019-12-14;2022-10-31;33872801;BACKGROUND;"Mennecier A, Kankasa C, Fao P, Moles JP, Eymard-Duvernay S, Mwiya M, Kania D, Chunda-Liyoka C, Sakana L, Rutagwera D, Tassembedo S, Wilfred-Tonga MM, Mosqueira B, Tylleskar T, Nagot N, Van de Perre P; ANRS 12397 Study group. Design and challenges of a large HIV prevention clinical study on mother-to-child transmission: ANRS 12397 PROMISE-EPI study in Zambia and Burkina Faso. Contemp Clin Trials. 2021 Jun;105:106402. doi: 10.1016/j.cct.2021.106402. Epub 2021 Apr 17.";Design and challenges of a large HIV prevention clinical study on mother-to-child transmission: ANRS 12397 PROMISE-EPI study in Zambia and Burkina Faso.;"Mennecier A; Kankasa C; Fao P; Moles JP; Eymard-Duvernay S; Mwiya M; Kania D; Chunda-Liyoka C; Sakana L; Rutagwera D; Tassembedo S; Wilfred-Tonga MM; Mosqueira B; Tylleskär T; Nagot N; Van de Perre P; ANRS 12397 Study group";10.1016/j.cct.2021.106402;2021/06/01 00:00;['Journal Article']
NCT03870438;Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention;ANRS, Emerging Infectious Diseases;University Teaching Hospital, Lusaka, Zambia | Centre Muraz | Institut National de la Santé Et de la Recherche Médicale, France | University of Bergen;COMPLETED;INTERVENTIONAL;False;2019-03-12;2019-12-14;2022-10-31;38484756;PUBMED;;Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial.;"Kankasa C; Mennecier A; Sakana BLD; Molès JP; Mwiya M; Chunda-Liyoka C; D'Ottavi M; Tassembedo S; Wilfred-Tonga MM; Fao P; Rutagwera D; Matoka B; Kania D; Taofiki OA; Tylleskär T; Van de Perre P; Nagot N; PROMISE-EPI Trial Group";10.1016/S0140-6736(23)02464-9;2024/04/06 00:00;['Randomized Controlled Trial', 'Journal Article']
NCT01942655;IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2013-09-16;2014-06-01;2018-03-01;;;;;;;;
NCT02488395;Superior Colliculus Activity in Parkinson Disease: a Potential Marker?;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2015-07-02;2015-10-07;2018-01-19;6774653;RESULT;"Wurtz RH, Albano JE. Visual-motor function of the primate superior colliculus. Annu Rev Neurosci. 1980;3:189-226. doi: 10.1146/annurev.ne.03.030180.001201. No abstract available.";Visual-motor function of the primate superior colliculus.;"Wurtz RH; Albano JE";10.1146/annurev.ne.03.030180.001201;1980/01/01 00:00;['Journal Article', 'Review']
NCT02488395;Superior Colliculus Activity in Parkinson Disease: a Potential Marker?;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2015-07-02;2015-10-07;2018-01-19;23916713;RESULT;"Rolland M, Carcenac C, Overton PG, Savasta M, Coizet V. Enhanced visual responses in the superior colliculus and subthalamic nucleus in an animal model of Parkinson's disease. Neuroscience. 2013 Nov 12;252:277-88. doi: 10.1016/j.neuroscience.2013.07.047. Epub 2013 Jul 31.";Enhanced visual responses in the superior colliculus and subthalamic nucleus in an animal model of Parkinson's disease.;"Rolland M; Carcenac C; Overton PG; Savasta M; Coizet V";10.1016/j.neuroscience.2013.07.047;2013/11/12 00:00;['Journal Article']
NCT02488395;Superior Colliculus Activity in Parkinson Disease: a Potential Marker?;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2015-07-02;2015-10-07;2018-01-19;22639796;RESULT;"Marino RA, Levy R, Boehnke S, White BJ, Itti L, Munoz DP. Linking visual response properties in the superior colliculus to saccade behavior. Eur J Neurosci. 2012 Jun;35(11):1738-52. doi: 10.1111/j.1460-9568.2012.08079.x. Epub 2012 May 28.";Linking visual response properties in the superior colliculus to saccade behavior.;"Marino RA; Levy R; Boehnke S; White BJ; Itti L; Munoz DP";10.1111/j.1460-9568.2012.08079.x;2012/06/01 00:00;['Journal Article']
NCT02469350;Serious Game for Parkinson's Disease Patients;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-06-11;2015-06;2017-10-04;29636105;DERIVED;"Nuic D, Vinti M, Karachi C, Foulon P, Van Hamme A, Welter ML. The feasibility and positive effects of a customised videogame rehabilitation programme for freezing of gait and falls in Parkinson's disease patients: a pilot study. J Neuroeng Rehabil. 2018 Apr 10;15(1):31. doi: 10.1186/s12984-018-0375-x.";The feasibility and positive effects of a customised videogame rehabilitation programme for freezing of gait and falls in Parkinson's disease patients: a pilot study.;"Nuic D; Vinti M; Karachi C; Foulon P; Van Hamme A; Welter ML";10.1186/s12984-018-0375-x;2018/04/10 00:00;['Clinical Trial', 'Journal Article']
NCT04945655;Impact of a School- and Primary Care-based Multicomponent Intervention on HPV Vaccination Acceptability;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2021-06-30;2021-11-15;2023-04-30;35332045;DERIVED;"Bocquier A, Michel M, Giraudeau B, Bonnay S, Gagneux-Brunon A, Gauchet A, Gilberg S, Le Duc-Banaszuk AS, Mueller JE, Chevreul K, Thilly N; PrevHPV Study group. Impact of a school-based and primary care-based multicomponent intervention on HPV vaccination coverage among French adolescents: a cluster randomised controlled trial protocol (the PrevHPV study). BMJ Open. 2022 Mar 24;12(3):e057943. doi: 10.1136/bmjopen-2021-057943.";Impact of a school-based and primary care-based multicomponent intervention on HPV vaccination coverage among French adolescents: a cluster randomised controlled trial protocol (the PrevHPV study).;"Bocquier A; Michel M; Giraudeau B; Bonnay S; Gagneux-Brunon A; Gauchet A; Gilberg S; Le Duc-Banaszuk AS; Mueller JE; Chevreul K; Thilly N; PrevHPV Study group";10.1136/bmjopen-2021-057943;2022/03/24 00:00;['Journal Article']
NCT02314208;Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-11;2015-01;2018-01-01;;;;;;;;
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;24337723;RESULT;"Faure C, Gocho K, Le Mer Y, Sahel JA, Paques M, Audo I. Functional and high resolution retinal imaging assessment in a case of ocular siderosis. Doc Ophthalmol. 2014 Feb;128(1):69-75. doi: 10.1007/s10633-013-9421-y. Epub 2013 Dec 13.";Functional and high resolution retinal imaging assessment in a case of ocular siderosis.;"Faure C; Gocho K; Le Mer Y; Sahel JA; Paques M; Audo I";10.1007/s10633-013-9421-y;2014/02/01 00:00;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;28900746;RESULT;"Faure C, Paques M, Audo I. Electrophysiological features and multimodal imaging in ritonavir-related maculopathy. Doc Ophthalmol. 2017 Dec;135(3):241-248. doi: 10.1007/s10633-017-9612-z. Epub 2017 Sep 12.";Electrophysiological features and multimodal imaging in ritonavir-related maculopathy.;"Faure C; Paques M; Audo I";10.1007/s10633-017-9612-z;2017/12/01 00:00;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;26418443;DERIVED;"Jacob J, Krivosic V, Paques M, Tadayoni R, Gaudric A. CONE DENSITY LOSS ON ADAPTIVE OPTICS IN EARLY MACULAR TELANGIECTASIA TYPE 2. Retina. 2016 Mar;36(3):545-51. doi: 10.1097/IAE.0000000000000737.";CONE DENSITY LOSS ON ADAPTIVE OPTICS IN EARLY MACULAR TELANGIECTASIA TYPE 2.;"Jacob J; Krivosic V; Paques M; Tadayoni R; Gaudric A";10.1097/IAE.0000000000000737;2016/03/01 00:00;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;27065002;RESULT;"Rosenbaum D, Mattina A, Koch E, Rossant F, Gallo A, Kachenoura N, Paques M, Redheuil A, Girerd X. Effects of age, blood pressure and antihypertensive treatments on retinal arterioles remodeling assessed by adaptive optics. J Hypertens. 2016 Jun;34(6):1115-22. doi: 10.1097/HJH.0000000000000894.";Effects of age, blood pressure and antihypertensive treatments on retinal arterioles remodeling assessed by adaptive optics.;"Rosenbaum D; Mattina A; Koch E; Rossant F; Gallo A; Kachenoura N; Paques M; Redheuil A; Girerd X";10.1097/HJH.0000000000000894;2016/06/01 00:00;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;25077537;RESULT;"Paques M, Miloudi C, Kulcsar C, Leseigneur A, Chaumette C, Koch E. High-resolution imaging of gunn's dots. Retina. 2015 Jan;35(1):120-4. doi: 10.1097/IAE.0000000000000269.";High-resolution imaging of gunn's dots.;"Paques M; Miloudi C; Kulcsar C; Leseigneur A; Chaumette C; Koch E";10.1097/IAE.0000000000000269;2015/01/01 00:00;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;23620431;RESULT;"Gocho K, Sarda V, Falah S, Sahel JA, Sennlaub F, Benchaboune M, Ullern M, Paques M. Adaptive optics imaging of geographic atrophy. Invest Ophthalmol Vis Sci. 2013 May 1;54(5):3673-80. doi: 10.1167/iovs.12-10672.";Adaptive optics imaging of geographic atrophy.;"Gocho K; Sarda V; Falah S; Sahel JA; Sennlaub F; Benchaboune M; Ullern M; Paques M";10.1167/iovs.12-10672;2013/05/01 00:00;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;25997175;RESULT;"Paques M, Brolly A, Benesty J, Lerme N, Koch E, Rossant F, Bloch I, Girmens JF. Venous Nicking Without Arteriovenous Contact: The Role of the Arteriolar Microenvironment in Arteriovenous Nickings. JAMA Ophthalmol. 2015 Aug;133(8):947-50. doi: 10.1001/jamaophthalmol.2015.1132.";Venous Nicking Without Arteriovenous Contact: The Role of the Arteriolar Microenvironment in Arteriovenous Nickings.;"Paques M; Brolly A; Benesty J; Lermé N; Koch E; Rossant F; Bloch I; Girmens JF";10.1001/jamaophthalmol.2015.1132;2015/08/01 00:00;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;30947025;RESULT;"Boileve A, Jozwiak M, Malka D, Boige V, Le Roy F, Paques M, Ducreux M. Vision loss after chemotherapy: an irinotecan-induced retinopathy. Eur J Cancer. 2019 May;112:80-82. doi: 10.1016/j.ejca.2019.02.015. Epub 2019 Apr 1. No abstract available.";Vision loss after chemotherapy: an irinotecan-induced retinopathy.;"Boilève A; Jozwiak M; Malka D; Boige V; Le Roy F; Paques M; Ducreux M";10.1016/j.ejca.2019.02.015;2019/05/01 00:00;['Letter']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;29369084;RESULT;"Bottin C, Grieve K, Rossant F, Pedinielli A, Mrejen S, Paques M. DIRECTIONAL VARIABILITY OF FUNDUS REFLECTANCE IN ACUTE MACULAR NEURORETINOPATHY: EVIDENCE FOR A CONTRIBUTION OF THE STILES-CRAWFORD EFFECT. Retin Cases Brief Rep. 2018 Fall;12 Suppl 1:S19-S24. doi: 10.1097/ICB.0000000000000701.";DIRECTIONAL VARIABILITY OF FUNDUS REFLECTANCE IN ACUTE MACULAR NEURORETINOPATHY: EVIDENCE FOR A CONTRIBUTION OF THE STILES-CRAWFORD EFFECT.;"Bottin C; Grieve K; Rossant F; Pedinielli A; Mrejen S; Paques M";10.1097/ICB.0000000000000701;2018/01/01 00:00;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;26344727;RESULT;"Audo I, Gocho K, Rossant F, Mohand-Said S, Loquin K, Bloch I, Sahel JA, Paques M. Functional and high-resolution retinal imaging monitoring photoreceptor damage in acute macular neuroretinopathy. Graefes Arch Clin Exp Ophthalmol. 2016 May;254(5):855-64. doi: 10.1007/s00417-015-3136-6. Epub 2015 Sep 7.";Functional and high-resolution retinal imaging monitoring photoreceptor damage in acute macular neuroretinopathy.;"Audo I; Gocho K; Rossant F; Mohand-Saïd S; Loquin K; Bloch I; Sahel JA; Paques M";10.1007/s00417-015-3136-6;2016/05/01 00:00;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;27009576;RESULT;"Rosenbaum D, Kachenoura N, Koch E, Paques M, Cluzel P, Redheuil A, Girerd X. Relationships between retinal arteriole anatomy and aortic geometry and function and peripheral resistance in hypertensives. Hypertens Res. 2016 Jul;39(7):536-42. doi: 10.1038/hr.2016.26. Epub 2016 Mar 24.";Relationships between retinal arteriole anatomy and aortic geometry and function and peripheral resistance in hypertensives.;"Rosenbaum D; Kachenoura N; Koch E; Paques M; Cluzel P; Redheuil A; Girerd X";10.1038/hr.2016.26;2016/07/01 00:00;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;31573376;RESULT;"Errera MH, Laguarrigue M, Rossant F, Koch E, Chaumette C, Fardeau C, Westcott M, Sahel JA, Bodaghi B, Benesty J, Paques M. High-Resolution Imaging of Retinal Vasculitis by Flood Illumination Adaptive Optics Ophthalmoscopy: A Follow-up Study. Ocul Immunol Inflamm. 2020 Nov 16;28(8):1171-1180. doi: 10.1080/09273948.2019.1646773. Epub 2019 Oct 1.";High-Resolution Imaging of Retinal Vasculitis by Flood Illumination Adaptive Optics Ophthalmoscopy: A Follow-up Study.;"Errera MH; Laguarrigue M; Rossant F; Koch E; Chaumette C; Fardeau C; Westcott M; Sahel JA; Bodaghi B; Benesty J; Paques M";10.1080/09273948.2019.1646773;2020/11/16 00:00;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;30010022;RESULT;"Paques M, Meimon S, Rossant F, Rosenbaum D, Mrejen S, Sennlaub F, Grieve K. Adaptive optics ophthalmoscopy: Application to age-related macular degeneration and vascular diseases. Prog Retin Eye Res. 2018 Sep;66:1-16. doi: 10.1016/j.preteyeres.2018.07.001. Epub 2018 Jul 17.";Adaptive optics ophthalmoscopy: Application to age-related macular degeneration and vascular diseases.;"Paques M; Meimon S; Rossant F; Rosenbaum D; Mrejen S; Sennlaub F; Grieve K";10.1016/j.preteyeres.2018.07.001;2018/09/01 00:00;['Journal Article', 'Review']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;31568064;RESULT;"Sodi A, Germain DP, Bacherini D, Finocchio L, Pacini B, Marziali E, Lenzetti C, Tanini I, Koraichi F, Coriat C, Nencini P, Olivotto I, Virgili G, Rizzo S, Paques M. IN VIVO OBSERVATION OF RETINAL VASCULAR DEPOSITS USING ADAPTIVE OPTICS IMAGING IN FABRY DISEASE. Retina. 2020 Aug;40(8):1623-1629. doi: 10.1097/IAE.0000000000002648.";IN VIVO OBSERVATION OF RETINAL VASCULAR DEPOSITS USING ADAPTIVE OPTICS IMAGING IN FABRY DISEASE.;"Sodi A; Germain DP; Bacherini D; Finocchio L; Pacini B; Marziali E; Lenzetti C; Tanini I; Koraichi F; Coriat C; Nencini P; Olivotto I; Virgili G; Rizzo S; Paques M";10.1097/IAE.0000000000002648;2020/08/01 00:00;['Journal Article', 'Multicenter Study']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;24576889;RESULT;"Errera MH, Coisy S, Fardeau C, Sahel JA, Kallel S, Westcott M, Bodaghi B, Paques M. Retinal vasculitis imaging by adaptive optics. Ophthalmology. 2014 Jun;121(6):1311-2.e2. doi: 10.1016/j.ophtha.2013.12.036. Epub 2014 Feb 25. No abstract available.";Retinal vasculitis imaging by adaptive optics.;"Errera MH; Coisy S; Fardeau C; Sahel JA; Kallel S; Westcott M; Bodaghi B; Paques M";10.1016/j.ophtha.2013.12.036;2014/06/01 00:00;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;25284764;RESULT;"Jacob J, Paques M, Krivosic V, Dupas B, Couturier A, Kulcsar C, Tadayoni R, Massin P, Gaudric A. Meaning of visualizing retinal cone mosaic on adaptive optics images. Am J Ophthalmol. 2015 Jan;159(1):118-23.e1. doi: 10.1016/j.ajo.2014.09.043. Epub 2014 Oct 2.";Meaning of visualizing retinal cone mosaic on adaptive optics images.;"Jacob J; Paques M; Krivosic V; Dupas B; Couturier A; Kulcsar C; Tadayoni R; Massin P; Gaudric A";10.1016/j.ajo.2014.09.043;2015/01/01 00:00;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;31972545;RESULT;"Gallo A, Chaigneau E, Jublanc C, Rosenbaum D, Mattina A, Paques M, Rossant F, Girerd X, Leban M, Bruckert E. IGF-1 is an independent predictor of retinal arterioles remodeling in subjects with uncontrolled acromegaly. Eur J Endocrinol. 2020 Mar;182(3):375-383. doi: 10.1530/EJE-19-0390.";IGF-1 is an independent predictor of retinal arterioles remodeling in subjects with uncontrolled acromegaly.;"Gallo A; Chaigneau E; Jublanc C; Rosenbaum D; Mattina A; Paques M; Rossant F; Girerd X; Leban M; Bruckert E";10.1530/EJE-19-0390;2020/03/01 00:00;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;24406779;RESULT;"Koch E, Rosenbaum D, Brolly A, Sahel JA, Chaumet-Riffaud P, Girerd X, Rossant F, Paques M. Morphometric analysis of small arteries in the human retina using adaptive optics imaging: relationship with blood pressure and focal vascular changes. J Hypertens. 2014 Apr;32(4):890-8. doi: 10.1097/HJH.0000000000000095.";Morphometric analysis of small arteries in the human retina using adaptive optics imaging: relationship with blood pressure and focal vascular changes.;"Koch E; Rosenbaum D; Brolly A; Sahel JA; Chaumet-Riffaud P; Girerd X; Rossant F; Paques M";10.1097/HJH.0000000000000095;2014/04/01 00:00;['Clinical Trial', 'Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;26523388;RESULT;"Miloudi C, Rossant F, Bloch I, Chaumette C, Leseigneur A, Sahel JA, Meimon S, Mrejen S, Paques M. The Negative Cone Mosaic: A New Manifestation of the Optical Stiles-Crawford Effect in Normal Eyes. Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7043-50. doi: 10.1167/iovs.15-17022.";The Negative Cone Mosaic: A New Manifestation of the Optical Stiles-Crawford Effect in Normal Eyes.;"Miloudi C; Rossant F; Bloch I; Chaumette C; Leseigneur A; Sahel JA; Meimon S; Mrejen S; Paques M";10.1167/iovs.15-17022;2015/11/01 00:00;['Clinical Trial', 'Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;31922497;RESULT;"Paques M, Rossant F, Finocchio L, Grieve K, Sahel JA, Pedinielli A, Mrejen S. ATTENUATION OUTER RETINAL BANDS ON OPTICAL COHERENCE TOMOGRAPHY FOLLOWING MACULAR EDEMA: A Possible Manifestation of Photoreceptor Misalignment. Retina. 2020 Nov;40(11):2232-2239. doi: 10.1097/IAE.0000000000002738.";ATTENUATION OUTER RETINAL BANDS ON OPTICAL COHERENCE TOMOGRAPHY FOLLOWING MACULAR EDEMA: A Possible Manifestation of Photoreceptor Misalignment.;"Paques M; Rossant F; Finocchio L; Grieve K; Sahel JA; Pedinielli A; Mrejen S";10.1097/IAE.0000000000002738;2020/11/01 00:00;['Journal Article']
NCT03335995;Stroke Prognosis in Intensive CarE;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2017-11-08;2017-10-18;2020-11-18;32026446;DERIVED;"Sonneville R, Mazighi M, Bresson D, Crassard I, Crozier S, de Montmollin E, Degos V, Faugeras F, Gayat E, Josse L, Lamy C, Magalhaes E, Maldjian A, Ruckly S, Servan J, Vassel P, Vigue B, Timsit JF, Woimant F; SPICE investigators. Outcomes of Acute Stroke Patients Requiring Mechanical Ventilation: Study Protocol for the SPICE Multicenter Prospective Observational Study. Neurocrit Care. 2020 Apr;32(2):624-629. doi: 10.1007/s12028-019-00907-0.";Outcomes of Acute Stroke Patients Requiring Mechanical Ventilation: Study Protocol for the SPICE Multicenter Prospective Observational Study.;"Sonneville R; Mazighi M; Bresson D; Crassard I; Crozier S; de Montmollin E; Degos V; Faugeras F; Gayat E; Josse L; Lamy C; Magalhaes E; Maldjian A; Ruckly S; Servan J; Vassel P; Vigué B; Timsit JF; Woimant F; SPICE investigators";10.1007/s12028-019-00907-0;2020/04/01 00:00;['Journal Article']
NCT03335995;Stroke Prognosis in Intensive CarE;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2017-11-08;2017-10-18;2020-11-18;37497675;PUBMED;;One-Year Outcomes in Patients With Acute Stroke Requiring Mechanical Ventilation.;"Sonneville R; Mazighi M; Collet M; Gayat E; Degos V; Duranteau J; Grégoire C; Sharshar T; Naim G; Cortier D; Jost PH; Foucrier A; Bagate F; de Montmollin E; Papin G; Magalhaes E; Guidet B; Ben Hadj Salem O; Benghanem S; le Guennec L; Delpierre E; Legriel S; Megarbane B; Toumert K; Tran M; Geri G; Monchi M; Bodiguel E; Mariotte E; Demoule A; Zarka J; Diehl JL; Roux D; Barré E; Tanaka S; Osman D; Pasquier P; Lamara F; Crassard I; Boursin P; Ruckly S; Staiquly Q; Timsit JF; Woimant F; SPICE Investigators";10.1161/STROKEAHA.123.042910;2023/09/01 00:00;['Multicenter Study', 'Journal Article']
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;29890048;DERIVED;"Iwuji C, McGrath N, Calmy A, Dabis F, Pillay D, Newell ML, Baisley K, Porter K. Universal test and treat is not associated with sub-optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial. J Int AIDS Soc. 2018 Jun;21(6):e25112. doi: 10.1002/jia2.25112.";Universal test and treat is not associated with sub-optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial.;"Iwuji C; McGrath N; Calmy A; Dabis F; Pillay D; Newell ML; Baisley K; Porter K";10.1002/jia2.25112;2018/06/01 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;30027600;DERIVED;"Larmarange J, Diallo MH, McGrath N, Iwuji C, Plazy M, Thiebaut R, Tanser F, Barnighausen T, Pillay D, Dabis F, Orne-Gliemann J; ANRS 12249 TasP Study Group. The impact of population dynamics on the population HIV care cascade: results from the ANRS 12249 Treatment as Prevention trial in rural KwaZulu-Natal (South Africa). J Int AIDS Soc. 2018 Jul;21 Suppl 4(Suppl Suppl 4):e25128. doi: 10.1002/jia2.25128.";The impact of population dynamics on the population HIV care cascade: results from the ANRS 12249 Treatment as Prevention trial in rural KwaZulu-Natal (South Africa).;"Larmarange J; Diallo MH; McGrath N; Iwuji C; Plazy M; Thiébaut R; Tanser F; Bärnighausen T; Pillay D; Dabis F; Orne-Gliemann J; ANRS 12249 TasP Study Group";10.1002/jia2.25128;2018/07/01 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;30321314;DERIVED;"Derache A, Iwuji CC, Baisley K, Danaviah S, Marcelin AG, Calvez V, de Oliveira T, Dabis F, Porter K, Pillay D. Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial. Clin Infect Dis. 2019 Jul 2;69(2):207-214. doi: 10.1093/cid/ciy881.";Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial.;"Derache A; Iwuji CC; Baisley K; Danaviah S; Marcelin AG; Calvez V; de Oliveira T; Dabis F; Porter K; Pillay D";10.1093/cid/ciy881;2019/07/02 00:00;['Journal Article']
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;28329393;DERIVED;"Collier D, Iwuji C, Derache A, de Oliveira T, Okesola N, Calmy A, Dabis F, Pillay D, Gupta RK; French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) Study Group. Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis. Clin Infect Dis. 2017 Apr 15;64(8):1006-1016. doi: 10.1093/cid/cix015.";Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.;"Collier D; Iwuji C; Derache A; de Oliveira T; Okesola N; Calmy A; Dabis F; Pillay D; Gupta RK; French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) Study Group";10.1093/cid/cix015;2017/04/15 00:00;['Journal Article']
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;31637821;DERIVED;"Larmarange J, Diallo MH, McGrath N, Iwuji C, Plazy M, Thiebaut R, Tanser F, Barnighausen T, Orne-Gliemann J, Pillay D, Dabis F; ANRS 12249 TasP Study Group. Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa. J Int AIDS Soc. 2019 Oct;22(10):e25402. doi: 10.1002/jia2.25402.";Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa.;"Larmarange J; Diallo MH; McGrath N; Iwuji C; Plazy M; Thiébaut R; Tanser F; Bärnighausen T; Orne-Gliemann J; Pillay D; Dabis F; ANRS 12249 TasP Study Group";10.1002/jia2.25402;2019/10/01 00:00;['Journal Article']
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;29199100;DERIVED;"Iwuji CC, Orne-Gliemann J, Larmarange J, Balestre E, Thiebaut R, Tanser F, Okesola N, Makowa T, Dreyer J, Herbst K, McGrath N, Barnighausen T, Boyer S, De Oliveira T, Rekacewicz C, Bazin B, Newell ML, Pillay D, Dabis F; ANRS 12249 TasP Study Group. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV. 2018 Mar;5(3):e116-e125. doi: 10.1016/S2352-3018(17)30205-9. Epub 2017 Nov 30.";Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial.;"Iwuji CC; Orne-Gliemann J; Larmarange J; Balestre E; Thiebaut R; Tanser F; Okesola N; Makowa T; Dreyer J; Herbst K; McGrath N; Bärnighausen T; Boyer S; De Oliveira T; Rekacewicz C; Bazin B; Newell ML; Pillay D; Dabis F; ANRS 12249 TasP Study Group";10.1016/S2352-3018(17)30205-9;2018/03/01 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;23880306;DERIVED;"Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, Imrie J, Barnighausen T, Rekacewicz C, Bazin B, Newell ML, Dabis F; ANRS 12249 TasP Study Group. Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials. 2013 Jul 23;14:230. doi: 10.1186/1745-6215-14-230.";Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial.;"Iwuji CC; Orne-Gliemann J; Tanser F; Boyer S; Lessells RJ; Lert F; Imrie J; Bärnighausen T; Rekacewicz C; Bazin B; Newell ML; Dabis F; ANRS 12249 TasP Study Group";10.1186/1745-6215-14-230;2013/07/23 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;25880823;DERIVED;"Orne-Gliemann J, Larmarange J, Boyer S, Iwuji C, McGrath N, Barnighausen T, Zuma T, Dray-Spira R, Spire B, Rochat T, Lert F, Imrie J; ANRS 12249 TasP Group. Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal. BMC Public Health. 2015 Mar 1;15:209. doi: 10.1186/s12889-015-1344-y.";Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal.;"Orne-Gliemann J; Larmarange J; Boyer S; Iwuji C; McGrath N; Bärnighausen T; Zuma T; Dray-Spira R; Spire B; Rochat T; Lert F; Imrie J; ANRS 12249 TasP Group";10.1186/s12889-015-1344-y;2015/03/01 00:00;['Journal Article']
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;32970730;DERIVED;"Iwuji C, Chimukuche RS, Zuma T, Plazy M, Larmarange J, Orne-Gliemann J, Siedner M, Shahmanesh M, Seeley J. Test but not treat: Community members' experiences with barriers and facilitators to universal antiretroviral therapy uptake in rural KwaZulu-Natal, South Africa. PLoS One. 2020 Sep 24;15(9):e0239513. doi: 10.1371/journal.pone.0239513. eCollection 2020.";Test but not treat: Community members' experiences with barriers and facilitators to universal antiretroviral therapy uptake in rural KwaZulu-Natal, South Africa.;"Iwuji C; Chimukuche RS; Zuma T; Plazy M; Larmarange J; Orne-Gliemann J; Siedner M; Shahmanesh M; Seeley J";10.1371/journal.pone.0239513;2020/09/24 00:00;['Journal Article']
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;27504637;DERIVED;"Iwuji CC, Orne-Gliemann J, Larmarange J, Okesola N, Tanser F, Thiebaut R, Rekacewicz C, Newell ML, Dabis F; ANRS 12249 TasP trial group. Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised Trial. PLoS Med. 2016 Aug 9;13(8):e1002107. doi: 10.1371/journal.pmed.1002107. eCollection 2016 Aug.";Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised Trial.;"Iwuji CC; Orne-Gliemann J; Larmarange J; Okesola N; Tanser F; Thiebaut R; Rekacewicz C; Newell ML; Dabis F; ANRS 12249 TasP trial group";10.1371/journal.pmed.1002107;2016/08/09 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;30412926;DERIVED;"Perriat D, Plazy M, Gumede D, Boyer S, Pillay D, Dabis F, Seeley J, Orne-Gliemann J; ANRS 12249 TasP Study Group. ""If you are here at the clinic, you do not know how many people need help in the community"": Perspectives of home-based HIV services from health care workers in rural KwaZulu-Natal, South Africa in the era of universal test-and-treat. PLoS One. 2018 Nov 9;13(11):e0202473. doi: 10.1371/journal.pone.0202473. eCollection 2018.";"""If you are here at the clinic, you do not know how many people need help in the community"": Perspectives of home-based HIV services from health care workers in rural KwaZulu-Natal, South Africa in the era of universal test-and-treat.";"Perriat D; Plazy M; Gumede D; Boyer S; Pillay D; Dabis F; Seeley J; Orne-Gliemann J; ANRS 12249 TasP Study Group";10.1371/journal.pone.0202473;2018/11/09 00:00;['Clinical Trial', 'Journal Article']
NCT01348308;Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients;ANRS, Emerging Infectious Diseases;Pfizer;COMPLETED;INTERVENTIONAL;False;2011-05-05;2011-09;2016-03;32040959;DERIVED;"Levy Y, Lelievre JD, Assoumou L, Aznar E, Pulido F, Tambussi G, Crespo M, Meybeck A, Molina JM, Delaugerre C, Izopet J, Peytavin G, Cardon F, Diallo A, Lancar R, Beniguel L, Costagliola D. Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial. Ann Intern Med. 2020 Mar 3;172(5):297-305. doi: 10.7326/M19-2133. Epub 2020 Feb 11.";Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial.;"Lévy Y; Lelièvre JD; Assoumou L; Aznar E; Pulido F; Tambussi G; Crespo M; Meybeck A; Molina JM; Delaugerre C; Izopet J; Peytavin G; Cardon F; Diallo A; Lancar R; Béniguel L; Costagliola D";10.7326/M19-2133;2020/03/03 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT04824638;BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2021-04-01;2021-03-08;2023-12-02;;;;;;;;
NCT02323308;Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B Vaccination;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2014-12-23;2010-12;2014-06;;;;;;;;
NCT01647295;Social Interactions: Ocular Explorations and Pupillometry in Autism;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-07-23;2013-02-25;2019-06-18;;;;;;;;
NCT01332955;Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen;ANRS, Emerging Infectious Diseases;Janssen-Cilag Ltd.;COMPLETED;INTERVENTIONAL;False;2011-04-11;2011-04;2013-09;25139963;DERIVED;"Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevaliez S, Aboulker JP, Molina JM; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. Clin Infect Dis. 2014 Dec 15;59(12):1768-76. doi: 10.1093/cid/ciu659. Epub 2014 Aug 18.";Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.;"Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group";10.1093/cid/ciu659;2014/12/15 00:00;['Journal Article']
NCT00658346;Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2008-04-15;2010-06;2016-09;31063537;DERIVED;"Kouanfack C, Unal G, Schaeffer L, Kfutwah A, Aghokeng A, Mougnutou R, Tchemgui-Noumsi N, Alessandri-Gradt E, Delaporte E, Simon F, Vray M, Plantier JC; ANRS 12168 DynaMO Study. Comparative Immunovirological and Clinical Responses to Antiretroviral Therapy Between HIV-1 Group O and HIV-1 Group M Infected Patients. Clin Infect Dis. 2020 Mar 17;70(7):1471-1477. doi: 10.1093/cid/ciz371.";Comparative Immunovirological and Clinical Responses to Antiretroviral Therapy Between HIV-1 Group O and HIV-1 Group M Infected Patients.;"Kouanfack C; Unal G; Schaeffer L; Kfutwah A; Aghokeng A; Mougnutou R; Tchemgui-Noumsi N; Alessandri-Gradt E; Delaporte E; Simon F; Vray M; Plantier JC; ANRS 12168 DynaMO Study";10.1093/cid/ciz371;2020/03/17 00:00;['Journal Article']
NCT01226446;Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2010-10-22;2010-11;2013-01;25987791;DERIVED;"Terrier B, Lapidus N, Pol S, Serfaty L, Ratziu V, Asselah T, Thibault V, Souberbielle JC, Carrat F, Cacoub P. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. World J Gastroenterol. 2015 May 14;21(18):5647-53. doi: 10.3748/wjg.v21.i18.5647.";Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.;"Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P";10.3748/wjg.v21.i18.5647;2015/05/14 00:00;['Clinical Trial', 'Journal Article', 'Multicenter Study']
NCT01555450;Study of Patient Navigation to Reduce Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;National Cancer Institute, France;COMPLETED;INTERVENTIONAL;False;2012-03-15;2011-03;2013-11;21256688;BACKGROUND;"Dejardin O, Berchi C, Mignon A, Pornet C, Guillaume E, Guittet L, Bouvier V, Sailly M, Salinas A, Christophe V, Launoy G. [Social inequalities in health from observational studies to intervention: can the patient navigator reduce social inequalities in cancer patients?]. Rev Epidemiol Sante Publique. 2011 Feb;59(1):45-51. doi: 10.1016/j.respe.2010.10.008. Epub 2011 Jan 21. French.";[Social inequalities in health from observational studies to intervention: can the patient navigator reduce social inequalities in cancer patients?].;"Dejardin O; Berchi C; Mignon A; Pornet C; Guillaume E; Guittet L; Bouvier V; Sailly M; Salinas A; Christophe V; Launoy G";10.1016/j.respe.2010.10.008;2011/02/01 00:00;['Journal Article', 'Review']
NCT01555450;Study of Patient Navigation to Reduce Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;National Cancer Institute, France;COMPLETED;INTERVENTIONAL;False;2012-03-15;2011-03;2013-11;29909873;DERIVED;"De Mil R, Guillaume E, Guittet L, Dejardin O, Bouvier V, Pornet C, Christophe V, Notari A, Delattre-Massy H, De Seze C, Peng J, Launoy G, Berchi C. Cost-Effectiveness Analysis of a Navigation Program for Colorectal Cancer Screening to Reduce Social Health Inequalities: A French Cluster Randomized Controlled Trial. Value Health. 2018 Jun;21(6):685-691. doi: 10.1016/j.jval.2017.09.020. Epub 2017 Nov 10.";Cost-Effectiveness Analysis of a Navigation Program for Colorectal Cancer Screening to Reduce Social Health Inequalities: A French Cluster Randomized Controlled Trial.;"De Mil R; Guillaume E; Guittet L; Dejardin O; Bouvier V; Pornet C; Christophe V; Notari A; Delattre-Massy H; De Seze C; Peng J; Launoy G; Berchi C";10.1016/j.jval.2017.09.020;2018/06/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01555450;Study of Patient Navigation to Reduce Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;National Cancer Institute, France;COMPLETED;INTERVENTIONAL;False;2012-03-15;2011-03;2013-11;28823681;DERIVED;"Guillaume E, Dejardin O, Bouvier V, De Mil R, Berchi C, Pornet C, Christophe V, Notari A, Delattre Massy H, De Seze C, Peng J, Guittet L, Launoy G. Patient navigation to reduce social inequalities in colorectal cancer screening participation: A cluster randomized controlled trial. Prev Med. 2017 Oct;103:76-83. doi: 10.1016/j.ypmed.2017.08.012. Epub 2017 Aug 16.";Patient navigation to reduce social inequalities in colorectal cancer screening participation: A cluster randomized controlled trial.;"Guillaume E; Dejardin O; Bouvier V; De Mil R; Berchi C; Pornet C; Christophe V; Notari A; Delattre Massy H; De Seze C; Peng J; Guittet L; Launoy G";10.1016/j.ypmed.2017.08.012;2017/10/01 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT00946595;Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients;French National Agency for Research on AIDS and Viral Hepatitis;Abbott | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2009-07-27;2009-11;2014-01;30968368;DERIVED;"Garay OU, Nishimwe ML, Bousmah MA, Janah A, Girard PM, Chene G, Moinot L, Sagaon-Teyssier L, Meynard JL, Spire B, Boyer S. Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM). Pharmacoecon Open. 2019 Dec;3(4):505-515. doi: 10.1007/s41669-019-0130-7.";Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM).;"Garay OU; Nishimwe ML; Bousmah MA; Janah A; Girard PM; Chêne G; Moinot L; Sagaon-Teyssier L; Meynard JL; Spire B; Boyer S";10.1007/s41669-019-0130-7;2019/12/01 00:00;['Journal Article']
NCT00946595;Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients;French National Agency for Research on AIDS and Viral Hepatitis;Abbott | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2009-07-27;2009-11;2014-01;29767684;DERIVED;"Lambert-Niclot S, Grude M, Meynard JL, Marcelin AG, Valantin MA, Flandre P, Izopet J, Moinot L, Bouteloup V, Calvez V, Katlama C, Girard PM, Morand-Joubert L. Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies. Clin Infect Dis. 2018 Nov 28;67(12):1883-1889. doi: 10.1093/cid/ciy382.";Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies.;"Lambert-Niclot S; Grude M; Meynard JL; Marcelin AG; Valantin MA; Flandre P; Izopet J; Moinot L; Bouteloup V; Calvez V; Katlama C; Girard PM; Morand-Joubert L";10.1093/cid/ciy382;2018/11/28 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT02267304;Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Morphine and Naloxone on Motivation (MBBAnalgesic);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-10-17;2013-10-30;2016-08-30;;;;;;;;
NCT02073604;Role of the SMA During Unimanual and Bimanual Movements Preparation: the Mirror Movements Paradigm;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-02-27;2014-03;2016-02;;;;;;;;
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;28747274;DERIVED;"Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas-Castro D, Cua E, Pasquet A, Bernaud C, Pintado C, Delaugerre C, Sagaon-Teyssier L, Mestre SL, Chidiac C, Pialoux G, Ponscarme D, Fonsart J, Thompson D, Wainberg MA, Dore V, Meyer L; ANRS IPERGAY Study Group. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017 Sep;4(9):e402-e410. doi: 10.1016/S2352-3018(17)30089-9. Epub 2017 Jul 23.";Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.;"Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L; ANRS IPERGAY Study Group";10.1016/S2352-3018(17)30089-9;2017/09/01 00:00;['Journal Article', 'Multicenter Study']
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;26624850;DERIVED;"Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Preau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Dore V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1.";On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.;"Molina JM; Capitant C; Spire B; Pialoux G; Cotte L; Charreau I; Tremblay C; Le Gall JM; Cua E; Pasquet A; Raffi F; Pintado C; Chidiac C; Chas J; Charbonneau P; Delaugerre C; Suzan-Monti M; Loze B; Fonsart J; Peytavin G; Cheret A; Timsit J; Girard G; Lorente N; Préau M; Rooney JF; Wainberg MA; Thompson D; Rozenbaum W; Doré V; Marchand L; Simon MC; Etien N; Aboulker JP; Meyer L; Delfraissy JF; ANRS IPERGAY Study Group";10.1056/NEJMoa1506273;2015/12/03 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;36601747;PUBMED;;Hepatitis A and B vaccine uptake and immunisation among men who have sex with men seeking PrEP: a substudy of the ANRS IPERGAY trial.;"Le Turnier P; Charreau I; Gabassi A; Carette D; Cotte L; Pialoux G; Tremblay C; Spire B; Chaix ML; Meyer L; Capitant C; Delaugerre C; Raffi F; Molina JM; ANRS IPERGAY study group";10.1136/sextrans-2022-055634;2023/03/01 00:00;['Clinical Trial', 'Letter']
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;29229440;DERIVED;"Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, Capitant C, Rojas-Castro D, Fonsart J, Bercot B, Bebear C, Cotte L, Robineau O, Raffi F, Charbonneau P, Aslan A, Chas J, Niedbalski L, Spire B, Sagaon-Teyssier L, Carette D, Mestre SL, Dore V, Meyer L; ANRS IPERGAY Study Group. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018 Mar;18(3):308-317. doi: 10.1016/S1473-3099(17)30725-9. Epub 2017 Dec 8.";Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.;"Molina JM; Charreau I; Chidiac C; Pialoux G; Cua E; Delaugerre C; Capitant C; Rojas-Castro D; Fonsart J; Bercot B; Bébéar C; Cotte L; Robineau O; Raffi F; Charbonneau P; Aslan A; Chas J; Niedbalski L; Spire B; Sagaon-Teyssier L; Carette D; Mestre SL; Doré V; Meyer L; ANRS IPERGAY Study Group";10.1016/S1473-3099(17)30725-9;2018/03/01 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;31784343;DERIVED;"Antoni G, Tremblay C, Delaugerre C, Charreau I, Cua E, Rojas Castro D, Raffi F, Chas J, Huleux T, Spire B, Capitant C, Cotte L, Meyer L, Molina JM; ANRS IPERGAY study group. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. Lancet HIV. 2020 Feb;7(2):e113-e120. doi: 10.1016/S2352-3018(19)30341-8. Epub 2019 Nov 26.";On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.;"Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM; ANRS IPERGAY study group";10.1016/S2352-3018(19)30341-8;2020/02/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT03642704;HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-08-22;2017-02-22;2019-09-17;;;;;;;;
NCT00928187;Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé);ANRS, Emerging Infectious Diseases;Gilead Sciences | Janssen Pharmaceutica;COMPLETED;INTERVENTIONAL;True;2009-06-25;2009-11;2015-12;31273686;DERIVED;"Boyer S, Nishimwe ML, Sagaon-Teyssier L, March L, Koulla-Shiro S, Bousmah MQ, Toby R, Mpoudi-Etame MP, Ngom Gueye NF, Sawadogo A, Kouanfack C, Ciaffi L, Spire B, Delaporte E; 2-Lady Group. Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa. Pharmacoecon Open. 2020 Mar;4(1):45-60. doi: 10.1007/s41669-019-0157-9.";Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa.;"Boyer S; Nishimwe ML; Sagaon-Teyssier L; March L; Koulla-Shiro S; Bousmah MQ; Toby R; Mpoudi-Etame MP; Ngom Gueye NF; Sawadogo A; Kouanfack C; Ciaffi L; Spire B; Delaporte E; 2-Lady Group";10.1007/s41669-019-0157-9;2020/03/01 00:00;['Journal Article']
NCT02093754;Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-03-21;2014-05;2016-03;;;;;;;;
NCT02150993;First-Line Treatment for HIV-2;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-05-30;2016-01-26;2019-05-15;38740027;PUBMED;;Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial.;"Eholie SP; Ekouevi DK; Chazallon C; Charpentier C; Messou E; Diallo Z; Zoungrana J; Minga A; Ngom Gueye NF; Hawerlander D; Dembele F; Colin G; Tchounga B; Karcher S; Le Carrou J; Tchabert-Guié A; Toni TD; Ouédraogo AS; Bado G; Toure Kane C; Seydi M; Poda A; Mensah E; Diallo I; Drabo YJ; Anglaret X; Brun-Vezinet F; FIT-2 study group";10.1016/S2352-3018(24)00085-7;2024/05/10 00:00;['Journal Article']
NCT02082171;Multidomain Intervention to Prevent Disability in Elders;Institut National de la Santé Et de la Recherche Médicale, France;National Research Agency, France;COMPLETED;INTERVENTIONAL;False;2014-03-10;2013-10-16;2016-01-27;;;;;;;;
NCT02038842;Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-01-17;2014-03;2016-03;;;;;;;;
NCT01269632;Cohort of Young Adults Infected With HIV Since Birth or During Childhood;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2011-01-04;2010-06;2018-12-27;;;;;;;;
NCT02125500;Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-04-29;2014-08;2015-12;;;;;;;;
NCT02916732;Zika Virus Infection's Pregnancy Consequences in French Department of America;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2016-09-27;2016-04;2019-02;33657112;RESULT;"Funk AL, Hoen B, Vingdassalom I, Ryan C, Kadhel P, Schepers K, Gaete S, Tressieres B, Fontanet A. Reassessment of the risk of birth defects due to Zika virus in Guadeloupe, 2016. PLoS Negl Trop Dis. 2021 Mar 3;15(3):e0009048. doi: 10.1371/journal.pntd.0009048. eCollection 2021 Mar.";Reassessment of the risk of birth defects due to Zika virus in Guadeloupe, 2016.;"Funk AL; Hoen B; Vingdassalom I; Ryan C; Kadhel P; Schepers K; Gaete S; Tressières B; Fontanet A";10.1371/journal.pntd.0009048;2021/03/03 00:00;['Journal Article']
NCT02916732;Zika Virus Infection's Pregnancy Consequences in French Department of America;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2016-09-27;2016-04;2019-02;29539287;RESULT;"Hoen B, Schaub B, Funk AL, Ardillon V, Boullard M, Cabie A, Callier C, Carles G, Cassadou S, Cesaire R, Douine M, Herrmann-Storck C, Kadhel P, Laouenan C, Madec Y, Monthieux A, Nacher M, Najioullah F, Rousset D, Ryan C, Schepers K, Stegmann-Planchard S, Tressieres B, Volumenie JL, Yassinguezo S, Janky E, Fontanet A. Pregnancy Outcomes after ZIKV Infection in French Territories in the Americas. N Engl J Med. 2018 Mar 15;378(11):985-994. doi: 10.1056/NEJMoa1709481.";Pregnancy Outcomes after ZIKV Infection in French Territories in the Americas.;"Hoen B; Schaub B; Funk AL; Ardillon V; Boullard M; Cabié A; Callier C; Carles G; Cassadou S; Césaire R; Douine M; Herrmann-Storck C; Kadhel P; Laouénan C; Madec Y; Monthieux A; Nacher M; Najioullah F; Rousset D; Ryan C; Schepers K; Stegmann-Planchard S; Tressières B; Voluménie JL; Yassinguezo S; Janky E; Fontanet A";10.1056/NEJMoa1709481;2018/03/15 00:00;['Journal Article']
NCT03215732;Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal;ANRS, Emerging Infectious Diseases;Institute of Research for Development, France;COMPLETED;OBSERVATIONAL;False;2017-07-12;2017-10-19;2019-07-31;37143029;PUBMED;;Hepatitis B prevention and treatment needs in women in Senegal (ANRS 12356 AmBASS survey).;"Djaogol T; Périères L; Marcellin F; Diouf A; Carrieri MP; Diallo A; Boyer S; ANRS 12356 AmBASS Study Group";10.1186/s12889-023-15710-y;2023/05/05 00:00;['Journal Article']
NCT03215732;Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal;ANRS, Emerging Infectious Diseases;Institute of Research for Development, France;COMPLETED;OBSERVATIONAL;False;2017-07-12;2017-10-19;2019-07-31;31320358;DERIVED;"Coste M, De Seze M, Diallo A, Carrieri MP, Marcellin F, Boyer S; ANRS 12356 AmBASS Study Group. Burden and impacts of chronic hepatitis B infection in rural Senegal: study protocol of a cross-sectional survey in the area of Niakhar (AmBASS ANRS 12356). BMJ Open. 2019 Jul 17;9(7):e030211. doi: 10.1136/bmjopen-2019-030211.";Burden and impacts of chronic hepatitis B infection in rural Senegal: study protocol of a cross-sectional survey in the area of Niakhar (AmBASS ANRS 12356).;"Coste M; De Sèze M; Diallo A; Carrieri MP; Marcellin F; Boyer S; ANRS 12356 AmBASS Study Group";10.1136/bmjopen-2019-030211;2019/07/17 00:00;['Journal Article']
NCT02906137;Gut-Associated Lymphocyte Trafficking;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2016-09-19;2017-02-06;2020-02-25;;;;;;;;
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;21886816;BACKGROUND;"Cahn P, Montaner J, Junod P, Patterson P, Krolewiecki A, Andrade-Villanueva J, Cassetti I, Sierra-Madero J, Casiro AD, Bortolozzi R, Lupo SH, Longo N, Rampakakis E, Ackad N, Sampalis JS. Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen. PLoS One. 2011;6(8):e23726. doi: 10.1371/journal.pone.0023726. Epub 2011 Aug 19.";Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen.;"Cahn P; Montaner J; Junod P; Patterson P; Krolewiecki A; Andrade-Villanueva J; Cassetti I; Sierra-Madero J; Casiró AD; Bortolozzi R; Lupo SH; Longo N; Rampakakis E; Ackad N; Sampalis JS";10.1371/journal.pone.0023726;2011/01/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;18540803;BACKGROUND;"Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, Gilmore N, King MS, Bernstein BM, Brun SC, Hanna GJ. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 2008 Jul 15;198(2):234-40. doi: 10.1086/589622.";A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.;"Cameron DW; da Silva BA; Arribas JR; Myers RA; Bellos NC; Gilmore N; King MS; Bernstein BM; Brun SC; Hanna GJ";10.1086/589622;2008/07/15 00:00;['Journal Article']
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;20802298;BACKGROUND;"Gutmann C, Cusini A, Gunthard HF, Fux C, Hirschel B, Decosterd LA, Cavassini M, Yerly S, Vernazza PL; Swiss HIV Cohort Study (SHCS). Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS. 2010 Sep 24;24(15):2347-54. doi: 10.1097/QAD.0b013e32833db9a1.";Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.;"Gutmann C; Cusini A; Günthard HF; Fux C; Hirschel B; Decosterd LA; Cavassini M; Yerly S; Vernazza PL; Swiss HIV Cohort Study (SHCS)";10.1097/QAD.0b013e32833db9a1;2010/09/24 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;23075703;BACKGROUND;"Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Kerr SJ, Sophonphan J, Bhakeecheep S, Hirschel B, Ruxrungtham K; HIV STAR Study Group. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. Antivir Ther. 2012;17(7):1351-61. doi: 10.3851/IMP2443. Epub 2012 Jul 2. Erratum In: Antivir Ther. 2012;17(7):1389-90.";A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.;"Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K; HIV STAR Study Group";10.3851/IMP2443;2012/01/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;22814125;BACKGROUND;"Gilks CF, Walker AS, Dunn DT, Gibb DM, Kikaire B, Reid A, Musana H, Mambule I, Kasirye R, Robertson V, Ssali F, Spyer M, Pillay D, Yirrell D, Kaleebu P; DART Virology Group and Trial Team. Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA). Antivir Ther. 2012;17(7):1363-73. doi: 10.3851/IMP2253. Epub 2012 Jul 19.";Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).;"Gilks CF; Walker AS; Dunn DT; Gibb DM; Kikaire B; Reid A; Musana H; Mambule I; Kasirye R; Robertson V; Ssali F; Spyer M; Pillay D; Yirrell D; Kaleebu P; DART Virology Group and Trial Team";10.3851/IMP2253;2012/01/01 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;20802297;BACKGROUND;"Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, Molina JM, Hoen B, Pakianather S, Peytavin G, Marcelin AG, Flandre P. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010 Sep 24;24(15):2365-74. doi: 10.1097/QAD.0b013e32833dec20.";Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.;"Katlama C; Valantin MA; Algarte-Genin M; Duvivier C; Lambert-Niclot S; Girard PM; Molina JM; Hoen B; Pakianather S; Peytavin G; Marcelin AG; Flandre P";10.1097/QAD.0b013e32833dec20;2010/09/24 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;28566227;DERIVED;"Ciaffi L, Koulla-Shiro S, Sawadogo AB, Ndour CT, Eymard-Duvernay S, Mbouyap PR, Ayangma L, Zoungrana J, Gueye NFN, Diallo M, Izard S, Bado G, Kane CT, Aghokeng AF, Peeters M, Girard PM, Le Moing V, Reynes J, Delaporte E; MOBIDIP study group. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Lancet HIV. 2017 Sep;4(9):e384-e392. doi: 10.1016/S2352-3018(17)30069-3. Epub 2017 May 28.";Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.;"Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; MOBIDIP study group";10.1016/S2352-3018(17)30069-3;2017/09/01 00:00;['Clinical Trial', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;16249701;BACKGROUND;"Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, Arranz A, Gonzalez-Garcia JJ, Cepeda C, Hervas R, Pano JR, Gaya F, Carcas A, Montes ML, Costa JR, Pena JM. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):280-7. doi: 10.1097/01.qai.0000180077.59159.f4.";Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).;"Arribas JR; Pulido F; Delgado R; Lorenzo A; Miralles P; Arranz A; González-García JJ; Cepeda C; Hervás R; Paño JR; Gaya F; Carcas A; Montes ML; Costa JR; Peña JM";10.1097/01.qai.0000180077.59159.f4;2005/11/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;17545707;BACKGROUND;"Vernazza P, Daneel S, Schiffer V, Decosterd L, Fierz W, Klimkait T, Hoffmann M, Hirschel B. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS. 2007 Jun 19;21(10):1309-15. doi: 10.1097/QAD.0b013e32814e6b1c.";The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial.;"Vernazza P; Daneel S; Schiffer V; Decosterd L; Fierz W; Klimkait T; Hoffmann M; Hirschel B";10.1097/QAD.0b013e32814e6b1c;2007/06/19 00:00;['Journal Article']
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;18097218;BACKGROUND;"Pulido F, Arribas JR, Delgado R, Cabrero E, Gonzalez-Garcia J, Perez-Elias MJ, Arranz A, Portilla J, Pasquau J, Iribarren JA, Rubio R, Norton M; OK04 Study Group. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008 Jan 11;22(2):F1-9. doi: 10.1097/QAD.0b013e3282f4243b.";Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.;"Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M; OK04 Study Group";10.1097/QAD.0b013e3282f4243b;2008/01/11 00:00;['Classical Article', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;21811554;BACKGROUND;"Mathis S, Khanlari B, Pulido F, Schechter M, Negredo E, Nelson M, Vernazza P, Cahn P, Meynard JL, Arribas J, Bucher HC. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One. 2011;6(7):e22003. doi: 10.1371/journal.pone.0022003. Epub 2011 Jul 19.";Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis.;"Mathis S; Khanlari B; Pulido F; Schechter M; Negredo E; Nelson M; Vernazza P; Cahn P; Meynard JL; Arribas J; Bucher HC";10.1371/journal.pone.0022003;2011/01/01 00:00;['Journal Article', 'Meta-Analysis', 'Review']
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;22441252;BACKGROUND;"Bartlett JA, Ribaudo HJ, Wallis CL, Aga E, Katzenstein DA, Stevens WS, Norton MR, Klingman KL, Hosseinipour MC, Crump JA, Supparatpinyo K, Badal-Faesen S, Kallungal BA, Kumarasamy N. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS. 2012 Jul 17;26(11):1345-54. doi: 10.1097/QAD.0b013e328353b066.";Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.;"Bartlett JA; Ribaudo HJ; Wallis CL; Aga E; Katzenstein DA; Stevens WS; Norton MR; Klingman KL; Hosseinipour MC; Crump JA; Supparatpinyo K; Badal-Faesen S; Kallungal BA; Kumarasamy N";10.1097/QAD.0b013e328353b066;2012/07/17 00:00;['Journal Article', 'Multicenter Study']
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;16549962;BACKGROUND;"Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, Boeri E, Galli A, Cernuschi M, Hasson H, Clementi M, Lazzarin A. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006 Apr 4;20(6):795-803. doi: 10.1097/01.aids.0000218542.08845.b2.";Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).;"Castagna A; Danise A; Menzo S; Galli L; Gianotti N; Carini E; Boeri E; Galli A; Cernuschi M; Hasson H; Clementi M; Lazzarin A";10.1097/01.aids.0000218542.08845.b2;2006/04/04 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;20010070;BACKGROUND;"Arribas JR, Horban A, Gerstoft J, Fatkenheuer G, Nelson M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T, Moecklinghoff C. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010 Jan 16;24(2):223-30. doi: 10.1097/QAD.0b013e3283348944.";The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.;"Arribas JR; Horban A; Gerstoft J; Fätkenheuer G; Nelson M; Clumeck N; Pulido F; Hill A; van Delft Y; Stark T; Moecklinghoff C";10.1097/QAD.0b013e3283348944;2010/01/16 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT02542800;The Influence of Collective Schemas on Individual Memory;Institut National de la Santé Et de la Recherche Médicale, France;La Région Basse-Normandie | Université de Caen Normandie | University Hospital, Caen | Ecole Pratique des Hautes Etudes | Equipement d'Excellence Matrice;COMPLETED;INTERVENTIONAL;False;2015-09-07;2015-09;2017-06-02;;;;;;;;
NCT02051413;Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-01-31;2014-02-18;2018-05;;;;;;;;
NCT01569399;Efficacity of rTMS in Alcohol Dependance;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-04-03;2011-02-11;2016-08;;;;;;;;
NCT00265642;Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C;ANRS, Emerging Infectious Diseases;Sanofi;COMPLETED;INTERVENTIONAL;False;2005-12-15;2006-10;2013-11;;;;;;;;
NCT01917175;Early Identification and Treatment of Early HIV Infection in Côte d'Ivoire;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2013-08-06;1997-06;2018-09;;;;;;;;
NCT01779752;Vestibular Cortex and TMS;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2013-01-30;2013-01-20;2016-01;;;;;;;;
NCT02236832;Study of the Neural Basis of Analogical Reasoning;Institut National de la Santé Et de la Recherche Médicale, France;Fondation pour la Recherche Médicale;COMPLETED;INTERVENTIONAL;False;2014-09-11;2015-02;2021-02;;;;;;;;
NCT04409405;Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola);Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo | Institut de Recherche pour le Developpement;COMPLETED;OBSERVATIONAL;False;2020-06-01;2020-04-16;2021-10-18;38043556;PUBMED;;Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus disease in the Democratic Republic of the Congo: an observational cohort study.;"Nkuba-Ndaye A; Dilu-Keti A; Tovar-Sanchez T; Diallo MSK; Mukadi-Bamuleka D; Kitenge R; Formenty P; Legand A; Edidi-Atani F; Thaurignac G; Pelloquin R; Mbala-Kingebeni P; Toure A; Ayouba A; Muyembe-Tamfum JJ; Delaporte E; Peeters M; Ahuka-Mundeke S; Les Vainqueurs d’Ebola Study Group";10.1016/S1473-3099(23)00552-2;2024/03/01 00:00;['Journal Article']
NCT02101398;Study of the Effect of Transcranial Stimulations in Aphasic Subject Within a Year of Their Stroke;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-04-02;2014-10-02;2016-07;;;;;;;;
NCT02102737;Comparison of A New Technique of Measure of the Insulin Resistance By Scintigraphy With the Reference Technique;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-04-03;2014-05-13;2018-03;;;;;;;;
NCT01492985;Lipopeptide Immunisation With GTU-multiHIV Trial;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-12-15;2013-07;2017-04-08;33568510;DERIVED;"Levy Y, Lacabaratz C, Lhomme E, Wiedemann A, Bauduin C, Fenwick C, Foucat E, Surenaud M, Guillaumat L, Boilet V, Rieux V, Bouchaud O, Girard PM, Molina JM, Morlat P, Hocqueloux L, Richert L, Pantaleo G, Lelievre JD, Thiebaut R. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial. J Virol. 2021 Apr 12;95(9):e02165-20. doi: 10.1128/JVI.02165-20. Print 2021 Apr 12.";A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.;"Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R";10.1128/JVI.02165-20;2021/04/12 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT04392388;Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2020-05-18;2020-05-01;2023-04-11;34293141;PUBMED;;Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study.;"Carrat F; de Lamballerie X; Rahib D; Blanché H; Lapidus N; Artaud F; Kab S; Renuy A; Szabo de Edelenyi F; Meyer L; Lydié N; Charles MA; Ancel PY; Jusot F; Rouquette A; Priet S; Saba Villarroel PM; Fourié T; Lusivika-Nzinga C; Nicol J; Legot S; Druesne-Pecollo N; Esseddik Y; Lai C; Gagliolo JM; Deleuze JF; Bajos N; Severi G; Touvier M; Zins M; for the SAPRIS and SAPRIS-SERO study groups";10.1093/ije/dyab110;2021/11/10 00:00;['Journal Article']
NCT00918307;Efficacy and Safety of Varenicline Among HIV-infected Patients;ANRS, Emerging Infectious Diseases;Pfizer;COMPLETED;INTERVENTIONAL;False;2009-06-11;2009-10;2014-07;34611902;DERIVED;"Hartmann-Boyce J, Theodoulou A, Farley A, Hajek P, Lycett D, Jones LL, Kudlek L, Heath L, Hajizadeh A, Schenkels M, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2021 Oct 6;10(10):CD006219. doi: 10.1002/14651858.CD006219.pub4.";Interventions for preventing weight gain after smoking cessation.;"Hartmann-Boyce J; Theodoulou A; Farley A; Hajek P; Lycett D; Jones LL; Kudlek L; Heath L; Hajizadeh A; Schenkels M; Aveyard P";10.1002/14651858.CD006219.pub4;2021/10/06 00:00;['Journal Article', 'Meta-Analysis', 'Review']
NCT00918307;Efficacy and Safety of Varenicline Among HIV-infected Patients;ANRS, Emerging Infectious Diseases;Pfizer;COMPLETED;INTERVENTIONAL;False;2009-06-11;2009-10;2014-07;29329763;DERIVED;"Mercie P, Arsandaux J, Katlama C, Ferret S, Beuscart A, Spadone C, Duvivier C, Reynes J, Wirth N, Moinot L, Benard A, Zucman D, Duval X, Molina JM, Spire B, Fagard C, Chene G; ANRS 144 Inter-ACTIV study group. Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial. Lancet HIV. 2018 Mar;5(3):e126-e135. doi: 10.1016/S2352-3018(18)30002-X. Epub 2018 Jan 9.";Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial.;"Mercié P; Arsandaux J; Katlama C; Ferret S; Beuscart A; Spadone C; Duvivier C; Reynes J; Wirth N; Moinot L; Bénard A; Zucman D; Duval X; Molina JM; Spire B; Fagard C; Chêne G; ANRS 144 Inter-ACTIV study group";10.1016/S2352-3018(18)30002-X;2018/03/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT02656407;Intraoperative Functional Ultrasound;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-01-15;2016-02-11;2018-02;25955583;BACKGROUND;"Demene C, Deffieux T, Pernot M, Osmanski BF, Biran V, Gennisson JL, Sieu LA, Bergel A, Franqui S, Correas JM, Cohen I, Baud O, Tanter M. Spatiotemporal Clutter Filtering of Ultrafast Ultrasound Data Highly Increases Doppler and fUltrasound Sensitivity. IEEE Trans Med Imaging. 2015 Nov;34(11):2271-85. doi: 10.1109/TMI.2015.2428634. Epub 2015 Apr 30.";Spatiotemporal Clutter Filtering of Ultrafast Ultrasound Data Highly Increases Doppler and fUltrasound Sensitivity.;"Demené C; Deffieux T; Pernot M; Osmanski BF; Biran V; Gennisson JL; Sieu LA; Bergel A; Franqui S; Correas JM; Cohen I; Baud O; Tanter M";10.1109/TMI.2015.2428634;2015/11/01 00:00;['Journal Article']
NCT05090956;Developpement of 3T MRI Protocol;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2021-10-25;2012-06-08;2020-01-29;;;;;;;;
NCT02157311;4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-06-06;2014-07;2016-01;29186458;DERIVED;"de Truchis P, Assoumou L, Landman R, Mathez D, Le Du D, Bellet J, Amat K, Katlama C, Gras G, Bouchaud O, Duracinsky M, Abe E, Alvarez JC, Izopet J, Saillard J, Melchior JC, Leibowitch J, Costagliola D, Girard PM, Perronne C; ANRS 162-4D Study Group. Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial. J Antimicrob Chemother. 2018 Mar 1;73(3):738-747. doi: 10.1093/jac/dkx434.";Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial.;"de Truchis P; Assoumou L; Landman R; Mathez D; Le Dû D; Bellet J; Amat K; Katlama C; Gras G; Bouchaud O; Duracinsky M; Abe E; Alvarez JC; Izopet J; Saillard J; Melchior JC; Leibowitch J; Costagliola D; Girard PM; Perronne C; ANRS 162-4D Study Group";10.1093/jac/dkx434;2018/03/01 00:00;['Clinical Trial', 'Journal Article', 'Multicenter Study']
NCT02931097;DBS of the MLR for Gait and Balance Disorders in PD Patients;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-10-12;2016-10;2020-10;;;;;;;;
NCT04396288;Ultrasound Imaging-based Measurement of Intra-osseous Vascular Response;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-05-20;2021-09-14;2024-01-30;;;;;;;;
NCT02567071;Natural Microbiota Restoration After C-section Birth;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-10-02;2016-04-06;2019-04;;;;;;;;
NCT01698411;Study of the Influence of Sleep on Hemodynamic Parameters in Patients With Sleep Disorders;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-10-03;2012-10;2015-02;;;;;;;;
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);ANRS, Emerging Infectious Diseases;Institut Pasteur, Cambodia | National Pediatric Hospital, Cambodia | Angkor Hospital for Children | Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam | Number 2 Children's Hospital, Ho Chi Minh City | Hôpital Necker-Enfants Malades, Paris, France | Groupe Hospitalier Pitie-Salpetriere | CHRU Arnaud de Villeveuve, Montpellier, France | IRD, Yaounde, Cameroon | Fondation Chantal Biya,Yaounde, Cameroon | CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso | Centre Muraz | Centre Pasteur du Cameroun | Centre Hospitalier D'essos;COMPLETED;INTERVENTIONAL;False;2011-04-08;2011-04;2014-05;26908804;DERIVED;"Marcy O, Ung V, Goyet S, Borand L, Msellati P, Tejiokem M, Nguyen Thi NL, Nacro B, Cheng S, Eyangoh S, Pham TH, Ouedraogo AS, Tarantola A, Godreuil S, Blanche S, Delacourt C. Performance of Xpert MTB/RIF and Alternative Specimen Collection Methods for the Diagnosis of Tuberculosis in HIV-Infected Children. Clin Infect Dis. 2016 May 1;62(9):1161-1168. doi: 10.1093/cid/ciw036. Epub 2016 Feb 7.";Performance of Xpert MTB/RIF and Alternative Specimen Collection Methods for the Diagnosis of Tuberculosis in HIV-Infected Children.;"Marcy O; Ung V; Goyet S; Borand L; Msellati P; Tejiokem M; Nguyen Thi NL; Nacro B; Cheng S; Eyangoh S; Pham TH; Ouedraogo AS; Tarantola A; Godreuil S; Blanche S; Delacourt C";10.1093/cid/ciw036;2016/05/01 00:00;['Clinical Trial', 'Journal Article']
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);ANRS, Emerging Infectious Diseases;Institut Pasteur, Cambodia | National Pediatric Hospital, Cambodia | Angkor Hospital for Children | Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam | Number 2 Children's Hospital, Ho Chi Minh City | Hôpital Necker-Enfants Malades, Paris, France | Groupe Hospitalier Pitie-Salpetriere | CHRU Arnaud de Villeveuve, Montpellier, France | IRD, Yaounde, Cameroon | Fondation Chantal Biya,Yaounde, Cameroon | CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso | Centre Muraz | Centre Pasteur du Cameroun | Centre Hospitalier D'essos;COMPLETED;INTERVENTIONAL;False;2011-04-08;2011-04;2014-05;29174612;DERIVED;"Marcy O, Tejiokem M, Msellati P, Truong Huu K, Do Chau V, Tran Ngoc D, Nacro B, Ateba-Ndongo F, Tetang-Ndiang S, Ung V, Dim B, Neou L, Berteloot L, Borand L, Delacourt C, Blanche S; ANRS 12229 PAANTHER 01 Study Group. Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort study. Lancet HIV. 2018 Feb;5(2):e87-e95. doi: 10.1016/S2352-3018(17)30206-0. Epub 2017 Nov 23.";Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort study.;"Marcy O; Tejiokem M; Msellati P; Truong Huu K; Do Chau V; Tran Ngoc D; Nacro B; Ateba-Ndongo F; Tetang-Ndiang S; Ung V; Dim B; Neou L; Berteloot L; Borand L; Delacourt C; Blanche S; ANRS 12229 PAANTHER 01 Study Group";10.1016/S2352-3018(17)30206-0;2018/02/01 00:00;['Clinical Trial', 'Journal Article', 'Multicenter Study']
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);ANRS, Emerging Infectious Diseases;Institut Pasteur, Cambodia | National Pediatric Hospital, Cambodia | Angkor Hospital for Children | Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam | Number 2 Children's Hospital, Ho Chi Minh City | Hôpital Necker-Enfants Malades, Paris, France | Groupe Hospitalier Pitie-Salpetriere | CHRU Arnaud de Villeveuve, Montpellier, France | IRD, Yaounde, Cameroon | Fondation Chantal Biya,Yaounde, Cameroon | CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso | Centre Muraz | Centre Pasteur du Cameroun | Centre Hospitalier D'essos;COMPLETED;INTERVENTIONAL;False;2011-04-08;2011-04;2014-05;30689814;DERIVED;"Borand L, de Lauzanne A, Nguyen NL, Cheng S, Pham TH, Eyangoh S, Ouedraogo AS, Ung V, Msellati P, Tejiokem M, Nacro B, Inghammar M, Dim B, Delacourt C, Godreuil S, Blanche S, Marcy O; Pediatric Asian African Network for Tuberculosis and HIV Research (PAANTHER) Study Group. Isolation of Nontuberculous Mycobacteria in Southeast Asian and African Human Immunodeficiency Virus-infected Children With Suspected Tuberculosis. Clin Infect Dis. 2019 May 2;68(10):1750-1753. doi: 10.1093/cid/ciy897.";Isolation of Nontuberculous Mycobacteria in Southeast Asian and African Human Immunodeficiency Virus-infected Children With Suspected Tuberculosis.;"Borand L; de Lauzanne A; Nguyen NL; Cheng S; Pham TH; Eyangoh S; Ouedraogo AS; Ung V; Msellati P; Tejiokem M; Nacro B; Inghammar M; Dim B; Delacourt C; Godreuil S; Blanche S; Marcy O; Pediatric Asian African Network for Tuberculosis and HIV Research (PAANTHER) Study Group";10.1093/cid/ciy897;2019/05/02 00:00;['Clinical Trial', 'Journal Article', 'Multicenter Study']
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);ANRS, Emerging Infectious Diseases;Institut Pasteur, Cambodia | National Pediatric Hospital, Cambodia | Angkor Hospital for Children | Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam | Number 2 Children's Hospital, Ho Chi Minh City | Hôpital Necker-Enfants Malades, Paris, France | Groupe Hospitalier Pitie-Salpetriere | CHRU Arnaud de Villeveuve, Montpellier, France | IRD, Yaounde, Cameroon | Fondation Chantal Biya,Yaounde, Cameroon | CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso | Centre Muraz | Centre Pasteur du Cameroun | Centre Hospitalier D'essos;COMPLETED;INTERVENTIONAL;False;2011-04-08;2011-04;2014-05;31455612;DERIVED;"Marcy O, Borand L, Ung V, Msellati P, Tejiokem M, Huu KT, Do Chau V, Ngoc Tran D, Ateba-Ndongo F, Tetang-Ndiang S, Nacro B, Sanogo B, Neou L, Goyet S, Dim B, Pean P, Quillet C, Fournier I, Berteloot L, Carcelain G, Godreuil S, Blanche S, Delacourt C; ANRS 12229 PAANTHER 01 STUDY GROUP. A Treatment-Decision Score for HIV-Infected Children With Suspected Tuberculosis. Pediatrics. 2019 Sep;144(3):e20182065. doi: 10.1542/peds.2018-2065.";A Treatment-Decision Score for HIV-Infected Children With Suspected Tuberculosis.;"Marcy O; Borand L; Ung V; Msellati P; Tejiokem M; Huu KT; Do Chau V; Ngoc Tran D; Ateba-Ndongo F; Tetang-Ndiang S; Nacro B; Sanogo B; Neou L; Goyet S; Dim B; Pean P; Quillet C; Fournier I; Berteloot L; Carcelain G; Godreuil S; Blanche S; Delacourt C; ANRS 12229 PAANTHER 01 STUDY GROUP";10.1542/peds.2018-2065;2019/09/01 00:00;['Journal Article']
NCT02960698;Impulsivity in Tourette Syndrome : Behavioral and Neuroimaging Study;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-11-10;2016-10-14;2018-04-24;;;;;;;;
NCT02346409;Cerebello-thalamo-cortical Coupling in Essential Tremor;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-01-27;2015-02-04;2018-02-16;;;;;;;;
NCT02833961;Diffusion Spectroscopy in Stroke;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-07-14;2016-07-28;2019-10-25;36318030;PUBMED;;Longitudinal Monitoring of Microstructural Alterations in Cerebral Ischemia with in Vivo Diffusion-weighted MR Spectroscopy.;"Genovese G; Diaz-Fernandez B; Lejeune FX; Ronen I; Marjańska M; Yahia-Cherif L; Lehéricy S; Branzoli F; Rosso C";10.1148/radiol.220430;2023/03/01 00:00;['Journal Article']
NCT02014883;Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS;Institut National de la Santé Et de la Recherche Médicale, France;Ultragenyx Pharmaceutical Inc;COMPLETED;INTERVENTIONAL;False;2013-12-18;2013-12-04;2019-07-04;26536893;DERIVED;"Mochel F, Hainque E, Gras D, Adanyeguh IM, Caillet S, Heron B, Roubertie A, Kaphan E, Valabregue R, Rinaldi D, Vuillaumier S, Schiffmann R, Ottolenghi C, Hogrel JY, Servais L, Roze E. Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. J Neurol Neurosurg Psychiatry. 2016 May;87(5):550-3. doi: 10.1136/jnnp-2015-311475. Epub 2015 Nov 3.";Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency.;"Mochel F; Hainque E; Gras D; Adanyeguh IM; Caillet S; Héron B; Roubertie A; Kaphan E; Valabregue R; Rinaldi D; Vuillaumier S; Schiffmann R; Ottolenghi C; Hogrel JY; Servais L; Roze E";10.1136/jnnp-2015-311475;2016/05/01 00:00;['Clinical Trial', 'Journal Article']
NCT01534728;Identification of Hepatitis C Virus (HCV) Specific T Cells;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-02-17;2012-02;2014-03;;;;;;;;
NCT01693861;"""Cancersensor"" Chemotherapy";Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-09-26;2012-10;2015-02;;;;;;;;
NCT02647632;Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2016-01-06;2016-01;2017-04;29077864;DERIVED;"de Ledinghen V, Laforest C, Hezode C, Pol S, Renault A, Alric L, Larrey D, Metivier S, Tran A, Jezequel C, Samuel D, Zoulim F, Tual C, Pailhe A, Gibowski S, Bourliere M, Bellissant E, Pawlotsky JM. Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study. Clin Infect Dis. 2018 Mar 19;66(7):1013-1018. doi: 10.1093/cid/cix916.";Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.;"de Lédinghen V; Laforest C; Hézode C; Pol S; Renault A; Alric L; Larrey D; Métivier S; Tran A; Jézéquel C; Samuel D; Zoulim F; Tual C; Pailhé A; Gibowski S; Bourlière M; Bellissant E; Pawlotsky JM";10.1093/cid/cix916;2018/03/19 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT02453061;A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease;Institut National de la Santé Et de la Recherche Médicale, France;Ultragenyx Pharmaceutical Inc;COMPLETED;INTERVENTIONAL;False;2015-05-25;2015-06-29;2019-12-03;31381524;DERIVED;"Rodrigues FB, Ferreira JJ, Wild EJ. Huntington's Disease Clinical Trials Corner: June 2019. J Huntingtons Dis. 2019;8(3):363-371. doi: 10.3233/JHD-199003.";Huntington's Disease Clinical Trials Corner: June 2019.;"Rodrigues FB; Ferreira JJ; Wild EJ";10.3233/JHD-199003;2019/01/01 00:00;['Journal Article']
NCT04288128;Integrated Functional Evaluation of the Cerebellum;Institut National de la Santé Et de la Recherche Médicale, France;Biogen | Ionis Pharmaceuticals, Inc.;COMPLETED;OBSERVATIONAL;False;2020-02-28;2020-05-28;2022-06-01;38419144;PUBMED;;Digital Gait Measures Capture 1-Year Progression in Early-Stage Spinocerebellar Ataxia Type 2.;"Seemann J; Daghsen L; Cazier M; Lamy JC; Welter ML; Giese MA; Synofzik M; Durr A; Ilg W; Coarelli G";10.1002/mds.29757;2024/02/28 00:00;['Journal Article']
NCT04288128;Integrated Functional Evaluation of the Cerebellum;Institut National de la Santé Et de la Recherche Médicale, France;Biogen | Ionis Pharmaceuticals, Inc.;COMPLETED;OBSERVATIONAL;False;2020-02-28;2020-05-28;2022-06-01;38421662;PUBMED;;ATXN7-Related Cone-Rod Dystrophy: The Integrated Functional Evaluation of the Cerebellum (CERMOI) Study.;"Nassisi M; Coarelli G; Blanchard B; Dubec-Fleury C; Drine K; Kitic N; Sancho S; Hilab R; Tezenas du Montcel S; Junge C; Lane R; Arnold HM; Durr A; Audo I";10.1001/jamaophthalmol.2024.0001;2024/04/01 00:00;['Journal Article', 'Comment']
NCT01899196;Epicardial Adipose Tissue And Coronary Risk In HIV-Infected Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2013-07-15;2013-07;2016-03;;;;;;;;
NCT04684758;HIV Acquisition and Life Course of Born-abroad Men Who Have Sex With Men Living in Ile-de-France: the GANYMEDE Study;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;OBSERVATIONAL;False;2020-12-28;2021-04-14;2022-06-30;;;;;;;;
NCT02428816;Evaluation of a Multimodal Neuroimaging Method for Diagnosis in Parkinsonian Syndromes;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-04-29;2013-01-24;2016-07-28;;;;;;;;
NCT01842919;Dance and Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2013-04-30;2013-04;2016-07-08;;;;;;;;
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;18614870;RESULT;"Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group; Sabin CA, Smith CJ, d'Arminio Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A, Leport C, Dabis F, Pantazis N, Porter K, Raffi F, Thorne C, Torti C, Walker S, Warszawski J, Wintergerst U, Chene G, Lundgren J. Response to combination antiretroviral therapy: variation by age. AIDS. 2008 Jul 31;22(12):1463-73. doi: 10.1097/QAD.0b013e3282f88d02.";Response to combination antiretroviral therapy: variation by age.;"Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group; Sabin CA; Smith CJ; d'Arminio Monforte A; Battegay M; Gabiano C; Galli L; Geelen S; Gibb D; Guiguet M; Judd A; Leport C; Dabis F; Pantazis N; Porter K; Raffi F; Thorne C; Torti C; Walker S; Warszawski J; Wintergerst U; Chene G; Lundgren J";10.1097/QAD.0b013e3282f88d02;2008/07/31 00:00;['Journal Article', 'Multicenter Study']
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;21971357;RESULT;"Judd A; European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens. AIDS. 2011 Nov 28;25(18):2279-87. doi: 10.1097/QAD.0b013e32834d614c.";Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens.;"Judd A; European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord";10.1097/QAD.0b013e32834d614c;2011/11/28 00:00;['Journal Article']
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;26762993;RESULT;"Frange P, Faye A, Avettand-Fenoel V, Bellaton E, Descamps D, Angin M, David A, Caillat-Zucman S, Peytavin G, Dollfus C, Le Chenadec J, Warszawski J, Rouzioux C, Saez-Cirion A; ANRS EPF-CO10 Pediatric Cohort and the ANRS EP47 VISCONTI study group. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV. 2016 Jan;3(1):e49-54. doi: 10.1016/S2352-3018(15)00232-5. Epub 2015 Dec 9.";HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.;"Frange P; Faye A; Avettand-Fenoël V; Bellaton E; Descamps D; Angin M; David A; Caillat-Zucman S; Peytavin G; Dollfus C; Le Chenadec J; Warszawski J; Rouzioux C; Sáez-Cirión A; ANRS EPF-CO10 Pediatric Cohort and the ANRS EP47 VISCONTI study group";10.1016/S2352-3018(15)00232-5;2016/01/01 00:00;['Journal Article']
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;20536367;RESULT;"Dollfus C, Le Chenadec J, Faye A, Blanche S, Briand N, Rouzioux C, Warszawski J. Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10). Clin Infect Dis. 2010 Jul 15;51(2):214-24. doi: 10.1086/653674.";Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10).;"Dollfus C; Le Chenadec J; Faye A; Blanche S; Briand N; Rouzioux C; Warszawski J";10.1086/653674;2010/07/15 00:00;['Journal Article']
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;21511330;RESULT;"Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE); Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warsawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chene G, Phillips A. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet. 2011 May 7;377(9777):1580-7. doi: 10.1016/S0140-6736(11)60208-0. Epub 2011 Apr 20.";Risk of triple-class virological failure in children with HIV: a retrospective cohort study.;"Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE); Castro H; Judd A; Gibb DM; Butler K; Lodwick RK; van Sighem A; Ramos JT; Warsawski J; Thorne C; Noguera-Julian A; Obel N; Costagliola D; Tookey PA; Colin C; Kjaer J; Grarup J; Chene G; Phillips A";10.1016/S0140-6736(11)60208-0;2011/05/07 00:00;['Journal Article']
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;17712765;RESULT;"Warszawski J, Lechenadec J, Faye A, Dollfus C, Firtion G, Meyer L, Douard D, Monpoux F, Tricoire J, Benmebarek Y, Rouzioux C, Blanche S. Long-term nonprogression of HIV infection in children: evaluation of the ANRS prospective French Pediatric Cohort. Clin Infect Dis. 2007 Sep 15;45(6):785-94. doi: 10.1086/521165. Epub 2007 Aug 14.";Long-term nonprogression of HIV infection in children: evaluation of the ANRS prospective French Pediatric Cohort.;"Warszawski J; Lechenadec J; Faye A; Dollfus C; Firtion G; Meyer L; Douard D; Monpoux F; Tricoire J; Benmebarek Y; Rouzioux C; Blanche S";10.1086/521165;2007/09/15 00:00;['Journal Article']
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;22427678;RESULT;"Avettand-Fenoel V, Blanche S, Le Chenadec J, Scott-Algara D, Dollfus C, Viard JP, Bouallag N, Benmebarek Y, Riviere Y, Warszawski J, Rouzioux C, Buseyne F. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study. J Infect Dis. 2012 May 15;205(10):1520-8. doi: 10.1093/infdis/jis233. Epub 2012 Mar 15.";Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study.;"Avettand-Fenoel V; Blanche S; Le Chenadec J; Scott-Algara D; Dollfus C; Viard JP; Bouallag N; Benmebarek Y; Rivière Y; Warszawski J; Rouzioux C; Buseyne F";10.1093/infdis/jis233;2012/05/15 00:00;['Journal Article']
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;24705410;RESULT;"Sofeu CL, Warszawski J, Ateba Ndongo F, Penda IC, Tetang Ndiang S, Guemkam G, Makwet N, Owona F, Kfutwah A, Tchendjou P, Texier G, Tchuente M, Faye A, Tejiokem MC; ANRS-PEDIACAM Study Group. Low birth weight in perinatally HIV-exposed uninfected infants: observations in urban settings in Cameroon. PLoS One. 2014 Apr 3;9(4):e93554. doi: 10.1371/journal.pone.0093554. eCollection 2014.";Low birth weight in perinatally HIV-exposed uninfected infants: observations in urban settings in Cameroon.;"Sofeu CL; Warszawski J; Ateba Ndongo F; Penda IC; Tetang Ndiang S; Guemkam G; Makwet N; Owona F; Kfutwah A; Tchendjou P; Texier G; Tchuente M; Faye A; Tejiokem MC; ANRS-PEDIACAM Study Group";10.1371/journal.pone.0093554;2014/04/03 00:00;['Journal Article']
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;19194272;RESULT;"Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, Green H, Galli L, Ramos JT, Giaquinto C, Warszawski J, Levy J; European Infant Collaboration group. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS. 2009 Mar 13;23(5):597-604. doi: 10.1097/QAD.0b013e328326ca37.";Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants.;"Goetghebuer T; Haelterman E; Le Chenadec J; Dollfus C; Gibb D; Judd A; Green H; Galli L; Ramos JT; Giaquinto C; Warszawski J; Levy J; European Infant Collaboration group";10.1097/QAD.0b013e328326ca37;2009/03/13 00:00;['Journal Article', 'Multicenter Study']
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;24945880;RESULT;"Aupiais C, Faye A, Le Chenadec J, Rouzioux C, Bouallag N, Laurent C, Blanche S, Dollfus C, Warszawski J; ANRS EPF-CO10 French Pediatric Cohort. Interruption of cART in clinical practice is associated with an increase in the long-term risk of subsequent immunosuppression in HIV-1-infected children. Pediatr Infect Dis J. 2014 Dec;33(12):1237-45. doi: 10.1097/INF.0000000000000450.";Interruption of cART in clinical practice is associated with an increase in the long-term risk of subsequent immunosuppression in HIV-1-infected children.;"Aupiais C; Faye A; Le Chenadec J; Rouzioux C; Bouallag N; Laurent C; Blanche S; Dollfus C; Warszawski J; ANRS EPF-CO10 French Pediatric Cohort";10.1097/INF.0000000000000450;2014/12/01 00:00;['Journal Article', 'Multicenter Study']
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;24253249;RESULT;"Blanche S, Scott-Algara D, Le Chenadec J, Didier C, Montange T, Avettand-Fenoel V, Rouzioux C, Melard A, Viard JP, Dollfus C, Bouallag N, Warszawski J, Buseyne F. Naive T lymphocytes and recent thymic emigrants are associated with HIV-1 disease history in french adolescents and young adults infected in the perinatal period: the ANRS-EP38-IMMIP study. Clin Infect Dis. 2014 Feb;58(4):573-87. doi: 10.1093/cid/cit729. Epub 2013 Nov 18.";Naive T lymphocytes and recent thymic emigrants are associated with HIV-1 disease history in french adolescents and young adults infected in the perinatal period: the ANRS-EP38-IMMIP study.;"Blanche S; Scott-Algara D; Le Chenadec J; Didier C; Montange T; Avettand-Fenoel V; Rouzioux C; Mélard A; Viard JP; Dollfus C; Bouallag N; Warszawski J; Buseyne F";10.1093/cid/cit729;2014/02/01 00:00;['Journal Article']
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;22198788;RESULT;"Goetghebuer T, Le Chenadec J, Haelterman E, Galli L, Dollfus C, Thorne C, Judd A, Keiser O, Ramos JT, Levy J, Warszawski J; European Infant Collaboration Group. Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation. Clin Infect Dis. 2012 Mar;54(6):878-81. doi: 10.1093/cid/cir950. Epub 2011 Dec 23.";Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation.;"Goetghebuer T; Le Chenadec J; Haelterman E; Galli L; Dollfus C; Thorne C; Judd A; Keiser O; Ramos JT; Levy J; Warszawski J; European Infant Collaboration Group";10.1093/cid/cir950;2012/03/01 00:00;['Journal Article']
NCT02057796;Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-02-07;2014-09;2018-04;32558469;DERIVED;"Blanc FX, Badje AD, Bonnet M, Gabillard D, Messou E, Muzoora C, Samreth S, Nguyen BD, Borand L, Domergue A, Rapoud D, Natukunda N, Thai S, Juchet S, Eholie SP, Lawn SD, Domoua SK, Anglaret X, Laureillard D; STATIS ANRS 12290 Trial Team. Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults. N Engl J Med. 2020 Jun 18;382(25):2397-2410. doi: 10.1056/NEJMoa1910708.";Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults.;"Blanc FX; Badje AD; Bonnet M; Gabillard D; Messou E; Muzoora C; Samreth S; Nguyen BD; Borand L; Domergue A; Rapoud D; Natukunda N; Thai S; Juchet S; Eholié SP; Lawn SD; Domoua SK; Anglaret X; Laureillard D; STATIS ANRS 12290 Trial Team";10.1056/NEJMoa1910708;2020/06/18 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT02057796;Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-02-07;2014-09;2018-04;36883573;PUBMED;;High performance of systematic combined urine LAM test and sputum Xpert MTB/RIF® for tuberculosis screening in severely immunosuppressed ambulatory adults with HIV.;"Bonnet M; Gabillard D; Domoua S; Muzoora C; Messou E; Sovannarith S; Nguyen DB; Badje A; Juchet S; Bunnet D; Borand L; Natukunda N; Tran TH; Anglaret X; Laureillard D; Blanc FX; STATIS ANRS 12290 Trial Team";10.1093/cid/ciad125;2023/03/08 00:00;['Journal Article']
NCT01693835;"""Cancersensor"": Circadian Rhythms";Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-09-26;2012-08;2014-06;;;;;;;;
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;34425825;PUBMED;;The prevalence and socio-behavioural and clinical covariates of oral health related quality of life in Ugandan mothers with and without HIV-1.;"Birungi N; Fadnes LT; Engebretsen IMS; Tumwine JK; Åstrøm AN; ANRS 12174 and 12341 study groups";10.1186/s12955-021-01844-3;2021/08/23 00:00;['Journal Article']
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;17825642;BACKGROUND;"Kourtis AP, Jamieson DJ, de Vincenzi I, Taylor A, Thigpen MC, Dao H, Farley T, Fowler MG. Prevention of human immunodeficiency virus-1 transmission to the infant through breastfeeding: new developments. Am J Obstet Gynecol. 2007 Sep;197(3 Suppl):S113-22. doi: 10.1016/j.ajog.2007.03.003.";Prevention of human immunodeficiency virus-1 transmission to the infant through breastfeeding: new developments.;"Kourtis AP; Jamieson DJ; de Vincenzi I; Taylor A; Thigpen MC; Dao H; Farley T; Fowler MG";10.1016/j.ajog.2007.03.003;2007/09/01 00:00;['Journal Article', 'Review']
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;32991450;DERIVED;"Birungi N, Fadnes LT, Engebretsen IMS, Tumwine JK, Astrom AN; for ANRS 12174 AND 12341 study groups. Antiretroviral treatment and its impact on oral health outcomes in 5 to 7 year old Ugandan children: A 6 year follow-up visit from the ANRS 12174 randomized trial. Medicine (Baltimore). 2020 Sep 25;99(39):e22352. doi: 10.1097/MD.0000000000022352.";Antiretroviral treatment and its impact on oral health outcomes in 5 to 7 year old Ugandan children: A 6 year follow-up visit from the ANRS 12174 randomized trial.;"Birungi N; Fadnes LT; Engebretsen IMS; Tumwine JK; Åstrøm AN; for ANRS 12174 AND 12341 study groups";10.1097/MD.0000000000022352;2020/09/25 00:00;['Clinical Trial', 'Journal Article', 'Randomized Controlled Trial']
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;32067040;DERIVED;"Montoya-Ferrer A, Sanosyan A, Fayd'herbe de Maudave A, Pisoni A, Bollore K, Moles JP, Peries M, Tylleskar T, Tumwine JK, Ndeezi G, Gorgolas M, Nagot N, van de Perre P, Tuaillon E. Clinical and Biological Factors Associated With Early Epstein-Barr Virus Infection in Human Immunodeficiency Virus-Exposed Uninfected Infants in Eastern Uganda. Clin Infect Dis. 2021 Mar 15;72(6):1026-1032. doi: 10.1093/cid/ciaa161.";Clinical and Biological Factors Associated With Early Epstein-Barr Virus Infection in Human Immunodeficiency Virus-Exposed Uninfected Infants in Eastern Uganda.;"Montoya-Ferrer A; Sanosyan A; Fayd'herbe de Maudave A; Pisoni A; Bollore K; Molès JP; Peries M; Tylleskar T; Tumwine JK; Ndeezi G; Gorgolas M; Nagot N; van de Perre P; Tuaillon E";10.1093/cid/ciaa161;2021/03/15 00:00;['Journal Article']
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;28469697;DERIVED;"Some EN, Engebretsen IMS, Nagot N, Meda N, Lombard C, Vallo R, Peries M, Kankasa C, Tumwine JK, Hofmeyr GJ, Singata M, Harper K, Van De Perre P, Tylleskar T; ANRS 12174 Trial Group. Breastfeeding patterns and its determinants among mothers living with Human Immuno-deficiency Virus -1 in four African countries participating in the ANRS 12174 trial. Int Breastfeed J. 2017 May 2;12:22. doi: 10.1186/s13006-017-0112-2. eCollection 2016.";Breastfeeding patterns and its determinants among mothers living with Human Immuno-deficiency Virus -1 in four African countries participating in the ANRS 12174 trial.;"Somé EN; Engebretsen IMS; Nagot N; Meda N; Lombard C; Vallo R; Peries M; Kankasa C; Tumwine JK; Hofmeyr GJ; Singata M; Harper K; Van De Perre P; Tylleskar T; ANRS 12174 Trial Group";10.1186/s13006-017-0112-2;2017/05/02 00:00;['Journal Article']
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;23039034;DERIVED;"Nagot N, Kankasa C, Meda N, Hofmeyr J, Nikodem C, Tumwine JK, Karamagi C, Sommerfelt H, Neveu D, Tylleskar T, Van de Perre P; PROMISE-PEP group. Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174. BMC Infect Dis. 2012 Oct 6;12:246. doi: 10.1186/1471-2334-12-246.";Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174.;"Nagot N; Kankasa C; Meda N; Hofmeyr J; Nikodem C; Tumwine JK; Karamagi C; Sommerfelt H; Neveu D; Tylleskär T; Van de Perre P; PROMISE-PEP group";10.1186/1471-2334-12-246;2012/10/06 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;31994250;DERIVED;"Birungi N, Fadnes LT, Engebretsen IMS, Lie SA, Tumwine JK, Astrom AN; ANRS 12174 and 12341 study groups. Association of maternal HIV-1 severity with dental caries: an observational study of uninfected 5- to 7-yr-old children of HIV-1-infected mothers without severe immune suppression. Eur J Oral Sci. 2020 Feb;128(1):46-54. doi: 10.1111/eos.12669. Epub 2020 Jan 29.";Association of maternal HIV-1 severity with dental caries: an observational study of uninfected 5- to 7-yr-old children of HIV-1-infected mothers without severe immune suppression.;"Birungi N; Fadnes LT; Engebretsen IMS; Lie SA; Tumwine JK; Åstrøm AN; ANRS 12174 and 12341 study groups";10.1111/eos.12669;2020/02/01 00:00;['Journal Article']
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;26603917;DERIVED;"Nagot N, Kankasa C, Tumwine JK, Meda N, Hofmeyr GJ, Vallo R, Mwiya M, Kwagala M, Traore H, Sunday A, Singata M, Siuluta C, Some E, Rutagwera D, Neboua D, Ndeezi G, Jackson D, Marechal V, Neveu D, Engebretsen IMS, Lombard C, Blanche S, Sommerfelt H, Rekacewicz C, Tylleskar T, Van de Perre P; ANRS 12174 Trial Group. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. Lancet. 2016 Feb 6;387(10018):566-573. doi: 10.1016/S0140-6736(15)00984-8. Epub 2015 Nov 19. Erratum In: Lancet. 2019 Jun 22;393(10190):2492.";Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.;"Nagot N; Kankasa C; Tumwine JK; Meda N; Hofmeyr GJ; Vallo R; Mwiya M; Kwagala M; Traore H; Sunday A; Singata M; Siuluta C; Some E; Rutagwera D; Neboua D; Ndeezi G; Jackson D; Maréchal V; Neveu D; Engebretsen IMS; Lombard C; Blanche S; Sommerfelt H; Rekacewicz C; Tylleskär T; Van de Perre P; ANRS 12174 Trial Group";10.1016/S0140-6736(15)00984-8;2016/02/06 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;32228542;DERIVED;"Birungi N, Fadnes LT, Engebretsen IMS, Lie SA, Tumwine JK, Astrom AN; ANRS 12174 and 12341 study groups. Caries experience and oral health related quality of life in a cohort of Ugandan HIV-1 exposed uninfected children compared with a matched cohort of HIV unexposed uninfected children. BMC Public Health. 2020 Mar 30;20(1):423. doi: 10.1186/s12889-020-08564-1.";Caries experience and oral health related quality of life in a cohort of Ugandan HIV-1 exposed uninfected children compared with a matched cohort of HIV unexposed uninfected children.;"Birungi N; Fadnes LT; Engebretsen IMS; Lie SA; Tumwine JK; Åstrøm AN; ANRS 12174 and 12341 study groups";10.1186/s12889-020-08564-1;2020/03/30 00:00;['Journal Article']
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;27895016;DERIVED;"Foissac F, Blume J, Treluyer JM, Tylleskar T, Kankasa C, Meda N, Tumwine JK, Singata-Madliki M, Harper K, Illamola SM, Bouazza N, Nagot N, Van de Perre P, Blanche S, Hirt D. Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e01869-16. doi: 10.1128/AAC.01869-16. Print 2017 Feb.";Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding.;"Foissac F; Blume J; Tréluyer JM; Tylleskär T; Kankasa C; Meda N; Tumwine JK; Singata-Madliki M; Harper K; Illamola SM; Bouazza N; Nagot N; Van de Perre P; Blanche S; Hirt D";10.1128/AAC.01869-16;2017/01/24 00:00;['Journal Article']
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;30814028;DERIVED;"Blanche S, Tylleskar T, Peries M, Kankasa C, Engebretsen I, Meda N, Tumwine JK, Singata-Madliki M, Mwiya M, Van de Perre P, Nagot N; ANRS 12174 Trial Group. Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial. Lancet HIV. 2019 May;6(5):e307-e314. doi: 10.1016/S2352-3018(18)30361-8. Epub 2019 Feb 24.";Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial.;"Blanche S; Tylleskär T; Peries M; Kankasa C; Engebretsen I; Meda N; Tumwine JK; Singata-Madliki M; Mwiya M; Van de Perre P; Nagot N; ANRS 12174 Trial Group";10.1016/S2352-3018(18)30361-8;2019/05/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;31633158;DERIVED;"Kariyawasam D, Peries M, Foissac F, Eymard-Duvernay S, Tylleskar T, Singata-Madliki M, Kankasa C, Meda N, Tumwine J, Mwiya M, Engebretsen I, Fluck CE, Hartmann MF, Wudy SA, Hirt D, Treluyer JM, Moles JP, Blanche S, Van De Perre P, Polak M, Nagot N; ANRS 12174 Trial Group. Lopinavir-Ritonavir Impairs Adrenal Function in Infants. Clin Infect Dis. 2020 Aug 14;71(4):1030-1039. doi: 10.1093/cid/ciz888.";Lopinavir-Ritonavir Impairs Adrenal Function in Infants.;"Kariyawasam D; Peries M; Foissac F; Eymard-Duvernay S; Tylleskär T; Singata-Madliki M; Kankasa C; Meda N; Tumwine J; Mwiya M; Engebretsen I; Flück CE; Hartmann MF; Wudy SA; Hirt D; Treluyer JM; Molès JP; Blanche S; Van De Perre P; Polak M; Nagot N; ANRS 12174 Trial Group";10.1093/cid/ciz888;2020/08/14 00:00;['Journal Article']
NCT03071458;Mutational Landscape in Hepatocellular Carcinoma;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2017-03-07;2008-01;2015-05;;;;;;;;
NCT02192658;Disability and HIV: Vulnerability of People With Disabilities to HIV Infection in Sub-Saharan Africa;ANRS, Emerging Infectious Diseases;Handicap International | Institut de Recherche pour le Developpement | Institut de Formation et de Recherche Démographique | Forum Camerounais de Psychologie | Centre de Recherche Internationale pour la Santé de l'Université de Ouagadougou;COMPLETED;OBSERVATIONAL;False;2014-07-17;2014-11;2016-07;26846895;DERIVED;"De Beaudrap P, Pasquier E, Tchoumkeu A, Touko A, Essomba F, Brus A, Desgrees du Lou A, Aderemi TJ, Hanass-Hancock J, Eide AH, Mont D, Mac-Seing M, Beninguisse G. HandiVIH--A population-based survey to understand the vulnerability of people with disabilities to HIV and other sexual and reproductive health problems in Cameroon: protocol and methodological considerations. BMJ Open. 2016 Feb 4;6(2):e008934. doi: 10.1136/bmjopen-2015-008934.";HandiVIH--A population-based survey to understand the vulnerability of people with disabilities to HIV and other sexual and reproductive health problems in Cameroon: protocol and methodological considerations.;"De Beaudrap P; Pasquier E; Tchoumkeu A; Touko A; Essomba F; Brus A; Desgrées du Loû A; Aderemi TJ; Hanass-Hancock J; Eide AH; Mont D; Mac-Seing M; Beninguisse G";10.1136/bmjopen-2015-008934;2016/02/04 00:00;['Journal Article']
NCT02626286;Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa;ANRS, Emerging Infectious Diseases;Expertise France | Université Montpellier | IRD Unité SESSTIM (IRD, Inserm, Université Aix-Marseille) | Coalition Internationale Sida | ARCAD-SIDA MALI | Espace Confiance, Côte d'Ivoire | Programme PAC-CI, Abidjan, Côte d'Ivoire | Association African Solidarité | Centre de Recherche Internationale pour la Santé, Ouagadougou, Burkina Faso | Espoir Vie-Togo - ONG;COMPLETED;INTERVENTIONAL;False;2015-12-10;2015-06;2021-01-05;34022820;DERIVED;"Dah TTE, Yaya I, Sagaon-Teyssier L, Coulibaly A, Kouame MJ, Agboyibor MK, Maiga K, Traore I, Mora M, Palvadeau P, Rojas-Castro D, Diallo F, Mensah E, Anoma C, Keita BD, Spire B, Laurent C; CohMSM Study Group. Adherence to quarterly HIV prevention services and its impact on HIV incidence in men who have sex with men in West Africa (CohMSM ANRS 12324 - Expertise France). BMC Public Health. 2021 May 22;21(1):972. doi: 10.1186/s12889-021-10994-4.";Adherence to quarterly HIV prevention services and its impact on HIV incidence in men who have sex with men in West Africa (CohMSM ANRS 12324 - Expertise France).;"Dah TTE; Yaya I; Sagaon-Teyssier L; Coulibaly A; Kouamé MJ; Agboyibor MK; Maiga K; Traoré I; Mora M; Palvadeau P; Rojas-Castro D; Diallo F; Mensah E; Anoma C; Keita BD; Spire B; Laurent C; CohMSM Study Group";10.1186/s12889-021-10994-4;2021/05/22 00:00;['Journal Article']
NCT02626286;Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa;ANRS, Emerging Infectious Diseases;Expertise France | Université Montpellier | IRD Unité SESSTIM (IRD, Inserm, Université Aix-Marseille) | Coalition Internationale Sida | ARCAD-SIDA MALI | Espace Confiance, Côte d'Ivoire | Programme PAC-CI, Abidjan, Côte d'Ivoire | Association African Solidarité | Centre de Recherche Internationale pour la Santé, Ouagadougou, Burkina Faso | Espoir Vie-Togo - ONG;COMPLETED;INTERVENTIONAL;False;2015-12-10;2015-06;2021-01-05;34352834;DERIVED;"Dah TTE, Yaya I, Mensah E, Coulibaly A, Kouame JM, Traore I, Mora M, Palvadeau P, Anoma C, Keita BD, Spire B, Laurent C; CohMSM Study Group. Rapid antiretroviral therapy initiation and its effect on treatment response in MSM in West Africa. AIDS. 2021 Nov 1;35(13):2201-2210. doi: 10.1097/QAD.0000000000003046.";Rapid antiretroviral therapy initiation and its effect on treatment response in MSM in West Africa.;"Dah TTE; Yaya I; Mensah E; Coulibaly A; Kouamé JM; Traoré I; Mora M; Palvadeau P; Anoma C; Keita BD; Spire B; Laurent C; CohMSM Study Group";10.1097/QAD.0000000000003046;2021/11/01 00:00;['Journal Article']
NCT02626286;Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa;ANRS, Emerging Infectious Diseases;Expertise France | Université Montpellier | IRD Unité SESSTIM (IRD, Inserm, Université Aix-Marseille) | Coalition Internationale Sida | ARCAD-SIDA MALI | Espace Confiance, Côte d'Ivoire | Programme PAC-CI, Abidjan, Côte d'Ivoire | Association African Solidarité | Centre de Recherche Internationale pour la Santé, Ouagadougou, Burkina Faso | Espoir Vie-Togo - ONG;COMPLETED;INTERVENTIONAL;False;2015-12-10;2015-06;2021-01-05;33753460;DERIVED;"Yaya I, Diallo F, Kouame MJ, Agboyibor MK, Traore I, Coulibaly A, Maiga K, Mora M, Palvadeau P, Dah ETT, Mensah E, Anoma C, Dembele Keita B, Spire B, Laurent C; CohMSM Study Group. Decrease in incidence of sexually transmitted infections symptoms in men who have sex with men enrolled in a quarterly HIV prevention and care programme in West Africa (CohMSM ANRS 12324-Expertise France). Sex Transm Infect. 2022 Mar;98(2):85-94. doi: 10.1136/sextrans-2020-054755. Epub 2021 Mar 22.";Decrease in incidence of sexually transmitted infections symptoms in men who have sex with men enrolled in a quarterly HIV prevention and care programme in West Africa (CohMSM ANRS 12324-Expertise France).;"Yaya I; Diallo F; Kouamé MJ; Agboyibor MK; Traoré I; Coulibaly A; Maiga K; Mora M; Palvadeau P; Dah ETT; Mensah E; Anoma C; Dembélé Keita B; Spire B; Laurent C; CohMSM Study Group";10.1136/sextrans-2020-054755;2022/03/01 00:00;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23553643;BACKGROUND;"Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF, Goldberg DJ, Dore GJ, Hickman M. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013 Nov;58(5):1598-609. doi: 10.1002/hep.26431. Epub 2013 Aug 26.";Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals.;"Martin NK; Vickerman P; Grebely J; Hellard M; Hutchinson SJ; Lima VD; Foster GR; Dillon JF; Goldberg DJ; Dore GJ; Hickman M";10.1002/hep.26431;2013/11/01 00:00;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;26298331;BACKGROUND;"Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. Int J Drug Policy. 2015 Oct;26(10):911-21. doi: 10.1016/j.drugpo.2015.07.004. Epub 2015 Jul 26.";Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.;"Smith DJ; Combellick J; Jordan AE; Hagan H";10.1016/j.drugpo.2015.07.004;2015/10/01 00:00;['Journal Article', 'Meta-Analysis', 'Review']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;20041309;BACKGROUND;"Clatts MC, Colon-Lopez V, Giang LM, Goldsamt LA. Prevalence and incidence of HCV infection among Vietnam heroin users with recent onset of injection. J Urban Health. 2010 Mar;87(2):278-291. doi: 10.1007/s11524-009-9417-9.";Prevalence and incidence of HCV infection among Vietnam heroin users with recent onset of injection.;"Clatts MC; Colón-López V; Giang LM; Goldsamt LA";10.1007/s11524-009-9417-9;2010/03/01 00:00;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23172780;BACKGROUND;"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013 Apr;57(4):1333-42. doi: 10.1002/hep.26141. Epub 2013 Feb 4.";Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.;"Mohd Hanafiah K; Groeger J; Flaxman AD; Wiersma ST";10.1002/hep.26141;2013/04/01 00:00;['Journal Article', 'Meta-Analysis', 'Review']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;33208326;DERIVED;"Rapoud D, Quillet C, Pham Minh K, Vu Hai V, Nguyen Thanh B, Nham Thi Tuyet T, Tran Thi H, Moles JP, Vallo R, Michel L, Feelemyer J, Weiss L, Lemoine M, Vickerman P, Fraser H, Duong Thi H, Khuat Thi Hai O, Des Jarlais D, Nagot N, Laureillard D; DRIVE-C Study Group. Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C). BMJ Open. 2020 Nov 18;10(11):e039234. doi: 10.1136/bmjopen-2020-039234.";Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C).;"Rapoud D; Quillet C; Pham Minh K; Vu Hai V; Nguyen Thanh B; Nham Thi Tuyet T; Tran Thi H; Molès JP; Vallo R; Michel L; Feelemyer J; Weiss L; Lemoine M; Vickerman P; Fraser H; Duong Thi H; Khuat Thi Hai O; Des Jarlais D; Nagot N; Laureillard D; DRIVE-C Study Group";10.1136/bmjopen-2020-039234;2020/11/18 00:00;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23884064;BACKGROUND;"Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013 Aug;57 Suppl 2(Suppl 2):S39-45. doi: 10.1093/cid/cit296. Erratum In: Clin Infect Dis. 2014 Apr;58(8):1203.";Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.;"Martin NK; Hickman M; Hutchinson SJ; Goldberg DJ; Vickerman P";10.1093/cid/cit296;2013/08/01 00:00;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23675659;BACKGROUND;"Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013 May 16;368(20):1907-17. doi: 10.1056/NEJMra1213651.";Current and future therapies for hepatitis C virus infection.;"Liang TJ; Ghany MG";10.1056/NEJMra1213651;2013/05/16 00:00;['Journal Article', 'Review']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27148964;BACKGROUND;"Nguyen Truong T, Laureillard D, Lacombe K, Duong Thi H, Pham Thi Hanh P, Truong Thi Xuan L, Chu Thi N, Luong Que A, Vu Hai V, Nagot N, Tuaillon E, Dominguez S, Lemoine M. High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262). PLoS One. 2016 May 5;11(5):e0153744. doi: 10.1371/journal.pone.0153744. eCollection 2016.";High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262).;"Nguyen Truong T; Laureillard D; Lacombe K; Duong Thi H; Pham Thi Hanh P; Truong Thi Xuan L; Chu Thi N; Luong Que A; Vu Hai V; Nagot N; Tuaillon E; Dominguez S; Lemoine M";10.1371/journal.pone.0153744;2016/05/05 00:00;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;25245939;BACKGROUND;"Bruggmann P, Grebely J. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015 Feb;26 Suppl 1:S22-6. doi: 10.1016/j.drugpo.2014.08.014. Epub 2014 Aug 30.";Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.;"Bruggmann P; Grebely J";10.1016/j.drugpo.2014.08.014;2015/02/01 00:00;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;22828983;BACKGROUND;"Sereno L, Mesquita F, Kato M, Jacka D, Nguyen TT, Nguyen TN. Epidemiology, responses, and way forward: the silent epidemic of viral hepatitis and HIV coinfection in Vietnam. J Int Assoc Physicians AIDS Care (Chic). 2012 Sep-Oct;11(5):311-20. doi: 10.1177/1545109712453939. Epub 2012 Jul 24.";Epidemiology, responses, and way forward: the silent epidemic of viral hepatitis and HIV coinfection in Vietnam.;"Sereno L; Mesquita F; Kato M; Jacka D; Nguyen TT; Nguyen TN";10.1177/1545109712453939;2012/09/01 00:00;['Journal Article', 'Review']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;25086286;BACKGROUND;"Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014 Nov;61(1 Suppl):S45-57. doi: 10.1016/j.jhep.2014.07.027. Epub 2014 Jul 30.";Global epidemiology and genotype distribution of the hepatitis C virus infection.;"Gower E; Estes C; Blach S; Razavi-Shearer K; Razavi H";10.1016/j.jhep.2014.07.027;2014/11/01 00:00;['Journal Article', 'Review']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;25920094;BACKGROUND;"Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015 Apr;62(1 Suppl):S87-99. doi: 10.1016/j.jhep.2015.02.006.";From non-A, non-B hepatitis to hepatitis C virus cure.;"Pawlotsky JM; Feld JJ; Zeuzem S; Hoofnagle JH";10.1016/j.jhep.2015.02.006;2015/04/01 00:00;['Journal Article', 'Review']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27667367;BACKGROUND;"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017 Jan;66(1):153-194. doi: 10.1016/j.jhep.2016.09.001. Epub 2016 Sep 22. No abstract available.";EASL Recommendations on Treatment of Hepatitis C 2016.;European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu;10.1016/j.jhep.2016.09.001;2017/01/01 00:00;['Journal Article', 'Practice Guideline']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27349488;BACKGROUND;"Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti S. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.";Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.;"Conti F; Buonfiglioli F; Scuteri A; Crespi C; Bolondi L; Caraceni P; Foschi FG; Lenzi M; Mazzella G; Verucchi G; Andreone P; Brillanti S";10.1016/j.jhep.2016.06.015;2016/10/01 00:00;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;20196807;BACKGROUND;"Kallman JB, Tran S, Arsalla A, Haddad D, Stepanova M, Fang Y, Wrobel VJ, Srishord M, Younossi ZM. Vietnamese community screening for hepatitis B virus and hepatitis C virus. J Viral Hepat. 2011 Jan;18(1):70-6. doi: 10.1111/j.1365-2893.2010.01278.x.";Vietnamese community screening for hepatitis B virus and hepatitis C virus.;"Kallman JB; Tran S; Arsalla A; Haddad D; Stepanova M; Fang Y; Wrobel VJ; Srishord M; Younossi ZM";10.1111/j.1365-2893.2010.01278.x;2011/01/01 00:00;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23728143;BACKGROUND;"Grebely J, Matthews GV, Lloyd AR, Dore GJ. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clin Infect Dis. 2013 Oct;57(7):1014-20. doi: 10.1093/cid/cit377. Epub 2013 May 31.";Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.;"Grebely J; Matthews GV; Lloyd AR; Dore GJ";10.1093/cid/cit377;2013/10/01 00:00;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;20572071;BACKGROUND;"Tanimoto T, Nguyen HC, Ishizaki A, Chung PT, Hoang TT, Nguyen VT, Kageyama S, Oka S, Pham VT, Ichimura H. Multiple routes of hepatitis C virus transmission among injection drug users in Hai Phong, Northern Vietnam. J Med Virol. 2010 Aug;82(8):1355-63. doi: 10.1002/jmv.21787.";Multiple routes of hepatitis C virus transmission among injection drug users in Hai Phong, Northern Vietnam.;"Tanimoto T; Nguyen HC; Ishizaki A; Chung PT; Hoang TT; Nguyen VT; Kageyama S; Oka S; Pham VT; Ichimura H";10.1002/jmv.21787;2010/08/01 00:00;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27178119;BACKGROUND;"Des Jarlais D, Duong HT, Pham Minh K, Khuat OH, Nham TT, Arasteh K, Feelemyer J, Heckathorn DD, Peries M, Moles JP, Laureillard D, Nagot N; (The Drive Study Team). Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions. AIDS Care. 2016 Oct;28(10):1312-5. doi: 10.1080/09540121.2016.1178698. Epub 2016 May 13.";Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.;"Des Jarlais D; Duong HT; Pham Minh K; Khuat OH; Nham TT; Arasteh K; Feelemyer J; Heckathorn DD; Peries M; Moles JP; Laureillard D; Nagot N; (The Drive Study Team)";10.1080/09540121.2016.1178698;2016/10/01 00:00;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;22098550;BACKGROUND;"Gish RG, Bui TD, Nguyen CT, Nguyen DT, Tran HV, Tran DM, Trinh HN; International Group for Liver Health in Viet Nam. Liver disease in Viet Nam: screening, surveillance, management and education: a 5-year plan and call to action. J Gastroenterol Hepatol. 2012 Feb;27(2):238-47. doi: 10.1111/j.1440-1746.2011.06974.x.";Liver disease in Viet Nam: screening, surveillance, management and education: a 5-year plan and call to action.;"Gish RG; Bui TD; Nguyen CT; Nguyen DT; Tran HV; Tran DM; Trinh HN; International Group for Liver Health in Viet Nam";10.1111/j.1440-1746.2011.06974.x;2012/02/01 00:00;['Journal Article', 'Review']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;19839502;BACKGROUND;"Pham DA, Leuangwutiwong P, Jittmittraphap A, Luplertlop N, Bach HK, Akkarathamrongsin S, Theamboonlers A, Poovorawan Y. High prevalence of Hepatitis C virus genotype 6 in Vietnam. Asian Pac J Allergy Immunol. 2009 Jun-Sep;27(2-3):153-60.";High prevalence of Hepatitis C virus genotype 6 in Vietnam.;"Pham DA; Leuangwutiwong P; Jittmittraphap A; Luplertlop N; Bach HK; Akkarathamrongsin S; Theamboonlers A; Poovorawan Y";;2009/06/01 00:00;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;22564041;BACKGROUND;"Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction. 2012 Nov;107(11):1984-95. doi: 10.1111/j.1360-0443.2012.03932.x. Epub 2012 Jul 12.";Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings.;"Vickerman P; Martin N; Turner K; Hickman M";10.1111/j.1360-0443.2012.03932.x;2012/11/01 00:00;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27427455;BACKGROUND;"Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, Taxman FS, El-Bassel N, Martin NK, Booth R, Stover H, Dolan K, Vickerman P. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016 Sep 17;388(10050):1228-48. doi: 10.1016/S0140-6736(16)30856-X. Epub 2016 Jul 14.";The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.;"Altice FL; Azbel L; Stone J; Brooks-Pollock E; Smyrnov P; Dvoriak S; Taxman FS; El-Bassel N; Martin NK; Booth R; Stöver H; Dolan K; Vickerman P";10.1016/S0140-6736(16)30856-X;2016/09/17 00:00;['Journal Article', 'Review']
NCT02527096;A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol);ANRS, Emerging Infectious Diseases;ViiV Healthcare;COMPLETED;INTERVENTIONAL;False;2015-08-18;2015-09-17;2017-03;;;;;;;;
NCT02978924;Trans-spinal Direct Current Stimulation in Primary Orthostatic Tremor;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-01;2017-01-17;2017-11-28;;;;;;;;
NCT02160119;Emotional and Change-related Attention in Autism;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2014-06-10;2014-05-27;2018-05-27;;;;;;;;
NCT04120415;A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02);ANRS, Emerging Infectious Diseases;EuroVacc Foundation | European AIDS Treatment Group (EATG) | Medical Research Council | University College London Hospitals | University of Liverpool | Erasmus Medical Center | Henri Mondor University Hospital | European Georges Pompidou Hospital | Saint-Louis Hospital, Paris, France | Centre Hospitalier Universitaire Vaudois | Chelsea and Westminster Hospital, UK | Universitätsklinikum Hamburg-Eppendorf | Hospital Clinic of Barcelona | Istituto Nazionale Malattie Infettive Lazaro Spallanzani | Imperial College London | Institut d'Investigacions Biomèdiques August Pi i Sunyer | European Commission | Swiss Government;COMPLETED;INTERVENTIONAL;False;2019-10-09;2022-06-21;2023-07-12;;;;;;;;
NCT04265742;Microbiota and Bone Fragility:Study of the Relation Between Gut Microbiota and Bone Microarchitecture;Institut National de la Santé Et de la Recherche Médicale, France;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2020-02-12;2019-02-08;2022-02-04;;;;;;;;
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-29;2017-04-21;2018-09-18;35853750;DERIVED;"Demnitz-King H, Gonneaud J, Klimecki OM, Chocat A, Collette F, Dautricourt S, Jessen F, Krolak-Salmon P, Lutz A, Morse RM, Molinuevo JL, Poisnel G, Touron E, Wirth M, Walker Z, Chetelat G, Marchant NL; Medit-Ageing Research Group. Association of Self-reflection With Cognition and Brain Health in Cognitively Unimpaired Older Adults. Neurology. 2022 Sep 27;99(13):e1422-e1431. doi: 10.1212/WNL.0000000000200951. Epub 2022 Jul 19.";Association of Self-reflection With Cognition and Brain Health in Cognitively Unimpaired Older Adults.;"Demnitz-King H; Gonneaud J; Klimecki OM; Chocat A; Collette F; Dautricourt S; Jessen F; Krolak-Salmon P; Lutz A; Morse RM; Molinuevo JL; Poisnel G; Touron E; Wirth M; Walker Z; Chételat G; Marchant NL; Medit-Ageing Research Group";10.1212/WNL.0000000000200951;2022/09/27 00:00;['Clinical Trial', 'Journal Article']
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-29;2017-04-21;2018-09-18;33873195;DERIVED;"Marchant NL, Barnhofer T, Coueron R, Wirth M, Lutz A, Arenaza-Urquijo EM, Collette F, Poisnel G, Demnitz-King H, Schild AK, Coll-Padros N, Delphin-Combe F, Whitfield T, Schlosser M, Gonneaud J, Asselineau J, Walker Z, Krolak-Salmon P, Molinuevo JL, Frison E, Chetelat G, Jessen F, Klimecki OM; The Medit-Ageing Research Group. Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial. Psychother Psychosom. 2021;90(5):341-350. doi: 10.1159/000515669. Epub 2021 Apr 19.";Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial.;"Marchant NL; Barnhofer T; Coueron R; Wirth M; Lutz A; Arenaza-Urquijo EM; Collette F; Poisnel G; Demnitz-King H; Schild AK; Coll-Padros N; Delphin-Combe F; Whitfield T; Schlosser M; Gonneaud J; Asselineau J; Walker Z; Krolak-Salmon P; Molinuevo JL; Frison E; Chételat G; Jessen F; Klimecki OM; The Medit-Ageing Research Group";10.1159/000515669;2021/01/01 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-29;2017-04-21;2018-09-18;38100477;PUBMED;;Effects of a mindfulness-based intervention and a health self-management programme on psychological well-being in older adults with subjective cognitive decline: Secondary analyses from the SCD-Well randomised clinical trial.;"Schlosser M; Demnitz-King H; Barnhofer T; Collette F; Gonneaud J; Chételat G; Jessen F; Kliegel M; Klimecki OM; Lutz A; Marchant NL; Medit-Ageing Research Group";10.1371/journal.pone.0295175;2023/12/15 00:00;['Randomized Controlled Trial', 'Journal Article']
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-29;2017-04-21;2018-09-18;36068621;DERIVED;"Whitfield T, Demnitz-King H, Schlosser M, Barnhofer T, Frison E, Coll-Padros N, Dautricourt S, Requier F, Delarue M, Gonneaud J, Klimecki OM, Lutz A, Paly L, Salmon E, Schild AK, Walker Z, Jessen F, Chetelat G, Collette F, Wirth M, Marchant NL; Medit-Ageing Research Group. Effects of a mindfulness-based versus a health self-management intervention on objective cognitive performance in older adults with subjective cognitive decline (SCD): a secondary analysis of the SCD-Well randomized controlled trial. Alzheimers Res Ther. 2022 Sep 6;14(1):125. doi: 10.1186/s13195-022-01057-w.";Effects of a mindfulness-based versus a health self-management intervention on objective cognitive performance in older adults with subjective cognitive decline (SCD): a secondary analysis of the SCD-Well randomized controlled trial.;"Whitfield T; Demnitz-King H; Schlosser M; Barnhofer T; Frison E; Coll-Padros N; Dautricourt S; Requier F; Delarue M; Gonneaud J; Klimecki OM; Lutz A; Paly L; Salmon E; Schild AK; Walker Z; Jessen F; Chételat G; Collette F; Wirth M; Marchant NL; Medit-Ageing Research Group";10.1186/s13195-022-01057-w;2022/09/06 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT04808986;Seroprevalence of IgG Antibodies to SARS-CoV-2 (COVID-19) in Primary Health Care Workers and Their Household Contacts;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2021-03-22;2021-05-10;2021-10-12;;;;;;;;
NCT01725542;Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb;COMPLETED;INTERVENTIONAL;False;2012-11-14;2012-12;2014-06;25977266;DERIVED;"Piroth L, Paniez H, Taburet AM, Vincent C, Rosenthal E, Lacombe K, Billaud E, Rey D, Zucman D, Bailly F, Bronowicki JP, Simony M, Diallo A, Izopet J, Aboulker JP, Meyer L, Molina JM; ANRS HC30 QUADRIH Study Group. High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study. Clin Infect Dis. 2015 Sep 1;61(5):817-25. doi: 10.1093/cid/civ381. Epub 2015 May 14.";High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.;"Piroth L; Paniez H; Taburet AM; Vincent C; Rosenthal E; Lacombe K; Billaud E; Rey D; Zucman D; Bailly F; Bronowicki JP; Simony M; Diallo A; Izopet J; Aboulker JP; Meyer L; Molina JM; ANRS HC30 QUADRIH Study Group";10.1093/cid/civ381;2015/09/01 00:00;['Journal Article', 'Multicenter Study']
NCT03831906;Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia);Institut National de la Santé Et de la Recherche Médicale, France;UNITAID;COMPLETED;INTERVENTIONAL;False;2019-02-06;2019-03-20;2021-06-30;32853411;DERIVED;"Kay AW, Gonzalez Fernandez L, Takwoingi Y, Eisenhut M, Detjen AK, Steingart KR, Mandalakas AM. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Cochrane Database Syst Rev. 2020 Aug 27;8(8):CD013359. doi: 10.1002/14651858.CD013359.pub2.";Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children.;"Kay AW; González Fernández L; Takwoingi Y; Eisenhut M; Detjen AK; Steingart KR; Mandalakas AM";10.1002/14651858.CD013359.pub2;2020/08/27 00:00;['Journal Article', 'Meta-Analysis']
NCT03831906;Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia);Institut National de la Santé Et de la Recherche Médicale, France;UNITAID;COMPLETED;INTERVENTIONAL;False;2019-02-06;2019-03-20;2021-06-30;33743621;BACKGROUND;"Vessiere A, Font H, Gabillard D, Adonis-Koffi L, Borand L, Chabala C, Khosa C, Mavale S, Moh R, Mulenga V, Mwanga-Amumpere J, Taguebue JV, Eang MT, Delacourt C, Seddon JA, Lounnas M, Godreuil S, Wobudeya E, Bonnet M, Marcy O. Impact of systematic early tuberculosis detection using Xpert MTB/RIF Ultra in children with severe pneumonia in high tuberculosis burden countries (TB-Speed pneumonia): a stepped wedge cluster randomized trial. BMC Pediatr. 2021 Mar 20;21(1):136. doi: 10.1186/s12887-021-02576-5.";Impact of systematic early tuberculosis detection using Xpert MTB/RIF Ultra in children with severe pneumonia in high tuberculosis burden countries (TB-Speed pneumonia): a stepped wedge cluster randomized trial.;"Vessière A; Font H; Gabillard D; Adonis-Koffi L; Borand L; Chabala C; Khosa C; Mavale S; Moh R; Mulenga V; Mwanga-Amumpere J; Taguebue JV; Eang MT; Delacourt C; Seddon JA; Lounnas M; Godreuil S; Wobudeya E; Bonnet M; Marcy O";10.1186/s12887-021-02576-5;2021/03/20 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT03831906;Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia);Institut National de la Santé Et de la Recherche Médicale, France;UNITAID;COMPLETED;INTERVENTIONAL;False;2019-02-06;2019-03-20;2021-06-30;36395782;DERIVED;"Marcy O, Wobudeya E, Font H, Vessiere A, Chabala C, Khosa C, Taguebue JV, Moh R, Mwanga-Amumpaire J, Lounnas M, Mulenga V, Mavale S, Chilundo J, Rego D, Nduna B, Shankalala P, Chirwa U, De Lauzanne A, Dim B, Tiogouo Ngouana E, Folquet Amorrissani M, Cisse L, Amon Tanoh Dick F, Komena EA, Kwedi Nolna S, Businge G, Natukunda N, Cumbe S, Mbekeka P, Kim A, Kheang C, Pol S, Maleche-Obimbo E, Seddon JA, Mao TE, Graham SM, Delacourt C, Borand L, Bonnet M; TB-Speed Pneumonia Study Group. Effect of systematic tuberculosis detection on mortality in young children with severe pneumonia in countries with high incidence of tuberculosis: a stepped-wedge cluster-randomised trial. Lancet Infect Dis. 2023 Mar;23(3):341-351. doi: 10.1016/S1473-3099(22)00668-5. Epub 2022 Nov 14.";Effect of systematic tuberculosis detection on mortality in young children with severe pneumonia in countries with high incidence of tuberculosis: a stepped-wedge cluster-randomised trial.;"Marcy O; Wobudeya E; Font H; Vessière A; Chabala C; Khosa C; Taguebue JV; Moh R; Mwanga-Amumpaire J; Lounnas M; Mulenga V; Mavale S; Chilundo J; Rego D; Nduna B; Shankalala P; Chirwa U; De Lauzanne A; Dim B; Tiogouo Ngouana E; Folquet Amorrissani M; Cisse L; Amon Tanoh Dick F; Komena EA; Kwedi Nolna S; Businge G; Natukunda N; Cumbe S; Mbekeka P; Kim A; Kheang C; Pol S; Maleche-Obimbo E; Seddon JA; Mao TE; Graham SM; Delacourt C; Borand L; Bonnet M; TB-Speed Pneumonia Study Group";10.1016/S1473-3099(22)00668-5;2023/03/01 00:00;['Randomized Controlled Trial', 'Journal Article']
NCT01779713;Transcriptomic Signature of Vasospasm Consecutive to Sub-arachnoid Aneurismal Hemorrhage;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2013-01-30;2013-02-04;2016-07-04;30354977;DERIVED;"Pulcrano-Nicolas AS, Proust C, Clarencon F, Jacquens A, Perret C, Roux M, Shotar E, Thibord F, Puybasset L, Garnier S, Degos V, Tregouet DA. Whole-Blood miRNA Sequencing Profiling for Vasospasm in Patients With Aneurysmal Subarachnoid Hemorrhage. Stroke. 2018 Sep;49(9):2220-2223. doi: 10.1161/STROKEAHA.118.021101.";Whole-Blood miRNA Sequencing Profiling for Vasospasm in Patients With Aneurysmal Subarachnoid Hemorrhage.;"Pulcrano-Nicolas AS; Proust C; Clarençon F; Jacquens A; Perret C; Roux M; Shotar E; Thibord F; Puybasset L; Garnier S; Degos V; Trégouët DA";10.1161/STROKEAHA.118.021101;2018/09/01 00:00;['Journal Article']
NCT01164436;Cohort of HIV Associated Lymphomas;ANRS, Emerging Infectious Diseases;Dr Yassine Taoufik Dr Houria Chavez Hôpital Bicêtre CIB Paris Sud France | Dr Guislaine Garcelain Hôpital Pitié Slapétrière Paris France | University Hospital, Grenoble | Dr Irène Joab Hôpital Paul Brousse Villejuif France | Dr Alex Duval Fondation Jean Dausset CEPH | Hopital Antoine Beclere;COMPLETED;OBSERVATIONAL;False;2010-07-16;2008-06;2017-06;;;;;;;;
NCT03193099;Decoding Presymptomatic White Matter Changes in Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;University College, London;COMPLETED;INTERVENTIONAL;False;2017-06-20;2017-07-11;2019-12-30;;;;;;;;
NCT00604149;Cardiac AResT And GENEtic;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2008-01-30;2008-01;2014-01;;;;;;;;
NCT01895920;Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread?;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2013-07-11;2013-01;2018-02;;;;;;;;
NCT02405013;Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2015-04-01;2015-10;2017-11;36686592;PUBMED;;Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial).;"Marcellin F; Mourad A; Lemoine M; Kouanfack C; Seydi M; Carrieri P; Attia A; Protopopescu C; Lacombe K; Boyer S";10.1016/j.jhepr.2022.100665;2022/12/28 00:00;['Journal Article']
NCT01207986;Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2010-09-23;2011-02;2014-08;;;;;;;;
NCT01094899;Abnormal Structure and Bone Density in Diabetes;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-03-29;2010-03-10;2014-07-10;;;;;;;;
NCT01592175;Magnetoencephalography (MEG), Attention and Conscience;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-05-07;2012-03-08;2013-07-02;;;;;;;;
NCT00445575;Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone;Institut National de la Santé Et de la Recherche Médicale, France;ZonMw: The Netherlands Organisation for Health Research and Development | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Charite University, Berlin, Germany;COMPLETED;INTERVENTIONAL;False;2007-03-09;2007-07-22;2017-12-07;;;;;;;;
NCT01463956;Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2011-11-02;2012-01-06;2015-01-22;;;;;;;;
NCT02214511;Biomarkers of Social Sensitivity in Major Depression;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2014-08-12;2014-10-23;2017-03-01;;;;;;;;
NCT01495897;Abnormal Movements, Cerebellum and Sensorimotor : Oculomotor Study;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-20;2011-03;2014-03;;;;;;;;
NCT05472051;Health and Migration Trajectories of Housekeepers in Bamako;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2022-07-25;2022-02-28;2023-06-22;;;;;;;;
NCT00116454;Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2005-06-30;2005-07;2013-08;;;;;;;;
NCT03954054;Therapeutic Education for Harm Reduction in People With Alcohol Use Disorder;Institut National de la Santé Et de la Recherche Médicale, France;Regional Agency for Health PACA | SESSTIM UMR1252 (Aix-Marseille Univ, INSERM, IRD);COMPLETED;OBSERVATIONAL;False;2019-05-17;2019-10-28;2021-07-31;35012570;DERIVED;"Antwerpes S, Costa M, Coste M, Bureau M, Maradan G, Cutarella C, Leloutre J, Riccobono-Soulier O, Hedoire S, Frot E, Vernier F, Vassas-Goyard S, Barre T, Casanova D, Carrieri P. Evaluation of a novel therapeutic education programme for people with alcohol use disorder in France: a mixed-methods intervention study protocol (ETHER). Harm Reduct J. 2022 Jan 10;19(1):2. doi: 10.1186/s12954-021-00587-0.";Evaluation of a novel therapeutic education programme for people with alcohol use disorder in France: a mixed-methods intervention study protocol (ETHER).;"Antwerpes S; Costa M; Coste M; Bureau M; Maradan G; Cutarella C; Leloutre J; Riccobono-Soulier O; Hedoire S; Frot E; Vernier F; Vassas-Goyard S; Barré T; Casanova D; Carrieri P";10.1186/s12954-021-00587-0;2022/01/10 00:00;['Journal Article']
NCT02027233;Clinical Trial to Assess the Influenza Vaccination of the Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-01-06;2014-01;2022-12-31;;;;;;;;
NCT02408354;Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-04-03;2015-04-15;2017-04-05;28969699;DERIVED;"Hainque E, Caillet S, Leroy S, Flamand-Roze C, Adanyeguh I, Charbonnier-Beaupel F, Retail M, Le Toullec B, Atencio M, Rivaud-Pechoux S, Brochard V, Habarou F, Ottolenghi C, Cormier F, Meneret A, Ruiz M, Doulazmi M, Roubergue A, Corvol JC, Vidailhet M, Mochel F, Roze E. A randomized, controlled, double-blind, crossover trial of triheptanoin in alternating hemiplegia of childhood. Orphanet J Rare Dis. 2017 Oct 2;12(1):160. doi: 10.1186/s13023-017-0713-2.";A randomized, controlled, double-blind, crossover trial of triheptanoin in alternating hemiplegia of childhood.;"Hainque E; Caillet S; Leroy S; Flamand-Roze C; Adanyeguh I; Charbonnier-Beaupel F; Retail M; Le Toullec B; Atencio M; Rivaud-Péchoux S; Brochard V; Habarou F; Ottolenghi C; Cormier F; Méneret A; Ruiz M; Doulazmi M; Roubergue A; Corvol JC; Vidailhet M; Mochel F; Roze E";10.1186/s13023-017-0713-2;2017/10/02 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT02052271;Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-02-03;2014-06-03;2018-03-27;;;;;;;;
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;24058636;BACKGROUND;"Legeai C, Vigouroux C, Souberbielle JC, Bouchaud O, Boufassa F, Bastard JP, Carlier R, Capeau J, Goujard C, Meyer L, Viard JP; ANRS-COPANA Cohort Study Group. Associations between 25-hydroxyvitamin D and immunologic, metabolic, inflammatory markers in treatment-naive HIV-infected persons: the ANRS CO9 <<COPANA>> cohort study. PLoS One. 2013 Sep 18;8(9):e74868. doi: 10.1371/journal.pone.0074868. eCollection 2013.";Associations between 25-hydroxyvitamin D and immunologic, metabolic, inflammatory markers in treatment-naive HIV-infected persons: the ANRS CO9 «COPANA» cohort study.;"Legeai C; Vigouroux C; Souberbielle JC; Bouchaud O; Boufassa F; Bastard JP; Carlier R; Capeau J; Goujard C; Meyer L; Viard JP; ANRS-COPANA Cohort Study Group";10.1371/journal.pone.0074868;2013/09/18 00:00;['Journal Article']
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;22267473;BACKGROUND;"Boufassa F, Goujard C, Viard JP, Carlier R, Lefebvre B, Yeni P, Bouchaud O, Capeau J, Meyer L, Vigouroux C; ANRS COPANA Cohort Study Group. Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort. Antivir Ther. 2012;17(1):91-100. doi: 10.3851/IMP1916.";Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort.;"Boufassa F; Goujard C; Viard JP; Carlier R; Lefebvre B; Yeni P; Bouchaud O; Capeau J; Meyer L; Vigouroux C; ANRS COPANA Cohort Study Group";10.3851/IMP1916;2012/01/01 00:00;['Journal Article', 'Multicenter Study']
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;26636578;BACKGROUND;"Ghislain M, Bastard JP, Meyer L, Capeau J, Fellahi S, Gerard L, May T, Simon A, Vigouroux C, Goujard C; ANRS-COPANA Cohort Study Group. Late Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic Abnormalities. PLoS One. 2015 Dec 4;10(12):e0144317. doi: 10.1371/journal.pone.0144317. eCollection 2015.";Late Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic Abnormalities.;"Ghislain M; Bastard JP; Meyer L; Capeau J; Fellahi S; Gérard L; May T; Simon A; Vigouroux C; Goujard C; ANRS-COPANA Cohort Study Group";10.1371/journal.pone.0144317;2015/12/04 00:00;['Clinical Trial', 'Journal Article', 'Multicenter Study']
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;27509048;BACKGROUND;"Ploquin MJ, Madec Y, Casrouge A, Huot N, Passaes C, Lecuroux C, Essat A, Boufassa F, Jacquelin B, Jochems SP, Petitjean G, Angin M, Gartner K, Garcia-Tellez T, Noel N, Booiman T, Boeser-Nunnink BD, Roques P, Saez-Cirion A, Vaslin B, Dereudre-Bosquet N, Barre-Sinoussi F, Ghislain M, Rouzioux C, Lambotte O, Albert ML, Goujard C, Kootstra N, Meyer L, Muller-Trutwin MC. Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset. PLoS Pathog. 2016 Aug 10;12(8):e1005774. doi: 10.1371/journal.ppat.1005774. eCollection 2016 Aug.";Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset.;"Ploquin MJ; Madec Y; Casrouge A; Huot N; Passaes C; Lécuroux C; Essat A; Boufassa F; Jacquelin B; Jochems SP; Petitjean G; Angin M; Gärtner K; Garcia-Tellez T; Noël N; Booiman T; Boeser-Nunnink BD; Roques P; Saez-Cirion A; Vaslin B; Dereudre-Bosquet N; Barré-Sinoussi F; Ghislain M; Rouzioux C; Lambotte O; Albert ML; Goujard C; Kootstra N; Meyer L; Müller-Trutwin MC";10.1371/journal.ppat.1005774;2016/08/10 00:00;['Journal Article']
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;25573889;BACKGROUND;"El Khoury P, Ghislain M, Villard EF, Le Goff W, Lascoux-Combe C, Yeni P, Meyer L, Vigouroux C, Goujard C, Guerin M. Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART. J Lipid Res. 2015 Mar;56(3):692-702. doi: 10.1194/jlr.M054510. Epub 2015 Jan 8.";Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART.;"El Khoury P; Ghislain M; Villard EF; Le Goff W; Lascoux-Combe C; Yeni P; Meyer L; Vigouroux C; Goujard C; Guerin M";10.1194/jlr.M054510;2015/03/01 00:00;['Clinical Trial', 'Journal Article', 'Multicenter Study']
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;22008658;BACKGROUND;"Dray-Spira R, Legeai C, Le Den M, Boue F, Lascoux-Combe C, Simon A, May T, Goujard C, Meyer L; ANRS-COPANA Cohort Study Group. Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies use. AIDS. 2012 Jan 14;26(2):207-15. doi: 10.1097/QAD.0b013e32834dcf61.";Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies use.;"Dray-Spira R; Legeai C; Le Den M; Boué F; Lascoux-Combe C; Simon A; May T; Goujard C; Meyer L; ANRS-COPANA Cohort Study Group";10.1097/QAD.0b013e32834dcf61;2012/01/14 00:00;['Journal Article', 'Multicenter Study']
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;23079802;BACKGROUND;"Rachas A, Warszawski J, Le Chenadec J, Legeai C, Teglas JP, Goujard C, Rouzioux C, Mandelbrot L, Tubiana R, Meyer L. Does pregnancy affect the early response to cART? AIDS. 2013 Jan 28;27(3):357-67. doi: 10.1097/QAD.0b013e32835ac8bc.";Does pregnancy affect the early response to cART?;"Rachas A; Warszawski J; Le Chenadec J; Legeai C; Teglas JP; Goujard C; Rouzioux C; Mandelbrot L; Tubiana R; Meyer L";10.1097/QAD.0b013e32835ac8bc;2013/01/28 00:00;['Journal Article', 'Multicenter Study']
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;24465584;BACKGROUND;"Boufassa F, Lechenadec J, Meyer L, Costagliola D, Hunt PW, Pereyra F, Deeks S, Pancino G, Taulera O, Lichterfeld M, Delobel P, Saez-Cirion A, Lambotte O; ANRS CO18 HIV Controllers Cohort; Cascade Collaboration in Eurocoord; SCOPE Cohort; International HIV Controllers Study. Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration. PLoS One. 2014 Jan 17;9(1):e85516. doi: 10.1371/journal.pone.0085516. eCollection 2014.";Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration.;"Boufassa F; Lechenadec J; Meyer L; Costagliola D; Hunt PW; Pereyra F; Deeks S; Pancino G; Taulera O; Lichterfeld M; Delobel P; Saez-Cirion A; Lambotte O; ANRS CO18 HIV Controllers Cohort; Cascade Collaboration in Eurocoord; SCOPE Cohort; International HIV Controllers Study";10.1371/journal.pone.0085516;2014/01/17 00:00;['Journal Article']
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;23936509;BACKGROUND;"Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combe C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L; ANRS PRIMO and COPANA Cohorts. Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts. PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. Print 2013. Erratum In: PLoS One. 2013;8(11). doi:10.1371/annotation/aed12a66-9c76-4e49-806b-881a2fe23bba. Goujard, Cecile [added].";Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.;"Krastinova E; Seng R; Yeni P; Viard JP; Vittecoq D; Lascoux-Combe C; Fourn E; Pahlavan G; Delfraissy JF; Goujard C; Meyer L; ANRS PRIMO and COPANA Cohorts";10.1371/journal.pone.0071473;2013/08/01 00:00;['Journal Article']
NCT02721745;Cause and Consequence of Neural Fatigue;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-03-29;2016-05-23;2020-12;;;;;;;;
NCT02976298;Effects of Cerebellum or Supplementary Motor Area Functional Inactivation on Gait and Balance Control;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-11-29;2013-02;2015-01;;;;;;;;
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;27073179;RESULT;"Marcellin F, Lions C, Rosenthal E, Roux P, Sogni P, Wittkop L, Protopopescu C, Spire B, Salmon-Ceron D, Dabis F, Carrieri MP; HEPAVIH ANRS CO13 Study Group*. No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort). Drug Alcohol Rev. 2017 Mar;36(2):227-238. doi: 10.1111/dar.12398. Epub 2016 Apr 13.";No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort).;"Marcellin F; Lions C; Rosenthal E; Roux P; Sogni P; Wittkop L; Protopopescu C; Spire B; Salmon-Ceron D; Dabis F; Carrieri MP; HEPAVIH ANRS CO13 Study Group*";10.1111/dar.12398;2017/03/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;24166726;RESULT;"Roux P, Lions C, Cohen J, Winnock M, Salmon-Ceron D, Bani-Sadr F, Sogni P, Spire B, Dabis F, Carrieri MP; ANRS-CO13-HEPAVIH Study Group. Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13-HEPAVIH cohort. Antivir Ther. 2014;19(2):171-8. doi: 10.3851/IMP2699. Epub 2013 Oct 28.";Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13-HEPAVIH cohort.;"Roux P; Lions C; Cohen J; Winnock M; Salmon-Céron D; Bani-Sadr F; Sogni P; Spire B; Dabis F; Carrieri MP; ANRS-CO13-HEPAVIH Study Group";10.3851/IMP2699;2014/01/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22535683;RESULT;"Carrieri MP, Sogni P, Cohen J, Loko MA, Winnock M, Spire B; HEPAVIH Study Group. Elevated coffee consumption and reduced risk of insulin resistance in HIV-HCV coinfected patients (HEPAVIH ANRS CO-13). Hepatology. 2012 Nov;56(5):2010. doi: 10.1002/hep.25813. No abstract available.";Elevated coffee consumption and reduced risk of insulin resistance in HIV-HCV coinfected patients (HEPAVIH ANRS CO-13).;"Carrieri MP; Sogni P; Cohen J; Loko MA; Winnock M; Spire B; HEPAVIH Study Group";10.1002/hep.25813;2012/11/01 00:00;['Letter', 'Comment']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;27339598;RESULT;"Ulveling D, Le Clerc S, Cobat A, Labib T, Noirel J, Laville V, Coulonges C, Carpentier W, Nalpas B, Heim MH, Poynard T, Cerny A, Pol S, Bochud PY, Dabis F, Theodorou I, Levy Y, Salmon D, Abel L, Dominguez S, Zagury JF; HEPAVIH ANRS CO13 Cohort Study Group; Swiss Hepatitis C Cohort Study Group; French ANRS HC EP 26 Genoscan Study Group. A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology. 2016 Nov;64(5):1462-1472. doi: 10.1002/hep.28695. Epub 2016 Jul 29.";A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.;"Ulveling D; Le Clerc S; Cobat A; Labib T; Noirel J; Laville V; Coulonges C; Carpentier W; Nalpas B; Heim MH; Poynard T; Cerny A; Pol S; Bochud PY; Dabis F; Theodorou I; Lévy Y; Salmon D; Abel L; Dominguez S; Zagury JF; HEPAVIH ANRS CO13 Cohort Study Group; Swiss Hepatitis C Cohort Study Group; French ANRS HC EP 26 Genoscan Study Group";10.1002/hep.28695;2016/11/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;27317796;RESULT;"Sogni P, Gilbert C, Lacombe K, Piroth L, Rosenthal E, Miailhes P, Gervais A, Esterle L, Chas J, Poizot-Martin I, Dominguez S, Simon A, Morlat P, Neau D, Zucman D, Bouchaud O, Lascoux-Combe C, Bani-Sadr F, Alric L, Goujard C, Vittecoq D, Billaud E, Aumaitre H, Boue F, Valantin MA, Dabis F, Salmon D, Wittkop L. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort. Clin Infect Dis. 2016 Sep 15;63(6):763-770. doi: 10.1093/cid/ciw379. Epub 2016 Jun 17.";All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.;"Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L";10.1093/cid/ciw379;2016/09/15 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21692942;RESULT;"Loko MA, Bani-Sadr F, Winnock M, Lacombe K, Carrieri P, Neau D, Morlat P, Serfaty L, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients. J Viral Hepat. 2011 Jul;18(7):e307-14. doi: 10.1111/j.1365-2893.2010.01417.x. Epub 2011 Jan 11.";Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.;"Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D; ANRS CO 13 HEPAVIH Study Group";10.1111/j.1365-2893.2010.01417.x;2011/07/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28942916;RESULT;"Carrieri MP, Protopopescu C, Marcellin F, Rosellini S, Wittkop L, Esterle L, Zucman D, Raffi F, Rosenthal E, Poizot-Martin I, Salmon-Ceron D, Dabis F, Spire B; ANRS CO13 HEPAVIH Study Group. Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. J Hepatol. 2017 Dec;67(6):1157-1167. doi: 10.1016/j.jhep.2017.08.005. Epub 2017 Sep 21.";Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.;"Carrieri MP; Protopopescu C; Marcellin F; Rosellini S; Wittkop L; Esterle L; Zucman D; Raffi F; Rosenthal E; Poizot-Martin I; Salmon-Ceron D; Dabis F; Spire B; ANRS CO13 HEPAVIH Study Group";10.1016/j.jhep.2017.08.005;2017/12/01 00:00;['Journal Article', 'Multicenter Study']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;20876416;RESULT;"Carrieri MP, Cohen J, Winnock M, Salmon D. Chocolate intake, depression, and clinical progression in HIV-HCV coinfected patients: still more questions than answers. Arch Intern Med. 2010 Sep 27;170(17):1607; author reply 1608-9. doi: 10.1001/archinternmed.2010.330. No abstract available.";Chocolate intake, depression, and clinical progression in HIV-HCV coinfected patients: still more questions than answers.;"Carrieri MP; Cohen J; Winnock M; Salmon D";10.1001/archinternmed.2010.330;2010/09/27 00:00;['Comment', 'Letter']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;24499953;RESULT;"Bani-Sadr F, Loko MA, Pambrun E, Winnock M, Carrieri P, Gilbert C, Duvivier C, Bouchaud O, Gervais A, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group. Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients: possible role of the hepatitis C virus sustained viral response. AIDS. 2014 May 15;28(8):1155-60. doi: 10.1097/QAD.0000000000000218.";Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients: possible role of the hepatitis C virus sustained viral response.;"Bani-Sadr F; Loko MA; Pambrun E; Winnock M; Carrieri P; Gilbert C; Duvivier C; Bouchaud O; Gervais A; Dabis F; Salmon D; ANRS CO 13 HEPAVIH Study Group";10.1097/QAD.0000000000000218;2014/05/15 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23461846;RESULT;"Winnock M, Bani-Sadr F, Pambrun E, Loko MA, Carrieri P, Neau D, Morlat P, Marchou B, Dabis F, Salmon D; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) CO13 HEPAVIH Study Group. Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions. HIV Med. 2013 Aug;14(7):430-6. doi: 10.1111/hiv.12023. Epub 2013 Mar 5.";Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions.;"Winnock M; Bani-Sadr F; Pambrun E; Loko MA; Carrieri P; Neau D; Morlat P; Marchou B; Dabis F; Salmon D; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) CO13 HEPAVIH Study Group";10.1111/hiv.12023;2013/08/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;20969743;RESULT;"Loko MA, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, Gillet S, Pambrun E, Delaune J, Valantin MA, Poizot-Martin I, Neau D, Bonnard P, Rosenthal E, Barange K, Morlat P, Lacombe K, Gervais A, Rouges F, See AB, Lascoux-Combe C, Vittecoq D, Goujard C, Duvivier C, Spire B, Izopet J, Sogni P, Serfaty L, Benhamou Y, Bani-Sadr F, Dabis F; ANRS CO 13 HEPAVIH Study Group. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. BMC Infect Dis. 2010 Oct 22;10:303. doi: 10.1186/1471-2334-10-303.";The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.;"Loko MA; Salmon D; Carrieri P; Winnock M; Mora M; Merchadou L; Gillet S; Pambrun E; Delaune J; Valantin MA; Poizot-Martin I; Neau D; Bonnard P; Rosenthal E; Barange K; Morlat P; Lacombe K; Gervais A; Rouges F; See AB; Lascoux-Combe C; Vittecoq D; Goujard C; Duvivier C; Spire B; Izopet J; Sogni P; Serfaty L; Benhamou Y; Bani-Sadr F; Dabis F; ANRS CO 13 HEPAVIH Study Group";10.1186/1471-2334-10-303;2010/10/22 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23978720;RESULT;"Carrieri MP, Lions C, Sogni P, Winnock M, Roux P, Mora M, Bonnard P, Salmon D, Dabis F, Spire B; ANRS CO13 HEPAVIH Study Group. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study. J Hepatol. 2014 Jan;60(1):46-53. doi: 10.1016/j.jhep.2013.08.014. Epub 2013 Aug 24.";Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study.;"Carrieri MP; Lions C; Sogni P; Winnock M; Roux P; Mora M; Bonnard P; Salmon D; Dabis F; Spire B; ANRS CO13 HEPAVIH Study Group";10.1016/j.jhep.2013.08.014;2014/01/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;32798585;DERIVED;"Chalouni M, Pol S, Sogni P, Fontaine H, Lacombe K, Marc-Lacombe J, Esterle L, Dorival C, Bourliere M, Bani-Sadr F, de Ledinghen V, Zucman D, Larrey D, Salmon D, Carrat F, Wittkop L; ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohort study groups. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. J Hepatol. 2021 Jan;74(1):37-47. doi: 10.1016/j.jhep.2020.08.008. Epub 2020 Aug 14.";Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.;"Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L; ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohort study groups";10.1016/j.jhep.2020.08.008;2021/01/01 00:00;['Journal Article', 'Multicenter Study']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21239121;RESULT;"Roux P, Cohen J, Lascoux-Combe C, Sogni P, Winnock M, Salmon-Ceron D, Spire B, Dabis F, Carrieri MP; ANRS-CO13-HEPAVIH study group. Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the role of the physician. Drug Alcohol Depend. 2011 Jul 1;116(1-3):228-32. doi: 10.1016/j.drugalcdep.2010.09.025. Epub 2011 Jan 15.";Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the role of the physician.;"Roux P; Cohen J; Lascoux-Combe C; Sogni P; Winnock M; Salmon-Ceron D; Spire B; Dabis F; Carrieri MP; ANRS-CO13-HEPAVIH study group";10.1016/j.drugalcdep.2010.09.025;2011/07/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23226258;RESULT;"Abravanel F, Raymond S, Pambrun E, Winnock M, Bonnard P, Sogni P, Trimoulet P, Dabis F, Salmon-Ceron D, Izopet J; ANRS CO13 HEPAVIH Study Group. HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients. PLoS One. 2012;7(11):e50289. doi: 10.1371/journal.pone.0050289. Epub 2012 Nov 30.";HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients.;"Abravanel F; Raymond S; Pambrun E; Winnock M; Bonnard P; Sogni P; Trimoulet P; Dabis F; Salmon-Ceron D; Izopet J; ANRS CO13 HEPAVIH Study Group";10.1371/journal.pone.0050289;2012/01/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28430385;RESULT;"Knight R, Roux P, Vilotitch A, Marcellin F, Rosenthal E, Esterle L, Boue F, Rey D, Piroth L, Dominguez S, Sogni P, Salmon-Ceron D, Spire B, Carrieri MP; ANRS CO13-HEPAVIH Study Group. Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort. Addiction. 2017 Sep;112(9):1669-1679. doi: 10.1111/add.13851. Epub 2017 Jun 6.";Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort.;"Knight R; Roux P; Vilotitch A; Marcellin F; Rosenthal E; Esterle L; Boué F; Rey D; Piroth L; Dominguez S; Sogni P; Salmon-Ceron D; Spire B; Carrieri MP; ANRS CO13-HEPAVIH Study Group";10.1111/add.13851;2017/09/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22285372;RESULT;"Trimoulet P, Merchadou L, Winnock M, Loko MA, Fleury H, Salmon D, Dabis F, Neau D; ANRS CO 13 HEPAVIH Study Group. Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: should the same test be applied to all samples? J Virol Methods. 2012 Apr;181(1):131-3. doi: 10.1016/j.jviromet.2012.01.006. Epub 2012 Jan 20.";Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: should the same test be applied to all samples?;"Trimoulet P; Merchadou L; Winnock M; Loko MA; Fleury H; Salmon D; Dabis F; Neau D; ANRS CO 13 HEPAVIH Study Group";10.1016/j.jviromet.2012.01.006;2012/04/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22173166;RESULT;"Salmon D, Bani-Sadr F, Loko MA, Stitou H, Gervais A, Durant J, Rosenthal E, Quertainmont Y, Barange K, Vittecoq D, Shoai-Tehrani M, Alvarez M, Winnock M, Trinchet JC, Dabis F, Sogni P. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH. J Hepatol. 2012 Apr;56(4):862-8. doi: 10.1016/j.jhep.2011.11.009. Epub 2011 Dec 13.";Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH.;"Salmon D; Bani-Sadr F; Loko MA; Stitou H; Gervais A; Durant J; Rosenthal E; Quertainmont Y; Barange K; Vittecoq D; Shoai-Tehrani M; Alvarez M; Winnock M; Trinchet JC; Dabis F; Sogni P";10.1016/j.jhep.2011.11.009;2012/04/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28418984;RESULT;"Marcellin F, Protopopescu C, Esterle L, Wittkop L, Piroth L, Aumaitre H, Bouchaud O, Goujard C, Vittecoq D, Dabis F, Salmon-Ceron D, Spire B, Roux P, Carrieri MP; ANRS CO13-HEPAVIH Study Group. Short article: Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH). Eur J Gastroenterol Hepatol. 2017 Jul;29(7):786-791. doi: 10.1097/MEG.0000000000000883.";Short article: Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH).;"Marcellin F; Protopopescu C; Esterle L; Wittkop L; Piroth L; Aumaitre H; Bouchaud O; Goujard C; Vittecoq D; Dabis F; Salmon-Ceron D; Spire B; Roux P; Carrieri MP; ANRS CO13-HEPAVIH Study Group";10.1097/MEG.0000000000000883;2017/07/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28780609;RESULT;"Yaya I, Roux P, Marcellin F, Salmon-Ceron D, Carrieri MP. Unstable Housing Still a Barrier to Receiving HCV Treatment in France (ANRS CO13 HEPAVIH Cohort). Dig Dis Sci. 2017 Oct;62(10):2943-2944. doi: 10.1007/s10620-017-4703-y. Epub 2017 Aug 5. No abstract available.";Unstable Housing Still a Barrier to Receiving HCV Treatment in France (ANRS CO13 HEPAVIH Cohort).;"Yaya I; Roux P; Marcellin F; Salmon-Ceron D; Carrieri MP";10.1007/s10620-017-4703-y;2017/10/01 00:00;['Letter', 'Comment']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;27177169;RESULT;"Marcellin F, Protopopescu C, Poizot-Martin I, Miailhes P, Esterle L, Wittkop L, Spire B, Bocquier A, Salmon-Ceron D, Dabis F, Carrieri MP; HEPAVIH ANRS CO13 Study Group. Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort). Eur J Gastroenterol Hepatol. 2016 Sep;28(9):1003-7. doi: 10.1097/MEG.0000000000000664.";Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).;"Marcellin F; Protopopescu C; Poizot-Martin I; Miailhes P; Esterle L; Wittkop L; Spire B; Bocquier A; Salmon-Ceron D; Dabis F; Carrieri MP; HEPAVIH ANRS CO13 Study Group";10.1097/MEG.0000000000000664;2016/09/01 00:00;['Journal Article', 'Multicenter Study']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;26372388;RESULT;"ANRS CO13 HEPAVIH Cohort. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients. AIDS. 2015 Sep 10;29(14):1821-30. doi: 10.1097/QAD.0000000000000787.";Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.;ANRS CO13 HEPAVIH Cohort;10.1097/QAD.0000000000000787;2015/09/10 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23052829;RESULT;"Loko MA, Bani-Sadr F, Valantin MA, Lascoux-Combe C, Fontaine H, Bonnard P, Gervais A, Bouchaud O, Garipuy D, Quertainmont Y, Vittecoq D, Tehrani MS, Winnock M, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort. Antivir Ther. 2012;17(7):1335-43. doi: 10.3851/IMP2419. Epub 2012 Oct 10.";Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.;"Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D; ANRS CO 13 HEPAVIH Study Group";10.3851/IMP2419;2012/01/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22409788;RESULT;"Salmon-Ceron D, Cohen J, Winnock M, Roux P, Sadr FB, Rosenthal E, Martin IP, Loko MA, Mora M, Sogni P, Spire B, Dabis F, Carrieri MP; HEPAVIH group. Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France). BMC Health Serv Res. 2012 Mar 12;12:59. doi: 10.1186/1472-6963-12-59.";Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France).;"Salmon-Ceron D; Cohen J; Winnock M; Roux P; Sadr FB; Rosenthal E; Martin IP; Loko MA; Mora M; Sogni P; Spire B; Dabis F; Carrieri MP; HEPAVIH group";10.1186/1472-6963-12-59;2012/03/12 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;24580042;RESULT;"Marcellin F, Roux P, Winnock M, Lions C, Dabis F, Salmon-Ceron D, Loko MA, Spire B, Carrieri MP. Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort. Expert Rev Gastroenterol Hepatol. 2014 May;8(4):351-8. doi: 10.1586/17474124.2014.888949. Epub 2014 Mar 3.";Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort.;"Marcellin F; Roux P; Winnock M; Lions C; Dabis F; Salmon-Ceron D; Loko MA; Spire B; Carrieri MP";10.1586/17474124.2014.888949;2014/05/01 00:00;['Journal Article', 'Review']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;34212476;DERIVED;"Chalouni M, Wittkop L, Bani-Sadr F, Lacombe K, Esterle L, Gilbert C, Miailhes P, Zucman D, Valantin MA, Bregigeon-Ronot S, Morlat P, Billaud E, Piroth L, Naqvi A, Sogni P, Salmon D; ANRS CO13 HEPAVIH Cohort Study Group. Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants. HIV Med. 2021 Oct;22(9):791-804. doi: 10.1111/hiv.13127. Epub 2021 Jul 1.";Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants.;"Chalouni M; Wittkop L; Bani-Sadr F; Lacombe K; Esterle L; Gilbert C; Miailhes P; Zucman D; Valantin MA; Brégigeon-Ronot S; Morlat P; Billaud E; Piroth L; Naqvi A; Sogni P; Salmon D; ANRS CO13 HEPAVIH Cohort Study Group";10.1111/hiv.13127;2021/10/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;26528903;RESULT;"Salmon D, Bani-Sadr F, Gilbert C, Rosenthal E, Valantin MA, Simon A, Neau D, Morlat P, Loko MA, Wittkop L, Dabis F; ANRS CO13HEPAVIH study group. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. J Clin Virol. 2015 Dec;73:32-35. doi: 10.1016/j.jcv.2015.10.010. Epub 2015 Oct 19.";HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.;"Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F; ANRS CO13HEPAVIH study group";10.1016/j.jcv.2015.10.010;2015/12/01 00:00;['Journal Article', 'Multicenter Study']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23421419;RESULT;"Marcellin F, Lions C, Winnock M, Salmon D, Durant J, Spire B, Mora M, Loko MA, Dabis F, Dominguez S, Roux P, Carrieri MP; ANRS CO13 HEPAVIH Study Group. Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ARNS CO13 cohort). Addiction. 2013 Jul;108(7):1250-8. doi: 10.1111/add.12149. Epub 2013 Mar 21.";Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ARNS CO13 cohort).;"Marcellin F; Lions C; Winnock M; Salmon D; Durant J; Spire B; Mora M; Loko MA; Dabis F; Dominguez S; Roux P; Carrieri MP; ANRS CO13 HEPAVIH Study Group";10.1111/add.12149;2013/07/01 00:00;['Journal Article', 'Multicenter Study']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21819472;RESULT;"Roux P, Fugon L, Winnock M, Salmon-Ceron D, Lacombe K, Sogni P, Spire B, Dabis F, Carrieri MP; ANRS-CO-13-HEPAVIH Study Group. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users. Addiction. 2012 Jan;107(1):152-9. doi: 10.1111/j.1360-0443.2011.03608.x. Epub 2011 Oct 12.";Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.;"Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP; ANRS-CO-13-HEPAVIH Study Group";10.1111/j.1360-0443.2011.03608.x;2012/01/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;25015913;RESULT;"Marcellin F, Roux P, Loko MA, Lions C, Caumont-Prim A, Dabis F, Salmon-Ceron D, Spire B, Carrieri MP; HEPAVIH (ANRS CO13) Study Group. High levels of alcohol consumption increase the risk of advanced hepatic fibrosis in HIV/hepatitis C virus-coinfected patients: a sex-based analysis using transient elastography at enrollment in the HEPAVIH ANRS CO13 cohort. Clin Infect Dis. 2014 Oct 15;59(8):1190-2. doi: 10.1093/cid/ciu525. Epub 2014 Jul 11. No abstract available.";High levels of alcohol consumption increase the risk of advanced hepatic fibrosis in HIV/hepatitis C virus-coinfected patients: a sex-based analysis using transient elastography at enrollment in the HEPAVIH ANRS CO13 cohort.;"Marcellin F; Roux P; Loko MA; Lions C; Caumont-Prim A; Dabis F; Salmon-Ceron D; Spire B; Carrieri MP; HEPAVIH (ANRS CO13) Study Group";10.1093/cid/ciu525;2014/10/15 00:00;['Letter', 'Comment']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21888878;RESULT;"Carrieri MP, Cohen J, Salmon-Ceron D, Winnock M. Coffee consumption and reduced self-reported side effects in HIV-HCV co-infected patients during PEG-IFN and ribavirin treatment: results from ANRS CO13 HEPAVIH. J Hepatol. 2012 Mar;56(3):745-7. doi: 10.1016/j.jhep.2011.08.005. Epub 2011 Aug 31. No abstract available.";Coffee consumption and reduced self-reported side effects in HIV-HCV co-infected patients during PEG-IFN and ribavirin treatment: results from ANRS CO13 HEPAVIH.;"Carrieri MP; Cohen J; Salmon-Ceron D; Winnock M";10.1016/j.jhep.2011.08.005;2012/03/01 00:00;['Letter']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21920402;RESULT;"Winnock M, Bani-Sadr F, Pambrun E, Loko MA, Lascoux-Combe C, Garipuy D, Rosenthal E, Carrieri P, Dabis F, Salmon D. Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCV-coinfected patients, and factors associated with HAV and HBV vaccination. Vaccine. 2011 Nov 3;29(47):8656-60. doi: 10.1016/j.vaccine.2011.08.125. Epub 2011 Sep 13.";Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCV-coinfected patients, and factors associated with HAV and HBV vaccination.;"Winnock M; Bani-Sadr F; Pambrun E; Loko MA; Lascoux-Combe C; Garipuy D; Rosenthal E; Carrieri P; Dabis F; Salmon D";10.1016/j.vaccine.2011.08.125;2011/11/03 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;20493576;RESULT;"Cales P, Halfon P, Batisse D, Carrat F, Perre P, Penaranda G, Guyader D, d'Alteroche L, Fouchard-Hubert I, Michelet C, Veillon P, Lambert J, Weiss L, Salmon D, Cacoub P. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol. 2010 Aug;53(2):238-44. doi: 10.1016/j.jhep.2010.03.007. Epub 2010 Apr 18.";Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection.;"Calès P; Halfon P; Batisse D; Carrat F; Perré P; Penaranda G; Guyader D; d'Alteroche L; Fouchard-Hubert I; Michelet C; Veillon P; Lambert J; Weiss L; Salmon D; Cacoub P";10.1016/j.jhep.2010.03.007;2010/08/01 00:00;['Journal Article', 'Multicenter Study']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;25778750;RESULT;"Carrieri MP, Serfaty L, Vilotitch A, Winnock M, Poizot-Martin I, Loko MA, Lions C, Lascoux-Combe C, Roux P, Salmon-Ceron D, Spire B, Dabis F; ANRS CO13 HEPAVIH Study Group. Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH). Clin Infect Dis. 2015 Jul 1;61(1):40-8. doi: 10.1093/cid/civ217. Epub 2015 Mar 16.";Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH).;"Carrieri MP; Serfaty L; Vilotitch A; Winnock M; Poizot-Martin I; Loko MA; Lions C; Lascoux-Combe C; Roux P; Salmon-Ceron D; Spire B; Dabis F; ANRS CO13 HEPAVIH Study Group";10.1093/cid/civ217;2015/07/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;30570526;DERIVED;"Poizot-Martin I, Rosenthal E, Gilbert C, Cano CE, Simon A, Lascoux-Combe C, Alric L, Gervais A, Neau D, Esterle L, Salmon D, Sogni P, Wittkop L; ANRS CO13 HEPAVIH Study Group. Nadir CD4 Is Negatively Associated With Antinuclear Antibody Detection in HCV/HIV-Coinfected Patients. J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):461-466. doi: 10.1097/QAI.0000000000001940.";Nadir CD4 Is Negatively Associated With Antinuclear Antibody Detection in HCV/HIV-Coinfected Patients.;"Poizot-Martin I; Rosenthal E; Gilbert C; Cano CE; Simon A; Lascoux-Combe C; Alric L; Gervais A; Neau D; Esterle L; Salmon D; Sogni P; Wittkop L; ANRS CO13 HEPAVIH Study Group";10.1097/QAI.0000000000001940;2019/04/01 00:00;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22781224;RESULT;"Solas C, Pambrun E, Winnock M, Salmon D, Poizot-Martin I, Dominguez S, Bani-Sadr F, Izopet J, Garraffo R, Peytavin G; ANRS CO-13 HEPAVIH Study Group. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? AIDS. 2012 Nov 13;26(17):2193-9. doi: 10.1097/QAD.0b013e32835763a4.";Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?;"Solas C; Pambrun E; Winnock M; Salmon D; Poizot-Martin I; Dominguez S; Bani-Sadr F; Izopet J; Garraffo R; Peytavin G; ANRS CO-13 HEPAVIH Study Group";10.1097/QAD.0b013e32835763a4;2012/11/13 00:00;['Journal Article', 'Multicenter Study']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28235612;RESULT;"Piroth L, Wittkop L, Lacombe K, Rosenthal E, Gilbert C, Miailhes P, Carrieri P, Chas J, Poizot-Martin I, Gervais A, Dominguez S, Neau D, Zucman D, Billaud E, Morlat P, Aumaitre H, Lascoux-Combe C, Simon A, Bouchaud O, Teicher E, Bani-Sadr F, Alric L, Vittecoq D, Boue F, Duvivier C, Valantin MA, Esterle L, Dabis F, Sogni P, Salmon D; ANRS CO13 HEPAVIH study group. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort. J Hepatol. 2017 Jul;67(1):23-31. doi: 10.1016/j.jhep.2017.02.012. Epub 2017 Feb 22.";Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.;"Piroth L; Wittkop L; Lacombe K; Rosenthal E; Gilbert C; Miailhes P; Carrieri P; Chas J; Poizot-Martin I; Gervais A; Dominguez S; Neau D; Zucman D; Billaud E; Morlat P; Aumaitre H; Lascoux-Combe C; Simon A; Bouchaud O; Teicher E; Bani-Sadr F; Alric L; Vittecoq D; Boué F; Duvivier C; Valantin MA; Esterle L; Dabis F; Sogni P; Salmon D; ANRS CO13 HEPAVIH study group";10.1016/j.jhep.2017.02.012;2017/07/01 00:00;['Journal Article']
NCT02172677;The Influence of Collective Schemas on Individual Memory;Institut National de la Santé Et de la Recherche Médicale, France;La Région Basse-Normandie | Université de Caen Normandie | University Hospital, Caen | Ecole Pratique des Hautes Etudes | Equipement d'Excellence Matrice;COMPLETED;INTERVENTIONAL;False;2014-06-24;2014-10;2016-10-14;;;;;;;;
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2009-12-23;2009-05-07;2017-12-14;35264424;DERIVED;"Wilke C, Mengel D, Schols L, Hengel H, Rakowicz M, Klockgether T, Durr A, Filla A, Melegh B, Schule R, Reetz K, Jacobi H, Synofzik M. Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1. Neurology. 2022 May 17;98(20):e1985-e1996. doi: 10.1212/WNL.0000000000200257. Epub 2022 Mar 9.";Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1.;"Wilke C; Mengel D; Schöls L; Hengel H; Rakowicz M; Klockgether T; Durr A; Filla A; Melegh B; Schüle R; Reetz K; Jacobi H; Synofzik M";10.1212/WNL.0000000000200257;2022/05/17 00:00;['Journal Article']
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2009-12-23;2009-05-07;2017-12-14;24780882;DERIVED;"Tezenas du Montcel S, Durr A, Rakowicz M, Nanetti L, Charles P, Sulek A, Mariotti C, Rola R, Schols L, Bauer P, Dufaure-Gare I, Jacobi H, Forlani S, Schmitz-Hubsch T, Filla A, Timmann D, van de Warrenburg BP, Marelli C, Kang JS, Giunti P, Cook A, Baliko L, Melegh B, Boesch S, Szymanski S, Berciano J, Infante J, Buerk K, Masciullo M, Di Fabio R, Depondt C, Ratka S, Stevanin G, Klockgether T, Brice A, Golmard JL. Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6. J Med Genet. 2014 Jul;51(7):479-86. doi: 10.1136/jmedgenet-2013-102200. Epub 2014 Apr 29. Erratum In: J Med Genet. 2014 Sep;51(9):613. Bela, Melegh [corrected to Melegh, Bela].";Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6.;"Tezenas du Montcel S; Durr A; Rakowicz M; Nanetti L; Charles P; Sulek A; Mariotti C; Rola R; Schols L; Bauer P; Dufaure-Garé I; Jacobi H; Forlani S; Schmitz-Hübsch T; Filla A; Timmann D; van de Warrenburg BP; Marelli C; Kang JS; Giunti P; Cook A; Baliko L; Melegh B; Boesch S; Szymanski S; Berciano J; Infante J; Buerk K; Masciullo M; Di Fabio R; Depondt C; Ratka S; Stevanin G; Klockgether T; Brice A; Golmard JL";10.1136/jmedgenet-2013-102200;2014/07/01 00:00;['Journal Article']
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2009-12-23;2009-05-07;2017-12-14;32822634;DERIVED;"Jacobi H, du Montcel ST, Romanzetti S, Harmuth F, Mariotti C, Nanetti L, Rakowicz M, Makowicz G, Durr A, Monin ML, Filla A, Roca A, Schols L, Hengel H, Infante J, Kang JS, Timmann D, Casali C, Masciullo M, Baliko L, Melegh B, Nachbauer W, Burk-Gergs K, Schulz JB, Riess O, Reetz K, Klockgether T. Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study. Lancet Neurol. 2020 Sep;19(9):738-747. doi: 10.1016/S1474-4422(20)30235-0.";Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study.;"Jacobi H; du Montcel ST; Romanzetti S; Harmuth F; Mariotti C; Nanetti L; Rakowicz M; Makowicz G; Durr A; Monin ML; Filla A; Roca A; Schöls L; Hengel H; Infante J; Kang JS; Timmann D; Casali C; Masciullo M; Baliko L; Melegh B; Nachbauer W; Bürk-Gergs K; Schulz JB; Riess O; Reetz K; Klockgether T";10.1016/S1474-4422(20)30235-0;2020/09/01 00:00;['Clinical Trial', 'Journal Article', 'Multicenter Study']
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2009-12-23;2009-05-07;2017-12-14;23707147;DERIVED;"Jacobi H, Reetz K, du Montcel ST, Bauer P, Mariotti C, Nanetti L, Rakowicz M, Sulek A, Durr A, Charles P, Filla A, Antenora A, Schols L, Schicks J, Infante J, Kang JS, Timmann D, Di Fabio R, Masciullo M, Baliko L, Melegh B, Boesch S, Burk K, Peltz A, Schulz JB, Dufaure-Gare I, Klockgether T. Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol. 2013 Jul;12(7):650-8. doi: 10.1016/S1474-4422(13)70104-2. Epub 2013 May 22. Erratum In: Lancet Neurol. 2013 Jul;12(7):630.";Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data.;"Jacobi H; Reetz K; du Montcel ST; Bauer P; Mariotti C; Nanetti L; Rakowicz M; Sulek A; Durr A; Charles P; Filla A; Antenora A; Schöls L; Schicks J; Infante J; Kang JS; Timmann D; Di Fabio R; Masciullo M; Baliko L; Melegh B; Boesch S; Bürk K; Peltz A; Schulz JB; Dufaure-Garé I; Klockgether T";10.1016/S1474-4422(13)70104-2;2013/07/01 00:00;['Journal Article']
NCT01842477;Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2013-04-29;2013-05;2016-02-05;;;;;;;;
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-31;2014-12;2015-09;25435054;BACKGROUND;"Mentre F, Taburet AM, Guedj J, Anglaret X, Keita S, de Lamballerie X, Malvy D. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis. 2015 Feb;15(2):150-1. doi: 10.1016/S1473-3099(14)71047-3. Epub 2014 Nov 28. No abstract available.";Dose regimen of favipiravir for Ebola virus disease.;"Mentré F; Taburet AM; Guedj J; Anglaret X; Keïta S; de Lamballerie X; Malvy D";10.1016/S1473-3099(14)71047-3;2015/02/01 00:00;['Letter']
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-31;2014-12;2015-09;27046271;RESULT;"Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Munoz VC, Doumbouya L, Harouna S, Kighoma PM, Koundouno FR, Lolamou R, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wolfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Uwamahoro MG, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, de Sainte Fare EB, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Duverger TA, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Gunther S, de Lamballerie X, Keita S, Mentre F, Anglaret X, Malvy D; JIKI Study Group. Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 2016 Apr 5;13(4):e1002009. doi: 10.1371/journal.pmed.1002009. eCollection 2016 Apr.";Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.;"Sissoko D; Laouenan C; Folkesson E; M'Lebing AB; Beavogui AH; Baize S; Camara AM; Maes P; Shepherd S; Danel C; Carazo S; Conde MN; Gala JL; Colin G; Savini H; Bore JA; Le Marcis F; Koundouno FR; Petitjean F; Lamah MC; Diederich S; Tounkara A; Poelart G; Berbain E; Dindart JM; Duraffour S; Lefevre A; Leno T; Peyrouset O; Irenge L; Bangoura N; Palich R; Hinzmann J; Kraus A; Barry TS; Berette S; Bongono A; Camara MS; Munoz VC; Doumbouya L; Harouna S; Kighoma PM; Koundouno FR; Lolamou R; Loua CM; Massala V; Moumouni K; Provost C; Samake N; Sekou C; Soumah A; Arnould I; Komano MS; Gustin L; Berutto C; Camara D; Camara FS; Colpaert J; Delamou L; Jansson L; Kourouma E; Loua M; Malme K; Manfrin E; Maomou A; Milinouno A; Ombelet S; Sidiboun AY; Verreckt I; Yombouno P; Bocquin A; Carbonnelle C; Carmoi T; Frange P; Mely S; Nguyen VK; Pannetier D; Taburet AM; Treluyer JM; Kolie J; Moh R; Gonzalez MC; Kuisma E; Liedigk B; Ngabo D; Rudolf M; Thom R; Kerber R; Gabriel M; Di Caro A; Wölfel R; Badir J; Bentahir M; Deccache Y; Dumont C; Durant JF; El Bakkouri K; Uwamahoro MG; Smits B; Toufik N; Van Cauwenberghe S; Ezzedine K; D'Ortenzio E; Pizarro L; Etienne A; Guedj J; Fizet A; de Sainte Fare EB; Murgue B; Tran-Minh T; Rapp C; Piguet P; Poncin M; Draguez B; Duverger TA; Barbe S; Baret G; Defourny I; Carroll M; Raoul H; Augier A; Eholie SP; Yazdanpanah Y; Levy-Marchal C; Antierrens A; Van Herp M; Günther S; de Lamballerie X; Keïta S; Mentre F; Anglaret X; Malvy D; JIKI Study Group";10.1371/journal.pmed.1002009;2016/04/05 00:00;['Published Erratum']
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-31;2014-12;2015-09;26930627;DERIVED;"Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Souley Harouna, Kighoma PM, Koundouno FR, Rene Lolamou, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wolfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Gasasira Uwamahoro M, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, Barte de Sainte Fare E, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Allaford Duverger T, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Gunther S, de Lamballerie X, Keita S, Mentre F, Anglaret X, Malvy D; JIKI Study Group. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 2016 Mar 1;13(3):e1001967. doi: 10.1371/journal.pmed.1001967. eCollection 2016 Mar. Erratum In: PLoS Med. 2016 Apr;13(4):e1002009. Dortenzio, Eric [corrected to D'Ortenzio, Eric]. PLoS Med. 2016 Jun;13(6):e1002066.";Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.;"Sissoko D; Laouenan C; Folkesson E; M'Lebing AB; Beavogui AH; Baize S; Camara AM; Maes P; Shepherd S; Danel C; Carazo S; Conde MN; Gala JL; Colin G; Savini H; Bore JA; Le Marcis F; Koundouno FR; Petitjean F; Lamah MC; Diederich S; Tounkara A; Poelart G; Berbain E; Dindart JM; Duraffour S; Lefevre A; Leno T; Peyrouset O; Irenge L; Bangoura N; Palich R; Hinzmann J; Kraus A; Barry TS; Berette S; Bongono A; Camara MS; Chanfreau Munoz V; Doumbouya L; Souley Harouna; Kighoma PM; Koundouno FR; Réné Lolamou; Loua CM; Massala V; Moumouni K; Provost C; Samake N; Sekou C; Soumah A; Arnould I; Komano MS; Gustin L; Berutto C; Camara D; Camara FS; Colpaert J; Delamou L; Jansson L; Kourouma E; Loua M; Malme K; Manfrin E; Maomou A; Milinouno A; Ombelet S; Sidiboun AY; Verreckt I; Yombouno P; Bocquin A; Carbonnelle C; Carmoi T; Frange P; Mely S; Nguyen VK; Pannetier D; Taburet AM; Treluyer JM; Kolie J; Moh R; Gonzalez MC; Kuisma E; Liedigk B; Ngabo D; Rudolf M; Thom R; Kerber R; Gabriel M; Di Caro A; Wölfel R; Badir J; Bentahir M; Deccache Y; Dumont C; Durant JF; El Bakkouri K; Gasasira Uwamahoro M; Smits B; Toufik N; Van Cauwenberghe S; Ezzedine K; D'Ortenzio E; Pizarro L; Etienne A; Guedj J; Fizet A; Barte de Sainte Fare E; Murgue B; Tran-Minh T; Rapp C; Piguet P; Poncin M; Draguez B; Allaford Duverger T; Barbe S; Baret G; Defourny I; Carroll M; Raoul H; Augier A; Eholie SP; Yazdanpanah Y; Levy-Marchal C; Antierrens A; Van Herp M; Günther S; de Lamballerie X; Keïta S; Mentre F; Anglaret X; Malvy D; JIKI Study Group";10.1371/journal.pmed.1001967;2016/03/01 00:00;['Clinical Trial', 'Journal Article']
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-31;2014-12;2015-09;28231247;DERIVED;"Nguyen TH, Guedj J, Anglaret X, Laouenan C, Madelain V, Taburet AM, Baize S, Sissoko D, Pastorino B, Rodallec A, Piorkowski G, Carazo S, Conde MN, Gala JL, Bore JA, Carbonnelle C, Jacquot F, Raoul H, Malvy D, de Lamballerie X, Mentre F; JIKI study group. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389. doi: 10.1371/journal.pntd.0005389. eCollection 2017 Feb.";Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.;"Nguyen TH; Guedj J; Anglaret X; Laouénan C; Madelain V; Taburet AM; Baize S; Sissoko D; Pastorino B; Rodallec A; Piorkowski G; Carazo S; Conde MN; Gala JL; Bore JA; Carbonnelle C; Jacquot F; Raoul H; Malvy D; de Lamballerie X; Mentré F; JIKI study group";10.1371/journal.pntd.0005389;2017/02/23 00:00;['Clinical Trial', 'Journal Article']
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;29776897;DERIVED;"Saez L, Langlois J, Legrand K, Quinet MH, Lecomte E, Omorou AY, Briancon S; PRALIMAP-INES Trial Group. Reach and Acceptability of a Mobile Reminder Strategy and Facebook Group Intervention for Weight Management in Less Advantaged Adolescents: Insights From the PRALIMAP-INES Trial. JMIR Mhealth Uhealth. 2018 May 18;6(5):e110. doi: 10.2196/mhealth.7657.";Reach and Acceptability of a Mobile Reminder Strategy and Facebook Group Intervention for Weight Management in Less Advantaged Adolescents: Insights From the PRALIMAP-INÈS Trial.;"Saez L; Langlois J; Legrand K; Quinet MH; Lecomte E; Omorou AY; Briançon S; PRALIMAP-INÈS Trial Group";10.2196/mhealth.7657;2018/05/18 00:00;['Journal Article']
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;32097754;DERIVED;"Omorou AY, Manneville F, Langlois J, Legrand K, Bohme P, Muller L, Guillemin F, Briancon S, Lecomte E; PRALIMAP-INES Trial Group. Physical activity rather than sedentary behaviour is socially determined in French adolescents with overweight and obesity. Prev Med. 2020 May;134:106043. doi: 10.1016/j.ypmed.2020.106043. Epub 2020 Feb 22.";Physical activity rather than sedentary behaviour is socially determined in French adolescents with overweight and obesity.;"Omorou AY; Manneville F; Langlois J; Legrand K; Böhme P; Muller L; Guillemin F; Briançon S; Lecomte E; PRALIMAP-INÈS Trial Group";10.1016/j.ypmed.2020.106043;2020/05/01 00:00;['Journal Article', 'Multicenter Study']
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;35272723;PUBMED;;Behavioural risk patterns in adolescents with excess weight participating in the PRALIMAP-INÈS trial.;"Julia C; Omorou A; Lecomte E; Langlois J; Touvier M; Hercberg S; Briançon S; Kesse-Guyot E; Guillemin F; PRALIMAP-INÈS Trial Group";10.1017/S136898002200057X;2023/01/01 00:00;['Journal Article']
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;34087324;DERIVED;"Manneville F, Omorou AY, Legrand K, Lecomte E, Rydberg JA, Briancon S, Guillemin F; PRALIMAP Trial Group. Sociodemographic and psychological characteristics associated with discrepancy between body satisfaction and weight change among adolescents. Prev Med. 2021 Sep;150:106668. doi: 10.1016/j.ypmed.2021.106668. Epub 2021 Jun 1.";Sociodemographic and psychological characteristics associated with discrepancy between body satisfaction and weight change among adolescents.;"Manneville F; Omorou AY; Legrand K; Lecomte E; Rydberg JA; Briançon S; Guillemin F; PRALIMAP Trial Group";10.1016/j.ypmed.2021.106668;2021/09/01 00:00;['Journal Article']
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;29696179;DERIVED;"Legrand K, Lecomte E, Langlois J, Muller L, Saez L, Quinet MH, Bohme P, Spitz E, Omorou AY, Briancon S; PRALIMAP-INES trial group. Reducing social inequalities in access to overweight and obesity care management for adolescents: The PRALIMAP-INES trial protocol and inclusion data analysis. Contemp Clin Trials Commun. 2017 Jun 16;7:141-157. doi: 10.1016/j.conctc.2017.05.010. eCollection 2017 Sep.";Reducing social inequalities in access to overweight and obesity care management for adolescents: The PRALIMAP-INÈS trial protocol and inclusion data analysis.;"Legrand K; Lecomte E; Langlois J; Muller L; Saez L; Quinet MH; Böhme P; Spitz E; Omorou AY; Briançon S; PRALIMAP-INÈS trial group";10.1016/j.conctc.2017.05.010;2017/06/16 00:00;['Journal Article']
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;29934380;DERIVED;"Saez L, Legrand K, Alleyrat C, Ramisasoa S, Langlois J, Muller L, Omorou AY, De Lavenne R, Kivits J, Lecomte E, Briancon S; PRALIMAP-INES Trial Group. Using facilitator-receiver peer dyads matched according to socioeconomic status to promote behaviour change in overweight adolescents: a feasibility study. BMJ Open. 2018 Jun 22;8(6):e019731. doi: 10.1136/bmjopen-2017-019731.";Using facilitator-receiver peer dyads matched according to socioeconomic status to promote behaviour change in overweight adolescents: a feasibility study.;"Saez L; Legrand K; Alleyrat C; Ramisasoa S; Langlois J; Muller L; Omorou AY; De Lavenne R; Kivits J; Lecomte E; Briançon S; PRALIMAP-INÈS Trial Group";10.1136/bmjopen-2017-019731;2018/06/22 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01089387;Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-03-18;2010-05;2015-03;25974235;DERIVED;"Khera M, Albersen M, Mulhall JP. Mesenchymal stem cell therapy for the treatment of erectile dysfunction. J Sex Med. 2015 May;12(5):1105-6. doi: 10.1111/jsm.12871. No abstract available.";Mesenchymal stem cell therapy for the treatment of erectile dysfunction.;"Khera M; Albersen M; Mulhall JP";10.1111/jsm.12871;2015/05/01 00:00;['Journal Article']
NCT01089387;Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-03-18;2010-05;2015-03;28753830;DERIVED;"Yiou R, Hamidou L, Birebent B, Bitari D, Le Corvoisier P, Contremoulins I, Rodriguez AM, Augustin D, Roudot-Thoraval F, de la Taille A, Rouard H. Intracavernous Injections of Bone Marrow Mononucleated Cells for Postradical Prostatectomy Erectile Dysfunction: Final Results of the INSTIN Clinical Trial. Eur Urol Focus. 2017 Dec;3(6):643-645. doi: 10.1016/j.euf.2017.06.009. Epub 2017 Jun 24.";Intracavernous Injections of Bone Marrow Mononucleated Cells for Postradical Prostatectomy Erectile Dysfunction: Final Results of the INSTIN Clinical Trial.;"Yiou R; Hamidou L; Birebent B; Bitari D; Le Corvoisier P; Contremoulins I; Rodriguez AM; Augustin D; Roudot-Thoraval F; de la Taille A; Rouard H";10.1016/j.euf.2017.06.009;2017/12/01 00:00;['Letter']
NCT01089387;Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-03-18;2010-05;2015-03;26439886;PUBMED;;Safety of Intracavernous Bone Marrow-Mononuclear Cells for Postradical Prostatectomy Erectile Dysfunction: An Open Dose-Escalation Pilot Study.;"Yiou R; Hamidou L; Birebent B; Bitari D; Lecorvoisier P; Contremoulins I; Khodari M; Rodriguez AM; Augustin D; Roudot-Thoraval F; de la Taille A; Rouard H";10.1016/j.eururo.2015.09.026;2016/06/01 00:00;['Journal Article']
NCT02481453;Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-06-25;2015-07-15;2018-01-22;24975859;BACKGROUND;"Lloyd TE, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014 Jul 29;83(5):426-33. doi: 10.1212/WNL.0000000000000642. Epub 2014 Jun 27.";Evaluation and construction of diagnostic criteria for inclusion body myositis.;"Lloyd TE; Mammen AL; Amato AA; Weiss MD; Needham M; Greenberg SA";10.1212/WNL.0000000000000642;2014/07/29 00:00;['Journal Article', 'Review']
NCT02481453;Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-06-25;2015-07-15;2018-01-22;38273639;PUBMED;;Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial.;"Benveniste O; Hogrel JY; Belin L; Annoussamy M; Bachasson D; Rigolet A; Laforet P; Dzangué-Tchoupou G; Salem JE; Nguyen LS; Stojkovic T; Zahr N; Hervier B; Landon-Cardinal O; Behin A; Guilloux E; Reyngoudt H; Amelin D; Uruha A; Mariampillai K; Marty B; Eymard B; Hulot JS; Greenberg SA; Carlier PG; Allenbach Y";10.1016/S2665-9913(20)30280-0;2021/01/01 00:00;['Journal Article']
NCT02481453;Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-06-25;2015-07-15;2018-01-22;20413309;BACKGROUND;"Benveniste O, Hilton-Jones D. International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Disord. 2010 Jun;20(6):414-21. doi: 10.1016/j.nmd.2010.03.014. Epub 2010 Apr 21. No abstract available.";International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009.;"Benveniste O; Hilton-Jones D";10.1016/j.nmd.2010.03.014;2010/06/01 00:00;[]
NCT02027051;Etude génétique Des Arméniens;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2014-01-03;2014-01;2017-01;;;;;;;;
NCT02658253;Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults;Institut National de la Santé Et de la Recherche Médicale, France;EVI Industries, Inc. | Recherche Clinique Paris Descartes Necker Cochin Sainte Anne | Centre national de recherche et de formation sur le paludisme | EUCLID Clinical Trial Platform;COMPLETED;INTERVENTIONAL;False;2016-01-18;2016-01;2019-02-21;33717176;DERIVED;"Gamain B, Chene A, Viebig NK, Tuikue Ndam N, Nielsen MA. Progress and Insights Toward an Effective Placental Malaria Vaccine. Front Immunol. 2021 Feb 25;12:634508. doi: 10.3389/fimmu.2021.634508. eCollection 2021.";Progress and Insights Toward an Effective Placental Malaria Vaccine.;"Gamain B; Chêne A; Viebig NK; Tuikue Ndam N; Nielsen MA";10.3389/fimmu.2021.634508;2021/02/25 00:00;['Journal Article', 'Review']
NCT02658253;Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults;Institut National de la Santé Et de la Recherche Médicale, France;EVI Industries, Inc. | Recherche Clinique Paris Descartes Necker Cochin Sainte Anne | Centre national de recherche et de formation sur le paludisme | EUCLID Clinical Trial Platform;COMPLETED;INTERVENTIONAL;False;2016-01-18;2016-01;2019-02-21;32032566;DERIVED;"Sirima SB, Richert L, Chene A, Konate AT, Campion C, Dechavanne S, Semblat JP, Benhamouda N, Bahuaud M, Loulergue P, Ouedraogo A, Nebie I, Kabore M, Kargougou D, Barry A, Ouattara SM, Boilet V, Allais F, Roguet G, Havelange N, Lopez-Perez E, Kuppers A, Konate E, Roussillon C, Kante M, Belarbi L, Diarra A, Henry N, Soulama I, Ouedraogo A, Esperou H, Leroy O, Batteux F, Tartour E, Viebig NK, Thiebaut R, Launay O, Gamain B. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. Lancet Infect Dis. 2020 May;20(5):585-597. doi: 10.1016/S1473-3099(19)30739-X. Epub 2020 Feb 4.";PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.;"Sirima SB; Richert L; Chêne A; Konate AT; Campion C; Dechavanne S; Semblat JP; Benhamouda N; Bahuaud M; Loulergue P; Ouédraogo A; Nébié I; Kabore M; Kargougou D; Barry A; Ouattara SM; Boilet V; Allais F; Roguet G; Havelange N; Lopez-Perez E; Kuppers A; Konaté E; Roussillon C; Kanté M; Belarbi L; Diarra A; Henry N; Soulama I; Ouédraogo A; Esperou H; Leroy O; Batteux F; Tartour E; Viebig NK; Thiebaut R; Launay O; Gamain B";10.1016/S1473-3099(19)30739-X;2020/05/01 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;25330161;DERIVED;"Danel C, Kabran M, Inwoley A, Badje A, Herrmann JL, Moh R, Lecarrou J, Gabillard D, Ntakpe JB, Deschamps N, Ouattara E, Perronne C, Eholie S, Anglaret X. Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Cote d'Ivoire, West Africa. PLoS One. 2014 Oct 16;9(10):e107245. doi: 10.1371/journal.pone.0107245. eCollection 2014.";Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa.;"Danel C; Kabran M; Inwoley A; Badje A; Herrmann JL; Moh R; Lecarrou J; Gabillard D; Ntakpe JB; Deschamps N; Ouattara E; Perronne C; Eholie S; Anglaret X";10.1371/journal.pone.0107245;2014/10/16 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;24985779;DERIVED;"Jean K, Gabillard D, Moh R, Danel C, Desgrees-du-Lou A, N'takpe JB, Le Carrou J, Badje A, Eholie S, Lert F, Anglaret X, Dray-Spira R. Decrease in sexual risk behaviours after early initiation of antiretroviral therapy: a 24-month prospective study in Cote d'Ivoire. J Int AIDS Soc. 2014 Jun 30;17(1):18977. doi: 10.7448/IAS.17.1.18977. eCollection 2014.";Decrease in sexual risk behaviours after early initiation of antiretroviral therapy: a 24-month prospective study in Côte d'Ivoire.;"Jean K; Gabillard D; Moh R; Danel C; Desgrées-du-Loû A; N'takpe JB; Le Carrou J; Badjé A; Eholié S; Lert F; Anglaret X; Dray-Spira R";10.7448/IAS.17.1.18977;2014/06/30 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;29020361;DERIVED;"Kouame GM, Boyd A, Moh R, Badje A, Gabillard D, Ouattara E, Ntakpe JB, Emieme A, Maylin S, Chekaraou MA, Eholie SP, Zoulim F, Lacombe K, Anglaret X, Danel C; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 12136 Temprano and ANRS 12240 VarBVA Study Groups. Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication. Clin Infect Dis. 2018 Jan 6;66(1):112-120. doi: 10.1093/cid/cix747.";Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication.;"Kouamé GM; Boyd A; Moh R; Badje A; Gabillard D; Ouattara E; Ntakpe JB; Emième A; Maylin S; Chekaraou MA; Eholié SP; Zoulim F; Lacombe K; Anglaret X; Danel C; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 12136 Temprano and ANRS 12240 VarBVA Study Groups";10.1093/cid/cix747;2018/01/06 00:00;['Journal Article']
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;35093007;DERIVED;"Moh DR, Ntakpe JB, Gabillard D, Yayo-Emieme AA, Badje A, Kouame GM, d'Aquin TT, Danel C, Anglaret X, Eholie SP. Association of cellular HIV-1 DNA and virological success of antiretroviral treatment in HIV-infected sub-Saharan African adults. BMC Infect Dis. 2022 Jan 29;22(1):100. doi: 10.1186/s12879-022-07082-2.";Association of cellular HIV-1 DNA and virological success of antiretroviral treatment in HIV-infected sub-Saharan African adults.;"Moh DR; Ntakpé JB; Gabillard D; Yayo-Emieme AA; Badjé A; Kouame GM; d'Aquin TT; Danel C; Anglaret X; Eholié SP";10.1186/s12879-022-07082-2;2022/01/29 00:00;['Journal Article', 'Randomized Controlled Trial']
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;26193126;DERIVED;"TEMPRANO ANRS 12136 Study Group; Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, Ouattara E, Anzian A, Ntakpe JB, Minga A, Kouame GM, Bouhoussou F, Emieme A, Kouame A, Inwoley A, Toni TD, Ahiboh H, Kabran M, Rabe C, Sidibe B, Nzunetu G, Konan R, Gnokoro J, Gouesse P, Messou E, Dohoun L, Kamagate S, Yao A, Amon S, Kouame AB, Koua A, Kouame E, Ndri Y, Ba-Gomis O, Daligou M, Ackoundze S, Hawerlander D, Ani A, Dembele F, Kone F, Guehi C, Kanga C, Koule S, Seri J, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatounde N, Bleoue G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Assi R, Bakayoko A, Mahassadi A, Attia A, Oussou A, Mobio M, Bamba D, Koman M, Horo A, Deschamps N, Chenal H, Sassan-Morokro M, Konate S, Aka K, Aoussi E, Journot V, Nchot C, Karcher S, Chaix ML, Rouzioux C, Sow PS, Perronne C, Girard PM, Menan H, Bissagnene E, Kadio A, Ettiegne-Traore V, Moh-Semde C, Kouame A, Massumbuko JM, Chene G, Dosso M, Domoua SK, N'Dri-Yoman T, Salamon R, Eholie SP, Anglaret X. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015 Aug 27;373(9):808-22. doi: 10.1056/NEJMoa1507198. Epub 2015 Jul 20.";A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.;"TEMPRANO ANRS 12136 Study Group; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X";10.1056/NEJMoa1507198;2015/08/27 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;29297443;DERIVED;"Moh R, Badje A, N'takpe JB, Kouame GM, Gabillard D, Ouassa T, Ouattara E, Le Carrou J, Bohoussou F, Messou E, Eholie S, Anglaret X, Danel C. Screening for active tuberculosis before isoniazid preventive therapy among HIV-infected West African adults. Int J Tuberc Lung Dis. 2017 Dec 1;21(12):1237-1244. doi: 10.5588/ijtld.17.0016.";Screening for active tuberculosis before isoniazid preventive therapy among HIV-infected West African adults.;"Moh R; Badjé A; N'takpé JB; Kouamé GM; Gabillard D; Ouassa T; Ouattara E; Le Carrou J; Bohoussou F; Messou E; Eholié S; Anglaret X; Danel C";10.5588/ijtld.17.0016;2017/12/01 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;23639243;DERIVED;"Ouattara E, Danel C, Moh R, Gabillard D, Peytavin G, Konan R, Carrou JL, Bohoussou F, Eholie SP, Anglaret X. Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts. J Int AIDS Soc. 2013 Apr 30;16(1):18059. doi: 10.7448/IAS.16.1.18059.";Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.;"Ouattara E; Danel C; Moh R; Gabillard D; Peytavin G; Konan R; Carrou JL; Bohoussou F; Eholie SP; Anglaret X";10.7448/IAS.16.1.18059;2013/04/30 00:00;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT04842851;Cardiac Resynchronization Therapy in Congenital Heart Diseases With Systemic Right Ventricle;Paris Cardiovascular Research Center (Inserm U970);Marie Lannelongue Hospital, Le Plessis Robinson, France | Clinique Pasteur Toulouse | Groupe Hospitalier Pitie-Salpetriere | Hopital Louis Pradel | University Hospital, Montpellier | European Georges Pompidou Hospital;COMPLETED;OBSERVATIONAL;False;2021-04-13;2004-01-01;2020-12-31;;;;;;;;
NCT01880151;Neuroelectrical Biomarkers for Alzheimer's Disease Stages;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2013-06-18;2013-07-12;2019-01;;;;;;;;
NCT01952587;X-linked Biological Response to HIV Sensing: the ANRS EP 53 Study;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2013-09-30;2013-11;2015-06;;;;;;;;
